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ABSTRACT OF DISSERTATION

COMBINATORIAL BIOSYNTHETIC DERIVATIZATION OF
THE ANTITUMORAL AGENT GILVOCARCIN V
Gilvocarcin V (GV), the principal product of Streptomyces griseoflavus Gö 3592
and other Streptomyces spp., is the most prominent member of a distinct class of
antitumor antibiotics that share a polyketide derived coumarin-based aromatic core. GV
and other members of this class including polycarcin V from Streptomyces polyformus,
often referred to as gilvocarcin-like aryl C-glycosides, are particularly interesting because
of their potent bactericidal, virucidal and antitumor activities at low concentrations while
maintaining low in vivo toxicity. Although the precise molecular mechanism of GV
bioactivity is unknown, gilvocarcin V has been shown to undergo a photoactivated [2+2]
cycloaddition of its vinyl side chain with thymine residues of DNA in near-UV or visible
blue light. In addition, GV was shown to selectively crosslink histone H3 with DNA,
thereby effectively disrupting normal cellular processes such as transcription.
Furthermore, GVs ability to inhibit topoisomerase II has also been attributed as a
mechanism of action for gilvocarcin V activity. The excellent antitumor activity, as well
as an unprecedented structural architecture, has made GV an ideal candidate for
biosynthetic studies toward the development of novel analogues with improved
pharmacological properties. Previous biosynthetic research has identified several
candidate genes responsible for key steps during the biosynthesis of gilvocarcin V
including an oxygenase cascade leading to C-C bond cleavage, methylations, lactone
formation, C-glycosylation and vinyl side chain formation.
In this study, we further examined two critical biosynthetic transformations
essential for the bioactivity of gilvocarcin V, namely starter unit incorporation and Cglycosylation, through the following specific aims: 1) creation of functional chimeric Cglycosyltransferases through domain swapping of gilvocarcin-like glycosyltransferases
and identification and evaluation of the donor substrate flexibility of PlcGT, the
polycarcin V pathway specific C-glycosyltransferase; 2) creation of a library of Omethylated-L-rhamnose analogues of polycarcin V for structure activity relationship
studies; 3) identification of the role of GilP and GilQ in starter unit specificity during
gilvocarcin V biosynthesis; and 4) creation of a plasmid based approach in which
selective gilvocarcin biosynthetic genes were utilized to produce important gilvocarcin
intermediates for further in vivo and in vitro experimentation.
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Chapter 1: Introduction
Natural product sources, whether from flora or fauna, have long been explored for
their medicinal properties. Prehistoric medicine, for example, involved a primitive form
of phytotherapy in which through trial and error materials from flora were recognized for
their beneficial effects. The natural mummy of a prehistoric man known as the Similaun
Man was found with Piptoporus betulinus, a type of bracket fungus whose oil shows
antiparasitic properties, in his possessions.1 It is believed that the Similaun Man, who
walked over 5,300 years ago, was ingesting Piptoporus betulinus to combat an intestinal
whipworm infection found upon examination of his body. The benefits of such natural
products were passed down, by word of mouth, through generations until the advent of
writing, in which we can trace medicinal natural product use back to ancient civilizations
such as the Babylonian, Egyptian and Chinese cultures. In this context, modern medicine
is the product of an amalgamation of thousands of years worth of natural product
research.
Today, medicinal natural products are classified into six broad categories based
on their building blocks and biosynthetic routes including: fatty acids and polyketides (1
and 2), terpenoids and steroids (3 and 4), alkaloids (5 and 6), phenylpropanoids (7 and 8),
specialized amino acids and peptides (9 and 10), and specialized carbohydrates (11 and
12) (Figure 1).2 Typically, bioactive natural products are found as secondary metabolites
of specific organisms or groups of organisms.

Secondary metabolites are natural

products that do not directly affect the normal growth, development or reproduction of
the producing organism.

This is in contrast to primary metabolites which are

characterized as compounds that occur in all cells and play a central role in metabolism
and reproduction of those cells. Examples of primary metabolites include nucleic acids,
proteinogenic amino acids (aa) and sugars.

1

Figure 1. Medicinal natural products.
Polyketides
Interestingly, about half of all discovered biologically active secondary
metabolites are produced by a group of Gram-positive bacteria known as actinomycetes.3
Particularly, the genus Streptomyces is the most prolific producer of pharmaceutically
and agriculturally relevant natural products covering all structural categories of secondary
2

metabolites. Of these, the polyketides have been the most extensively studied class of
secondary metabolites. Polyketides comprise one of the largest groups of bioactive
natural products and encompass several structurally diverse groups including polyethers,
polyphenols, polyenes, macrolides and enediynes as exemplified by monensin (13),
benastatin A (14), candicidin (15), spiramycin (16) and C-1027 (17), respectively (Figure
2).4

Figure 2. Structural diversity of polyketides.

Streptomycetes are not the only producer of polyketides.

In fact, examples of

polyketides can be found throughout prokaryotic and eukaryotic life including bacteria,
fungi, plants, and protists. Some polyketides have been reported from insects, mollusks
and sponges; however, these have been subsequently attributed to bacterial symbionts.
The exact roles of these polyketides in their original biological hosts are widely
3

unknown, but it is believed that some may be involved in pigmentation, pathogendefense, immune-response and symbiosis.5 Many polyketides, or their derivatives, have
become important commercial chemicals such as the antibiotics oxytetracycline (18),
erythromycin A (19) and rifampicin (20); the immunosuppressant fujimycin (21), the
antifungal amphotericin B (22); the antitumoral agents mithramycin (23) and epirubicin
(24); the antiparasitic and insecticide avermectin B1a (25) and spinosyn (26); and the
anticholesterolemic lovastatin (27).2 In contrast, other polyketides have been found to
serve as virulence factors and potent toxins such as mycolactone (28) and aflatoxin B1
(29) (Figure 3).

4

Figure 3. Bioactive polyketides.

5

Despite the enormous success of pharmaceutical polyketides, there is a growing need
for the generation of novel drug leads to combat the rapid development of drug-resistant
pathogens and emerging infectious microorganisms.

The structural complexity of

polyketides, however, presents an extremely difficult challenge for total synthetic
strategies toward a majority of polyketide scaffolding despite their biogenesis through
simple acetate derived building blocks.4

Extensive research on polyketide natural

product biosyntheses have provided a plethora of genetic and biochemical information
that allow for the engineered generation of novel “unnatural” polyketide derivatives
through a process known as combinatorial biosynthesis. This approach utilizes genetic
engineering and various strategies including gene inactivation, heterologous gene
expression and mutasynthesis to modify the natural biosynthetic pathway toward the
generation of novel compounds.6-7
As combinatorial biosynthesis requires a deep fundamental understanding of the
processes involved in the chemical modifications of natural products, the biosynthesis
and common decorating reactions of polyketides, typically referred to as polyketide
synthase (PKS) and post-polyketide synthase (post-PKS) reactions, will be described
below.

Biosynthesis of polyketides
Polyketide biosynthesis is reminiscent of fatty acid biosynthesis as both pathways
share a common biosynthetic logic. Generally derived from simple precursors such as
acetyl-coenzyme A (CoA) and malonyl-CoA (MCoA), both polyketides and fatty acids
are generated through repetitive decarboxylative Claisen thioester condensations of an
activated acyl starter unit with MCoA or MCoA-derived extender units.8 This process
typically requires the activity of a β-ketoacyl synthase (KS), an activated acyl carrier
protein (holo-ACP) and a malonyl/acyltransferase (MAT/AT). In fatty acid biosynthesis,
every chain elongation step catalyzed by the fatty acid synthase (FAS) is followed by βketoreduction, dehydration and enoyl reduction steps to produce a fully saturated
backbone (Figure 4, pathway A). This β-keto processing is referred to as the reduction
cycle and is formed through the concerted action of a ketoreductase (KR), dehydratase
(DH) and an enoyl reductase (ER), respectively. In polyketide biosynthesis, however, the
6

reduction cycle is optional, and can be partially (Figure 4, pathway B) or fully (Figure 4,
pathway C) omitted before the next round of elongation. This in addition to the ability of
the polyketide synthases (PKSs) to utilize a larger pool of acyl-CoA substrates set FAS
and PKS systems apart.

Nevertheless, both pathways repeat their respective

elongation/reduction cycles until a predetermined chain length is obtained at which point
the thioester-bound substrates are removed from the enzyme complex and are further
modified through post-PKS reactions.

7

Figure 4. Biosynthetic route toward fatty acids (A), partially or highly reduced
polyketides (B) and unreduced polyketides (C).
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Polyketide synthases are classified into three categories, type I, type II and type
III, based on their enzymatic properties and architecture.9-10 Type I PKSs are large
multifunctional enzymes consisting of distinct modules harboring a set of activities
responsible for one (modular) or more (iterative) cycles of chain elongation.11 The
modular type I PKS resembles an assembly line in which the growing polyketide is
passed from one module to the next. Each module contains an individual KS, AT and
ACP domain responsible for the stepwise decarboxylative extension described above. In
addition, each module also contains optional β-keto processing domains (KR, DH and
ER) that will determine the extent to which the newly formed β-keto group is modified.
Each module is used once as the growing chain is passed along the PKS assembly line.
In this context, through bioinformatical analysis of the modules encoded within the
multifunctional enzyme it is possible to predict the core structure, including the degree of
β-keto reduction, produced by a modular type I PKS.
The biosynthesis of pikromycin (30) follows that of a typical modular type I PKS
(Figure 5). The pikromycin (pik) polyketide synthase locus consists of five open reading
frames (ORFs), pikAI, pikAII, piKAIII, pikAIV and pikAV, consisting of six modules, a
loading module and an independent thioesterase.12 The loading module initiates
pikromycin biosynthesis by loading the starter unit propionyl-CoA (PCoA).

The

ketosynthase domain of module one self acylates with the extender unit methylmalonylCoA (MMCoA) and undergoes decarboxylative condensation with the propionyl-ACP of
module L. The resulting diketide undergoes ketoreduction by the KR domain of module
one installing the hydroxyl group at the C-3 position of the growing polyketide. The AT
domain then transfers the nascent polyketide to the ACP domain of module one and the
process continues down the subsequent modules. The amount of reduction varies from
module to module as does the choice for extender unit. The polyketide is elongated until
it reaches module six which carries a thioesterase responsible for catalyzing an
intramolecular cyclization which forms narbonolide (31), a 14-membered macrolide.
Interestingly, the pikromycin pathway contains an additional thioesterase, PikAV, that
was found to be non-essential for lactone formation.13 Further post-PKS modifications by
a glycosyltransferase (DesVII, produces 32) and cytochrome P-450 (CYP450)
monooxygenase (PikC) creates pikromycin.14
9

Figure 5. The biosynthetic pathway of pikromycin.

Not all type I PKSs behave the same, as examples of skipping and stuttering
events within this modular type I PKS system have been reported which deviates from
the linearity with which it is usually associated.15 In addition there are examples of ATless, and iteratively acting type I PKSs.16 The iteratively acting type I PKS, usually
found in fungi, differs from the modular system in that a single multifunctional enzyme
consisting of a KS, AT, ACP, KR, DH and ER domains is used repeatedly throughout the
elongation of the polyketide. As in modular type I PKSs, the degree of β-ketoreduction
10

can vary in each extended unit. The ability of iterative PKSs to control varying degrees
of β-ketoreduction remains to be elucidated. The anticholesterolemic lovastatin is an
example of an iteratively acting type I PKS.

In lovastatin biosynthesis, one large

multifunctional enzyme containing KS, AT, DH, MT, KR and ACP domains (LovB), in
conjunction with the free standing ER (LovC), is responsible for polyketide propagation
and reduction (Figure 6).17

Figure 6. Biosynthetic pathway of lovastatin.

Type II PKS systems are found exclusively in prokaryotes.4

They are usually

observed in actinomycetes; however, a few examples of Gram-negative bacteria
containing type II PKSs are known.18-19

Type II PKSs are made up of individual

iteratively acting enzymes, expressed from distinct genes, that form a multi-enzyme
complex for polyketide assembly. Type II PKSs differ from type I PKSs in that the
former does not include a β-ketoreduction cycle, and therefore produces a highly reactive
poly-β-keto-thioester intermediate. The minimal proteins required for type II PKS
functionality typically consists of two ketosynthase units (KSα and KSβ or chain length
factor (CLF)) and an ACP which make up the “minimal PKS”.20-21 Typically in type II
PKSs polyketide formation is initiated by the loading of an activated ACP with malonylCoA by a malonyl-CoA:ACP transacylase (MCAT), borrowed from fatty acid
11

biosynthesis, and subsequent decarboxylation to form an acetate-ACP species. The
acetate starter unit is then transferred from the ACP to the KSα subunit (Figure 4, C).
Again, an additional unit of malonyl-CoA is loaded to the ACP via an MCAT which
undergoes a decarboxylative Claisen condensation with the acetate primed KSα
catalyzing the first elongation step. The ACP therefore serves as the anchor for the
growing polyketide. The newly formed diketide is then transferred from the ACP back to
the KSα for additional rounds of elongation. This process is repeated until the desired
polyketide length is achieved, which is believed to be determined by the KSβ subunit,
hence the chain length factor (CLF).22

The minimal PKS is also accompanied by

additional subunits including ketoreductases, cyclases (CYC) and aromatases (ARO) that
determine the folding, cyclization and aromatization pattern of the nascent poly-β-ketothioester intermediate. These reactions provide the basis for structural diversity of type II
PKS

derived

polyketide

benzoisochromanequinones,

cores

as

tetracyclines,

observed

by

aureolic

acids,

linear

(anthracyclines,

pluramycins),

angular

(angucyclines and pentangular polyphenols) and discoid (resistomycins) polyphenols.4
The biosynthesis of tetracenomycin C (33) for example is a model type II PKS
(TcmK, L and M) that utilizes one acetate and nine malonate subunits to form a
decaketide intermediate that is further modified by the cyclase TcmN to produce TCM F2
(34) (Figure 7).21,23 The inclusion of TcmJ, believed to be a cyclase, was shown to
increase the production of TCM F2 in cell free assays, but was found to be non-essential
for the continued production of 34. TCM F2 is converted to TCM F1 (35) by the cyclase
TcmI to form the fourth fused ring.24-25 Additional modifications by methyltransferases
and oxygenases convert TCM F1 into tetracenomycin C (33).26-28
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Figure 7. Biosynthetic pathway of tetracenomycin C.

The last class of PKS enzymes is the type III PKSs, or chalcone/stilbene synthase-like
PKSs. Type III PKSs can be found in plants, bacteria and fungi as multifunctional
condensing enzymes that do not utilize ACP-bound substrates for extension.4 Instead,
they utilize acyl-CoA substrates directly, as observed in resveratrol (36) biosynthesis in
which p-coumaroyl-CoA is extended with three MCoA subunits (Figure 8).29 The type
III PKS then catalyzes a specific C2-C7 cyclization producing 36.
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Figure 8. Biosynthetic pathway of resveratrol.

In addition to the three general classes of PKSs, there are also examples of mixed
PKS systems. These include type I-type II, type I-type III, FAS-PKS and PKS-NRPS
(non-ribosomal peptide synthetase) hybrids as exemplified by hedamycin (37),
kendomycin (38), DIF-1 (39) and cryptophycin (40), respectively (Figure 9).4,30

Figure 9. Polyketides derived from mixed PKS systems.
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Polyketide tailoring enzymes
A majority of polyketides are further functionalized after their initial propagation
by a series of modifying enzymes referred to as post-PKS enzymes including oxygenases,
glycosyltransferases, methyltransferases and deoxysugar biosynthetic genes.6-7 These
tailoring reactions can lead to drastic alterations in the physio-chemical properties of
compounds and are often responsible for “activating” polyketides. Many examples exist
in which the polyketide intermediates produced by their respective PKSs are proven
inactive until modifying enzymes, most commonly oxygenases and glycosyltransferases,
tailor the polyketide into a bioactive compound. Specifically, the early PKS intermediates
of erythromycin A (19) and epirubicin (24) have little to no activity until they are further
modified by their post-PKS associated enzymes.31 Given the importance of these postPKS reactions they have been the subject of extensive combinatorial biosynthetic
investigations to allow for the production of modified polyketides with improved
pharmacological properties. This approach has led to the development of hundreds of
modified polyketide derivatives, many with improved bioactivity profiles.6-7 Common
post-PKS tailoring reactions, which are observed in many natural product biosynthetic
pathways, are briefly discussed below.
Glycosylation
Glycosylation is recognized as one of the most important post-PKS reactions because
of its ability to install bioactivity to an otherwise inactive biomolecule. In addition it may
serve as a crucial self-resistance mechanism as observed in macrolide biosynthesis.32-33
Enzymatic glycosylation involves a glycosyltransferase (GT) which attaches an NDPactivated sugar, as the donor substrate, to an acceptor substrate.34 There are a few
examples of GTs requiring a second enzyme known as a helper enzyme to efficiently
glycosylate an acceptor substrate.35 In these systems it remains unknown the exact role
these auxiliary proteins play in order to facilitate glycosylation.
Successful glycosylation of an acceptor substrate produces a glycosidic bond between
the acceptor substrate and the donor substrate. These can be O-, N-, S- or C-glycosidic
bonds depending on the functionality of the GT. O-glycosides are by far the most
prevalent with N-, S- and C-glycosides making up only a minority of all glycosides
15

produced

by

glycosylation

glycosyltransferases
is

thought

of

as

in

secondary

being

metabolites.

unidirectional;

Conventionally,

however,

some

O-

glycosyltransferases were recently shown to be reversible.36-37
Extensive bioinformatical analysis of glycosyltransferases have allowed them to be
grouped into ~90 sequence-based families.34

Despite the divergence in sequence

homology of glycosyltransferases, all reported three-dimensional structures of GTs, thus
far, fall into two major folds, GT-A and GT-B. Both folds contain two β/α/β Rossmann
domains, however, in GT-A class GTs the Rossmann folds are abutting one another while
in GT-B type GTs the Rossmann folds are facing each other. In addition,
glycosyltransferases are further divided by their ability to retain or invert stereochemistry
of the anomeric carbon of the donor substrate while forming their respective glycosidic
bond (Figure 10). Mechanistically, inverting glycosylation is believed to involve a GTmediated direct displacement SN2-like reaction in which an active-site base catalyst
deprotonates the nucleophile of the acceptor substrate facilitating direct displacement of
the nucleotidyl diphosphate (NDP) leaving group. (Figure 10, A).34,38

In contrast,

retaining GTs first attack the donor substrate thereby removing the NDP activating group
and tethering the donor substrate to the enzyme. A second base catalyst within the GT
then deprotonates the acceptor substrate allowing for nucleophilic attack of the enzymebound donor substrate forming a glycosidic bond retaining the original stereochemistry of
the anomeric carbon (Figure 10, B). Typically, glycosylation of secondary metabolites
involves inverting-GTs; however, there is one example from chromomycin biosynthesis
involving an α-1,4 glycosidic linkage that suggests the activity of a retaining
glycosyltransferase.39-40
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Figure 10. Hypothetical mechanisms for inverting (A) and retaining (B) O-glycoside
formation as well as inverting C-glycoside formation (C).
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C-glycosyltransferases are particularly interesting because of the chemical stability of
their resulting C-glycosidic bond. In addition, unlike O-glycosides, C-glycosides are
resistant to in vivo glycosidase activity. C-glycosides are typically found with sugar
attachment ortho- or para- to an electron rich aromatic functional group. The resonance of
these particular structures facilitates ortho- or para- attack of the anomeric carbon of the
donor substrate as observed in urdamycin and gilvocarcin V (49) glycosylation
reactions.41-42 The exact mechanism of C- and N-glycoside formation, however, remains
unclear (Figure 10, C).
Glycosyltransferases play an important role in combinatorial biosynthetic strategies
toward producing novel polyketide derivatives. Novel steffimycins, aranciamycins,
elloramycins, gilvocarcins, mithramycins, urdamycins and landomycins are just a few
examples in which glycosyltransferases were responsible for creating analogues of a
particular natural product. These results clearly show the tremendous potential displayed
by GTs in the rational design of natural product glycosides.
Deoxysugar biosynthesis
Sugar biosyntheses in microbial hosts are extremely important as the resulting
donor substrates are utilized by GTs in glycosylation reactions described above. Even
though several natural products contain fully oxygenated sugar molecules such as
glucose, a majority of secondary metabolites include sugar moieties that are
deoxygenated to various degrees prior to their utilization by a glycosyltransferase. In
either case, a dedicated NDP-hexose-nucleotidyltransferase (NT) is responsible for
appending an NDP species to hexose-1-phosphate, thereby creating an “activated” NDPhexose species.38 This reaction requires NTP (ATP, CTP, GTP, UTP or TTP) and in
microbial deoxysugar biosynthesis TTP and glucose-1-phoshpate are by far the most
prominently utilized substrates which results in the formation of TDP-D-glucose (41).
There are a few examples, however, of GDP- and UDP- activated deoxysugars derived
from glucose and mannose.43-44

The activated TDP-D-glucose (41) may be utilized

directly by GTs as in vancomycin biosynthesis, but 41 is typically deoxygenated by a
TDP-D-glucose 4,6-dehydratase (4,6-DH) producing TDP-4-keto-6-deoxy-D-glucose
(42), a common branching point for all 6-deoxysugar biosynthetic pathways (Figure
18

11).38,45

Additional deoxysugar biosynthetic enzymes including dehydratases,

epimerases, group transferases and ketoreductases determine the extent of deoxygenation
and decoration of the final deoxysugar proceeding from 42.

Figure 11. Common biosynthetic route toward the production of various 6-deoxysugars.

Deoxysugar biosynthetic genes offer additional resources for combinatorial
biosynthesis. It is possible to predict the deoxysugar produced from a set of deoxysugar
biosynthetic genes.

In this context, it is therefore possible to combine various

deoxysugar genes, sometimes from different pathways, in order to create a specific NDPdeoxysugar. These types of experiments have been successfully utilized with flexible
GTs to rationally design specific deoxysugar containing natural product analogues.46-50

Oxygenation
The products of PKSs are often further functionalized through a series of
oxidation reactions. In some instances these oxidation reactions are responsible for
rearranging the polyketide core which provides an additional source for the structural
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diversity observed in polyketide derived natural products. As with glycosylation,
oxygenation is often required for the biological activity exhibited by many polyketides.
Typically, these reactions are catalyzed by a large family of enzymes known as
oxygenases, most commonly cytochrome P-450 monooxygenases (CYP450s), flavin
(FAD or FMN)-dependent monooxygenases, anthrone oxygenases, and dioxygenases.6-7
These enzymes generally use flavin, heme or metal ions to activate molecular oxygen, or
the substrate, to mediate electron transfer during hydroxylation, epoxidation, anthrone
oxidation, peroxide formation, dioxetane formation, desaturation and oxidative cleavage.
Baeyer-Villiger monooxygenases are a class of flavin dependent monooxygenases that
differ mechanistically from typical monooxygenase catalyzed hydroxylation by attacking
keto groups rather than non-oxygen bearing carbon atoms. The classification of
monooxygenase refers to the incorporation of one oxygen atom from molecular oxygen,
while dioxygenases utilize both oxygen atoms. The additional oxygen atom remaining
from a monooxygenase reaction is typically removed as H2O or H2O2 by NADPH
assisted reduction.

Some examples of post-PKS oxygenation reactions in the

biosynthesis of epirubicin (24), oleandomycin (48) and mithramycin (23) are shown in
Figure 12.
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Figure 12. Oxygenase catalyzed modifications during epirubicin (24), oleandomycin (48)
and mithramycin (23) biosynthesis. The oxygen atoms were introduced via a cofactor
free anthrone oxygenase (purple), FAD dependant monooxygenase (green), CYTP450
monooxygenase (blue) or Baeyer-Villiger monooxygenase (red).
Oxygenases have been utilized heavily in combinatorial biosynthetic strategies
including gene inactivation experiments to produce polyketide pathway intermediates and
shunt products.6-7 In addition, oxygenases with substrate promiscuity have been utilized
in macrolide biosynthesis to create novel erythromycin and pikromycin derivatives.51-52

Methylation
Post-PKS tailoring events commonly involve methylation. These reactions are
catalyzed by methyltransferases (MTs) that typically utilize S-adenosyl methionine
(SAM) as a methyl donor to produce N-, S-, C- and O-tethered methyl groups. These
groups can be carboxyl, phenol and hydroxyl groups, aliphatic and aromatic amines,
thiols and thioethers, as well as alkenes and ring carbons.7 MTs are also prominent in the
deoxysugar biosynthetic pathways of L-mycarose, L-axenose, L-nogalose, L-oleandrose,
D-virenose

and many others.38 The methylation of some deoxysugar species in secondary

metabolites have been implicated in attributing biological activity.
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This is clearly

demonstrated in spinosyn and elloramycin derivatives containing various degrees of
methylated L-rhamnose.53-54
Gilvocarcin
Gilvocarcin V (49, GV, Figure 13) is a unique angucyclinone born anticancer
antibiotic produced by several Streptomyces species. This structurally unique molecule
was first reported without complete structural characterization by Mizuno and coworkers
as toromycin in 1980, and was found to be the principal product of S. collinus.55-57
Shortly thereafter, GV as well as the closely related analogues gilvocarcin M (50) and
gilvocarcin E (51) were fully characterized and found to be concomitant products of 49
production in S. gilvotanareus and S. anandii, respectively.58-60 Together 49, 50 and 51
comprise the gilvocarcins and are the most prominent members of a unique family of
anticancer

antibiotics

that

share

a

polyketide

derived

coumarin-based

benzo[d]naptho[1,2-b]pyran-6-one moiety. Additional members of this family of natural
products are often referred to as gilvocarcin-like aryl C-glycosides and include
chrysomycin V (52) ravidomycin V (53), deacetylravidomycin V (54), FE35A (55) and B
(56), Mer1020 dC (57) and dD (58), BE-12406A (59) and B (60) and polycarcin V (61)
(Figure 13).61-66 Members predominantly posses a C-glycosidically linked 6-deoxy-Dhexose moiety in C4 position while variants within this group exist as either furanose (I
and V, Figure 13) or pyranose sugars (II, III, IV and VI). Notably, BE-12406A (59) and
B (60) as well as polycarcin V (61) are the only examples of 6-deoxy-L-sugars found in
gilvocarcin-type compounds, with 59 and 60 representing the only O-glycosidically
linked analogues reported thus far.

Additional variations at the C8 side chain are

restricted to a single methyl, ethyl or vinyl functional group and are the basis for the M, E
and V abbreviations used in gilvocarcin nomenclature.

22

Figure 13. Glycodiversity of gilvocarcin-type anticancer drugs. Gilvocarcins V, M and E
(49-51), chrysomycin V (52), ravidomycin V (53), deacetylravidomycin V (54), FE35A
(55) and B (56), Mer1020 dC (57) and dD (58), BE-12406A (59) and B (60) and
polycarcin V (61).
Gilvocarcin V has spurred particular interest because of its potent bactericidal,
virucidal and antitumor activities at low concentrations while maintaining low in vivo
toxicity.58,67-70 49 has been reported to undergo photoactivated [2+2] cycloaddition of its
vinyl side chain with thymine residues of DNA in near-UV or visible blue light which
results in single strand scissions leading to covalent binding with DNA.71-76 This unique
photo-activation of gilvocarcin V explains the lack of activity exhibited by gilvocarcin M
and gilvocarcin E which do not contain the crucial vinyl functional group.77-79 GV’s
activity is also attributed to a unique selective cross linking of DNA and histone H3, a
core component of the histone complex that plays an important role for DNA replication
and transcription.80-84 The saccharide moiety, D-fucofuranose, of GV is essential for this
activity as it is believed to facilitate binding of histone H3.42,85 In addition, 49 has also
been reported as an inhibitor of topoisomerase II.86
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Biosynthetic Highlights of Gilvocarcin V
Initial incorporation studies of gilvocarcin, as well as ravidomycin and
chrysomycin, revealed their unique backbone to be derived from the oxidative
rearrangement of an angucyclinone core originating from acetate and propionate (Figure
14).87-90 This unusual rearrangement in addition to other intriguing structural features
including a C-glycosidically linked

D-fucofuranose

moiety and the use of a rare

propionate starter unit was the driving force for further in-depth characterization of GV
biosynthesis.

Figure 14. Labeling pattern and proposed ring opening during gilvocarcin biosynthesis.

Isolation of the complete GV biosynthetic gene cluster on a single cosmid,
cosG9B3, from S. griseoflavus Gö3592 by Rohr et al. established the genetic foundation
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for further biochemical analysis of the gilvocarcin biosynthetic pathway. The presence of
the complete gilvocarcin biosynthetic locus (gil) was confirmed through heterologous
reconstitution of the GV pathway by expressing cosG9B3 in S. lividans TK24.91
Sequencing and bioinformatic analysis of cosG9B3 revealed the presence of genes
encoding a type II PKS (gilA, B and C), a malonyl CoA:ACP transacylase (MCAT)
(gilP), an acyltransferase (gilQ), a PKS associated ketoreductase (gilF), a
cyclase/dehydratase (gilK), four oxygenases (gilOI, OII, OIII and OIV), a Cglycosyltransferase (gilGT), putative methyltransferases (gilMT and gilM), an
oxidoreductase (gilR), deoxysugar biosynthetic genes (gilE, D and U), putative regulatory
and resistance genes as well as several other genes with unknown functions including
gilN, L and V (Figure 15).91 Interestingly, the presence of an MCAT as well as an
acyltransferase in the gilvocarcin cluster was unusual. Often, the minimal type II PKS
(KSα/β and ACP) does not require a dedicated MCAT, and instead recruits the
endogenous FAS associated MCAT.21,92-93 As gilvocarcin V and E biosynthesis utilizes a
unique starter unit, namely propionate, it was hypothesized that GilQ might play a role in
starter unit specificity (propionate vs. acetate).

Figure 15. Biosynthetic gene cluster of gilvocarcin V and M.
The first biosynthetic experiments of GV, after the isolation of cosG9B3,
involved determining the mode of oxidative C-C bond cleavage. To determine the genes
responsible for oxidative cleavage, all four pathway oxygenases were inactivated on
cosG9B3, individually or sequentially, and the generated mutant cosmids were
heterologously expressed in S. lividans TK24. Accumulation of gilvocarcin E from the
ΔgilOIII mutant clearly showed GilOIII did not play a role in oxidative ring cleavage, but
instead was responsible for oxidizing the ethyl C8 side chain to the vinyl functional group
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observed in gilvocarcin V.42

The mutant cosmids ΔgilOIV and ΔgilOIV, OII both

produced rabelomycins (62 and 63) as their major metabolites while ΔgilOII accumulated
dehydro-rabelomycins (64-66) (Figure 16).90,94 Similarly, ΔgilOI and ΔgilOI, OII
mutually produced the 2,3-dehydro-UWM6s (67 and 68) and pregilvocarcin-o-quinones
(69 and 70).90,94 All of the metabolites produced by single or sequential inactivations of
gilOI, gilOII and/or gilOIV were not the products of an oxidative rearrangement,
therefore it was hypothesized that all three oxygenases were required for C5-C6 bond
cleavage. Initial bioinformatic analysis of gilOI, gilOII of gilOIV revealed high sequence
similarity to jadH, jadG and jadF, respectively from the jadomycin pathway (Figure 17).
Jadomycin B (71) is also derived from the oxidative rearrangement of an angucyclinone
core and has been extensively studied.94-100
Unlike gilvocarcin V, jadomycin B requires non-enzymatic incorporation of Lisoleucine and O-glycosylation (JadS) after the oxidative C-C bond cleavage (Figure 17).
Interestingly, JadS may glycosylate before the incorporation of

L-isoleucine.

97,169,170

Cross complementation of the individual gilvocarcin oxygenase mutants with their
corresponding jadomycin pathway homologues restored gilvocarcin V production, except
for ΔgilOII/jadG complementation.94 These complementation experiments indicated that
the gilvocarcin and jadomycin pathways share at least two functionally identical
oxygenases while the third, gilOII and jadG, may serve unique functions for their
respective pathways.

Furthermore, co-expression of gilOI, gilOII and gilOIV with

pWHM1238, a plasmid directing biosynthesis toward the putative pathway intermediate
UWM6 (72), was able to restore jadomycin A (74) production when the fermentation
media were supplemented with L-isoleucine.94 Together, these results suggest that GilOI,
GilOII and GilOIV together form a complex that is responsible for oxidative ring
cleavage during gilvocarcin biosynthesis, and that both gilvocarcin and jadomycin
oxygenase complexes act upon identical initial intermediates.

Despite extensive

experimentation, however, the ring cleavage mechanisms for both gilvocarcin and
jadomycin have yet to be elucidated.
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Figure 16. Proposed biosynthetic pathway for gilvocarcin V.

Additional post-PKS tailoring genes were inactivated by Rohr et al. in order to
determine their function during GV biosynthesis. The inactivation of gilR led to the
accumulation of glycosylated hemi-acetal intermediates referred to as pregilvocarcins
(75-77) which indicated GilR acted as the last biosynthetic step toward GV production.94
The presence of a hemi-acetal also provided evidence of an acid-aldehyde intermediate
after oxidative ring cleavage. Subsequent in vitro analysis concluded that GilR was in
fact an oxidoreductase responsible for the oxidation of the glycosylated hemi-acetal
intermediate to form the lactone observed in 49-51.101
27

The function of gilGT was

similarly investigated by heterologous expression of the glycosyltransferase deficient
cosmid ΔgilGT.

The major metabolites produced by ΔgilGT were the defuco-

gilvocarcins (78-80) which lack the expected

D-fucofuranose

moiety, and therefore

implicated GilGT as the pathway specific C-glycosyltransferase (Figure 16).42
Compounds 78-80 contain a lactone instead of the predicted hemi-acetal and are shunt
products produced by the somewhat substrate flexible GilR.42,101

Figure 17. Proposed biosynthetic pathway for jadomycin B.
The sugar moiety of gilvocarcins,

D-fucofuranose,

is rarely found in natural

products. Given that the sugar moiety is likely a crucial component for the biological
activity of GV, the biosynthesis of this unique deoxysugar and its attachment to the
gilvocarcin acceptor substrate was of particular interest. Inactivation of gilU, a putative
deoxysugar 4-ketoreductase, resulted in the accumulation of a new gilvocarcin derivative,
4′-hydroxy-GV (81, Figure 16), with improved biological activity.85

These results

provided clear evidence that GilU was responsible for 4-ketoreduction of 42 during the
biosynthesis toward TDP-D-fucofuranose (47) (Figure 18).
28

More importantly, the

accumulation of 81-83 showed the natural glycosyltransferase, GilGT, retained donor
substrate flexibility, and that modification of the sugar moiety of GV can lead to
analogues with improved biological activity. Combinatorial approaches to probe the
substrate flexibility of GilGT have been met with limited success and have resulted in the
production of only

D-olivosyl-gilvocarcins

(87-89) and polycarcins (61, 90 and 91)

containing L-rhamnose (92) and D-olivose (93), respectively (Figures 19 and 34).48

Figure 18. TDP-D-fucofuranose (47) and 4-OH-TDP-D-fucofuranose (94) biosynthetic
pathways.

Figure 19. Gilvocarcin analogues produced through the moderately flexible
glycosyltransferase GilGT.
Based on previous in vivo and in vitro experimentation one possible biosynthetic
pathway of gilvocarcin has been proposed (Figure 16). The gilPKS is responsible for
catalyzing the formation of the earliest isolated intermediates of GV biosynthesis, 72 and
73, which are identical except for their C8 side chains which arise from the use of acetate
or propionate, respectively during PKS initiation. As discussed above, GilOIV, GilOI and
GilOII catalyze an oxygenase cascade leading to an acid-aldehyde intermediate while
GilOIII installs the vinyl side chain by oxidizing the C8 ethyl side chain. Further
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modification by O-methyltransferases producing 84-86 and subsequent C-glycosylation
by GilGT creates the pre-gilvocarcins (75-77). Finally, oxidation of the hemi-acetal by
GilR produces the lactone found in gilvocarcins (49-51).

Summary
Polyketides comprise one of the largest and most structurally diverse groups of
natural products with examples found in use throughout the pharmaceutical and
agricultural industries. Biosynthetic research is focused on understanding the genetic and
biochemical basis for unique architecture found among natural products.

This

understanding has paved the way for combinatorial biosynthetic approaches to rationally
design natural products with modified structural features not possible or extremely
difficult through traditional chemical synthesis. Synthetic routes toward large natural
products are extremely difficult and are made even more complex when the natural
product contains one or more sugar moieties, as in gilvocarcin V (49) or mithramycin
(23). Our lab has been primarily focused on understanding and modifying, through
combinatorial biosynthesis, the biosynthetic pathway of gilvocarcin V. This has led to
extensive in vivo and in vitro experimentations which have allowed the functional roles
of many individual genes to be determined. Almost all of the biosynthetic knowledge of
gilvocarcin has come through inactivation experiments. This has led to several shunt
products which give indirect support for the role of the inactivated gene. Despite rigorous
efforts, however, there are still many elusive biosynthetic steps that remain to be solved.
For example, the genetic determinant for utilization of either acetate or propionate during
gilvocarcin biosynthesis remains unknown. As gilvocarcin V is the active congener
among gilvocarcins, it would be ideal to engineer a strain that produces only gilvocarcin
V and therefore does not waste valuable biosynthetic building blocks toward the
production of gilvocarcin M and E. A complete characterization of the putative genes,
gilP and gilQ, involved in acyl-unit incorporation during GV biosynthesis would provide
a means to rationally engineer a strain with increased GV production.
A complete understanding of the biosynthetic machinery of the gilvocarcin pathway
provides the foundation for our ultimate goal, which is to create gilvocarcin V analogues
with improved pharmaceutical properties.

In this context, we have focused on the
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glycodiversification of gilvocarcin V, as discussed earlier, through probing the substrate
flexibility of GilGT.

This approach has produced a small library of gilvocarcin V

analogues with comparable or improved biological activity. The narrow donor substrate
flexibility of GilGT limits its use as a combinatorial biosynthetic tool towards further
expanding the library of glycosylated GV analogues. The creation of an engineered
glycosyltransferase or the identification of a GilGT-like glycosyltransferase with
improved substrate flexibility would therefore be greatly beneficial toward our
combinatorial biosynthetic aims. In this context, we are also interested in the sugar
moieties effect on the biological activity of GV as well as of and any other members of
the gilvocarcin-like aryl C-glycosides. To date, there has not been an extensive structureactivity-relationship (SAR) study concerning each individual position of any gilvocarcin
like aryl C-glycoside sugar moiety, despite their required presence for antitumor activity.
The only such study involved synthetic derivatization of the 2′ and 4′ positions of
ravidomycin V (53).102

Specific Aims
The objectives of this research study were to, (a) expand the glycodiversity of GV
analogues by identifying/engineering gilvocarcin-like glycosyltransferases with improved
substrate flexibility; (b) to create O-methylated-L-rhamnose derivatives of polycarcin V
(61) for sugar oriented SAR studies; c) to determine the enzymes involved in unique
starter unit incorporation during GV (49) biosynthesis; and d) to design a plasmid based
system in which to produce gilvocarcin pathway intermediates. To achieve these goals,
the following four specific aims were addressed:

Specific Aim 1a: Create engineered C-glycosyltransferases through domain swapping
using gilGT, chryGT and ravGT.
Specific Aim 1b: Identify the polycarcin V pathway specific glycosyltransferase and
explore its donor substrate flexibility.
Creation or identification of a C-glycosyltransferase with improved donor substrate
flexibility will provide a powerful biosynthetic tool for further glycodiversification of GV
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and will shed light on the viability of domain swapping as a useful approach in
engineering C-glycosyltransferases.

Specific Aim 2: Utilize L-rhamnose-O-methyltransferases from elloramycin (ElmMII
and ElmMIII) and steffimycin (StfMII) biosynthesis to create O-methylated-L-rhamnose
analogues of polycarcin V.
Modification of L-rhamnose in polycarcin V will allow for an SAR study focused on
the individual functional groups of the sugar moiety and their role in conferring
biological activity. Insights gained through such a study would provide information for
more rationally guided attempts to improve the biological activities of gilvocarcin-like
aryl C-glycosides.

Specific Aim 3a: Characterize the putative MCAT, gilP, and acyltransferase, gilQ,
from gilvocarcin V biosynthesis in vivo.
Specific Aim 3b: Characterize the putative MCAT, GilP, and acyltransferase, GilQ,
from gilvocarcin V biosynthesis in vitro.
Understanding the role of GilP and GilQ in starter unit specificity may lead to
metabolic engineering of strains that produce only the active gilvocarcin V congener. In
addition, the use of a propionate starter unit, as in GV biosynthesis, is rare among type II
PKS natural products and understanding the enzyme/s responsible for this incorporation
may be used as a combinatorial biosynthetic tool to engineer other type II PKS pathways
to utilize a propionate starter unit.

Specific Aim 4: Design a plasmid based approach to produce proposed gilvocarcin V
pathway intermediates using genes from the gilvocarcin biosynthetic cluster.
An in vivo method to produce proposed gilvocarcin V pathway intermediates could
provide valuable insights into the biosynthesis of GV as well as a means to obtain
substrates for in vitro characterization of putative enzyme remaining in the GV cluster.
These results could also provide a means to delineate the entire gilvocarcin pathway by
shuffling various biosynthetic genes and determining the consequences of adding or
removing an individual gene.
Copyright © Micah Douglas Shepherd 2011
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Chapter 2: Glycodiversification of Gilvocarcin V
2.1 Engineering chimeric glycosyltransferases
As discussed previously, glycosylation is often a crucial requirement for the activity
of bioactive natural products. Glycosyltransferases therefore hold significant promise as
a combinatorial biosynthetic tool.

Presently, there are over 40,000 putative

glycosyltransferases within the NCBI gene databank, but only a small portion of these
GTs have been experimentally investigated. The biggest restriction for the use of
glycosyltransferases in combinatorial approaches is their common strict inherent
substrate specificity.

This has led to an explosion in glycosyltransferase structural

biology and enzymology research, focused on ultimately broadening this substrate
specificity.103
The glycosylation reaction during the biosynthesis of gilvocarcin is catalyzed by
GilGT, a C-glycosyltransferase utilizing presumably TDP-D-fucofuranose (47) as its
donor substrate. It is still possible that TDP-D-fucose (95) may first be attached and
converted to 47 after the glycosyltransferase reaction. Previous inactivation of the
deoxysugar 4-ketoreductase encoding gene, gilU, resulted in the formation of 4′-hydroxy
gilvocarcin V (81) which was found to be more active than the parent gilvocarcin V
compound (49).85 These results automatically placed GilGT in an elite class of Cglycosyltransferases, accompanied only by UrdGT2 (from urdamycin biosynthesis), with
marginal substrate flexibility. The donor substrate specificity of GilGT was further
explored by co-expressing plasmids encoding deoxysugar genes toward to the
biosynthesis of a particular deoxysugar (referred to as deoxysugar plasmids) with the
ΔgilU mutant cosmid, cosG9B3-GilU-.

The ΔgilU strain was used in lieu of the

unmodified cosG9B3 cosmid because it does not produce the natural donor substrate,
TDP-D-fucofuranose (47), and instead produces TDP-4-OH-fucofuranose (94). The low
production yields of 81-83 accumulated through heterologous expression of cosG9B3GilU- revealed that 94 was in fact accepted by GilGT, but at a much reduced rate when
compared to the natural donor substrate, 47. This provided a suitable, albeit not ideal,
host in which exogenous deoxysugar genes could be expressed to produce specific
deoxysugars that could then compete with 47 for GilGT activity. These experiments
resulted in the successful glycosylation with only TDP-D-olivose (109) and TDP-L33

rhamnose (112) producing D-olivosyl gilvocarcins (87-89) and polycarcins (61, 90 and
91), respectively; despite attempting a range of various deoxysugars including D- and Lbranched, amino and neutral deoxysugars.48 These results exhausted the use of GilGT to
further glycodiversify gilvocarcins as it seems to lack the broad substrate specificity
needed to truly expand the library of gilvocarcin analogues.

A possible route to

overcome this problem would be to engineer substrate flexibility into GilGT.
There are only a handful of examples showing the successful generation of functional
engineered O-glycosyltransferases through various methods including directed evolution,
“hot spot” mutagenesis and domain swapping.104-111 Directed evolution was used to
improve the substrate flexibility of the naturally flexible glycosyltransferase OleD,
involved in self resistance in the oleandomycin (48) pathway, by increasing its tolerance
for the fluorescent surrogate acceptor 4-methylumbelliferone (96) (Figure 20).33,104,111-112
Specifically, a small library of OleD variants were identified with improved ability to
produce 4-methyl-umbelliferyl β-D-glucopyranoside (97). Three mutants were identified
and the mutations were subsequently recombined to produce a triple mutant with marked
improvement in substrate flexibility. Later a “hot spot” saturation mutagenesis approach
was used in which the previously identified hot spots underwent single-site saturation
mutagenesis producing several libraries modified at the individual hot spot positions.106
High-throughput screening with the fluorescent 96 identified mutations showing
improved activity. The most active mutations were combined to produce an OleD variant
showing 150-fold improvement compared to wild type OleD.106 These results show the
promise of directed evolution and “hot spot” mutagenesis for improving GT activity,
however, the apparent downside is the lack of high-throughput screening possibilities for
a majority of natural product glycosyltransferases, including GilGT. The successful
engineering of OleD was facilitated by the ability to visualize, through fluorescence, the
glycosyltransferase reaction. The activity of OleD could quickly be assessed by the loss
of fluorescence exhibited by following the OleD catalyzed conversion of 96 to 97.
Unfortunately, this procedure can not be broadly applied to other GTs due to their
inability to glycosylate compounds applicable for colorimetric assays.
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Figure 20. Broadening OleD substrate specificity. (A) Wild-type role of OleD during
oleandomycin biosynthesis. (B) Directed evolution of OleD towards increased tolerance
toward 96. (C) Further optimization by “hot spot” saturation mutagenesis increases
substrate flexibility.
Domain swapping is an approach in which the substrate binding domains of a
particular glycosyltransferase are swapped with an alternative substrate binding domain
from a second glycosyltransferase.

This approach is based on the findings that

glycosyltransferases have distinct acceptor (N-terminal) and donor (C-terminal)
recognition domains which are connected by a linker loop region.113-116 Successful
glycosyltransferase domain swapping experiments have produced novel natural products
including urdamycin P (98) and several vancomycin derivatives (99-106).

107,109

The

production of hybrid vancomycin derivatives were achieved by swapping the N- and Ctermini between GtfA (chloroorienticin) and Orf1 (teicoplanin) which are responsible for
the

attachment

of

TDP-epi-vancosamine

and

UDP-N-acetylglucosamine

to

desvancosaminyl vancomycin (107) and teicoplanin glucosaminyl-pseudoaglycone (108),
respectively. One resultant chimeric glycosyltransferase, GtfAH1 (N-terminal GtfA, C35

terminal Orf1) was shown to attach UDP-glucose and UDP-N-acetylglucosamine to an
array of acceptor substrates producing novel vancomycin derivatives (Figure 21).109
These results showed that domain swapping was able to successfully increase substrate
tolerance compared to wild type GtfA and Orf1.
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Figure 21. Examples of domain swapping to increase GT substrate flexibility. (A)
Natural glycosylation function of Orf1 and GtfA in teicoplanin and chloroorienticin
biosynthesis, respectively. (B) Novel vancomycin analogues produced through the
chimeric glycosyltransferase GtfAH1 (N-term. GtfA, C-term. Orf1). (C) Structure of
urdamycin P, a new natural product produced through an engineered glycosyltransferase.
The recent isolation and characterization of the biosynthetic gene clusters for
ravidomycin V (53) and chrysomycin V (52) provided two additional gilvocarcin-like Cglycosyltransferases that could be utilized for a domain swapping approach to create
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substrate flexible C-glycosyltransferases.117 RavGT (ravidomycin) and ChryGT
(chrysomycin) are responsible for the attachment of an amino sugar and branched sugar,
respectively (Figure 22).

This is important as ChryGT is the only known C-

glycosyltransferase responsible for branched sugar (D-virenose) attachment and RavGT is
only the second known amino sugar (D-ravidosamine) transferring C-glycosyltransferase
besides Med-ORF8 (D-angolosamine) from medermycin biosynthesis.118 Amino sugar
attachment is particularly intriguing as amino sugars can improve solubility as well as
provide useful functionality for drug formulations. Surprisingly, RavGT and not ChryGT
was able to restore gilvocarcin production when complementing the GilGT deficient
mutant S. lividans TK24/cosG9B3-GilGT-.117

Figure 22. Structures of gilvocarcin, chrysomycin and ravidomycin.

Experimental design
In specific aim 1a, six chimeric glycosyltransferases will be constructed through
domain swapping between gilGT, chryGT and ravGT. Resulting chimeras will initially
be screened for functionality by co-expressing them with the cosG9B3-GilGT- mutant in
S. lividans TK24 and accessing their ability to restore gilvocarcin E (51) production.
Successful complementation of the gilGT deletion mutant does not produce the expected
gilvocarcin V (49) congener, and instead produces 51 because of a polar effect on the
downstream gilOIII gene responsible for converting the ethyl side chain to the vinyl side
chain.42 The chimeric glycosyltransferases will also be cloned into nine deoxysugar
plasmids directing the biosynthesis of various structurally diverse deoxysugars. These
plasmids will then be co-expressed with cosG9B3-GilGT- in S. lividans TK24 to probe
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their substrate flexibility. All recombinant strains will be fermented and metabolites will
first be screened on a small scale using high-performance liquid chromatography - mass
spectrometry (HPLC-MS). Promising candidates will then be scaled up and metabolites
will be isolated through chromatographic techniques and their structures will be
elucidated through spectroscopic characterization using nuclear magnetic resonance
(NMR), MS and ultraviolet-visible spectroscopy (UV-Vis).
Results
Construction of chimeric glycosyltransferases
Initial amino acid sequence comparison of gilGT, chryGT and ravGT revealed
chryGT and ravGT to be extremely similar (88%/73% amino acid similarity/identity).
The identity was reduced to 39% when gilGT was added to the alignment, possibly due to
the donor substrate preferences of GilGT (furanose) vs. ChryGT and RavGT (pyranose).
This was further explored by aligning the individual termini of each glycosyltransferase.
Again the addition of gilGT domains reduced the overall identity as ravGT and chryGT
identities were 77% and 68% compared to 44% and 35% with gilGT for N- and Cterminals, respectively. As GilGT, ChryGT and RavGT utilize different donor substrates
for the same aglycone acceptor it is expected that the N-terminals will show higher
similarities than the C-terminals; however, the differences are significantly higher when
comparing two GTs that transfer a furanose and a pyranose sugar (RavGT or ChryGT and
GilGT) as opposed to two pyranose sugar transferring GTs (RavGT and ChryGT).
Further

bioinformatical

analysis

using

SEARCHGTr

(http://www.nii.res.in/searchgtr.html) revealed the putative linker region for each
glycosyltransferase (solid box in Figure 23).119
(151)
GilGT(151)
ChryGT(151)
RavGT(151)

151

160

170

180

190

200

210

225

LEEMADELARIGSDALPDPSLKIDICPPGLVG--A-TGTFMRWTPHNMQRAIEPWMLTAPDAGRVCLTMGSFRYA
NDELAPELAQAGLERLPAPDLFIDICPPSLIPPGAERGRPMRWVPGNRQRKLEPWMYGKGERARVCVTLGSFRTA
AEELAPELERLGLAELPAPDMFLDICPPSLLPSFATPGRPMRWVPGNRQRSLEPWMYTKGERPRICVTYGSFRTA

Figure 23. Amino acid alignment of gilGT, chryGT and ravGT. The figure shows the
putative linker region (solid boxes) and the shuffling point (dotted box) for preparing the
chimeric glycosyltransferases.
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The linker region was the original site of interest for introducing a unique
restriction site for domain swapping.

The introduction of a restriction site would

inevitably alter one or more amino acid residues, and due to the highly conserved nature
of the linker region it was decided to instead focus on a small upstream region (toward Nterminal) with less conserved residues (dotted box in Figure 23). Using the polymerase
chain reaction (PCR), each glycosyltransferase was amplified as two fragments
individually covering the N- and C-terminals, respectively (Figure 24, step 1-2). Each
fragment was designed to contain an engineered NheI restriction site at the N- and Cterminal interface by altering the nucleotide sequence of the amino acid represented in
the dotted box shown in Figure 24. These modifications altered only two amino acids in
the GilGT sequence (ATG to ALA), one amino acid in the ChryGT sequence (PGA to
PLA) and one amino acid in the RavGT sequence (SFA to SLA). The resulting PCR
amplified fragments were cloned into PCR-Blunt II-TOPO (Invitrogen) and subsequently
combined to form intact glycosyltransferases as depicted in Figure 24, steps 3-4 (see
experimental section for further details). The successful combination of domains from
three individual glycosyltransferases produced six chimeric glycosyltransferases
designated cGT-CG, cGT-CR, cGT-GC, cGT-GR, cGT-RC and cGT-RG. The parent
glycosyltransferase contributing the N-terminal of the newly generated chimeric
glycosyltransferase (cGT) is signified by C (ChryGT), G (GilGT) or R (RavGT) followed
by the parent glycosyltransferase composing the C-terminal. For example, cGT-CG is
comprised of an N-terminal and C-terminal from ChryGT and GilGT, respectively.
Sequencing confirmed the expected sequence for each engineered glycosyltransferase.
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Figure 24. Representation of chimeric glycosyltransferase preparation (steps 1-4).
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In order to express the newly constructed glycosyltransferases in Streptomyces,
the GTs must be moved into a Streptomyces expression vector, such as pEM4.112
Through restriction digests the chimeric GTs were transferred into pEM4 downstream of
the constitutively activated erythromycin resistance promoter ermE*p (Figure 25, step
5). Finally, the intact chimeric glycosyltransferases were removed from pEM4 with
ermE*p and placed into nine individual sugar plasmids (Figure 25, step 6).

Figure 25. Representation of chimeric glycosyltransferase preparation (steps 5-6).
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Initial chimeric glycosyltransferase screening
Each engineered glycosyltransferase, cGT-CG, cGT-CR, cGT-GC, cGT-GR,
cGT-RC and cGT-RG was transformed via protoplast transformation into S. lividans
TK24/cosG9B3-GilGT- and screened for the reconstitution of gilvocarcin E (51)
production. Ideally, the engineered glycosyltransferases should be tested in RavGT- and
ChryGT-minus mutants. Unfortunately, these mutants do not exist making it nearly
impossible to truly test if the newly constructed GTs retain parental functionality. By
using S. lividans TK24/cosG9B3-GilGT-, parental functionality can only be tested for
cGT-CG and cGT-RG which both contain the sugar binding domain of GilGT. To some
extent this can also be tested for cGT-CR and cGT-GR as RavGT was observed to accept
TDP-D-fucofuranose, albeit at a much reduced rate. In this context, reconstitution of 51
biosynthesis by any of the cGTs, other than cGT-CG and cGT-RG, will indicate
improved donor substrate flexibility.
The fermentation of all recombinant strains revealed only S. lividans
TK24/cosG9B3-GilGT-/cGT-CR was able to transfer TDP-D-fucofuranose (47) (Figure
26). This was confirmed by the presence of 50 and 51 through UV-Vis and electrospray
ionization mass spectrometry (ESI-MS). Surprisingly, both constructs which contained
the C-terminal domain of GilGT failed to complement the strain. In addition, the activity
of cGT-CR and not cGT-GR was unexpected. Both constructs contain the C-terminal
domain of RavGT, which is known to accept TDP-D-fucofuranose, and differ in only
their N-terminal domains. It was expected that cGT-GR would restore 51 production as
both domains are from glycosyltransferases that can themselves restore gilvocarcin
biosynthesis. Likewise, cGT-RG contains the opposite shuffling pattern of cGT-GR and
was also unable to transfer TDP-D-fucofuranose.
Complete characterization of the products from S. lividans TK24/cosG9B3-

GilGT /cGT-CR confirmed the structures to be that of 50 and 51. The structures were
confirmed by NMR to eliminate the possibility of TDP-D-fucose (95) transfer, and not
TDP-D-fucofuranose (47) whose resulting products would be indiscernible from mass
and UV-Vis data alone. TDP-D-fucose (95) undergoes ring contraction by an as of yet
undetermined enzyme to produce TDP-D-fucofuranose (47) (Figure 18). The lack of a
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putative ring contracting enzyme in the gil cluster has prompted several hypotheses to
explain the generation of TDP-D-fucofuranose, including the hypothesis that GilGT may
itself catalyze ring contraction of TDP-D-fucose before glycosylation. These results
suggest ring contraction occurs separately from GilGT, and is more likely catalyzed by
one of the few remaining uncharacterized gil genes or from an endogenous Streptomyces
enzyme that is recruited by the gilvocarcin biosynthetic machinery.

gilvocarcin M (50)
gilvocarcin E (51)

defuco-gilvocarcin E (80)
defuco-gilvocarcin M
(79)

Figure 26. HPLC chromatogram trace of S. lividans TK24/cosG9B3-GilGT-/cGT-CR.

Chimeric glycosyltransferase and donor substrate flexibility
Each chimeric GT was transferred into individual sugar plasmids designed to
produce TDP-D-olivose (109), TDP-L-olivose (110), TDP-L-digitoxose (43), TDP-Lrhodinose (111), TDP-L-rhamnose (112), TDP-4-amino-4,6-dideoxy-D-glucose (113),
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TDP-L-daunosamine (114), N,N-didemethyl-TDP-D-desosamine (115) or TDP-3-keto4,6,-dideoxy-D-glucose (116) (Figure 27). The resulting 54 constructs (see Table 1) were
transformed into S. lividans TK24/cosG9B3-GilGT- via protoplast transformation and
were subsequently screened for the production of novel gilvocarcin analogues.

Figure 27. Deoxysugars produced by various sugar plasmids utilized in this study.

As expected, several cGT-CR containing sugar plasmids successfully produced
gilvocarcin E (m/z = 498, observed m/z = 497 in negative mode ESI-MS) as shown in S.
lividans TK24/cosG9B3-GilGT-/pLNRHO-CR (Figure 28). Interestingly, the analysis of
S. lividans TK24/cosG9B3-GilGT-/pDesI-CR revealed three new peaks with UV-Vis
profiles consistent with the gilvocarcin chromophore (Figure 29).

Due to the low

production yields of the three new peaks, we were unable to obtain clear mass data from
the initial fermentation sample.

To further characterize the new compounds the

fermentation of S. lividans TK24/cosG9B3-GilGT-/pDesI-CR was repeated in large scale.
Unfortunately, subsequent fermentations did not contain the previously observed
gilvocarcin analogues.

The sugar plasmid pDesI contains the deoxysugar genes

responsible for the production of the amino sugar NDP-4-amino-4,6-dideoxy-D-glucose
(113). If successfully transferred, it would be expected to have a shorter retention time
than that of 49 because of the added amino functionality of 113. As the gilGT deficient
strain can only produce gilvocarcin compounds with methyl and ethyl side chains, the
presence of three peaks in S. lividans TK24/cosG9B3-GilGT-/pDesI-CR was unexpected.
It is possible that the peak at 14.0 minutes does not actually correspond to a gilvocarcin
analogue at all and the UV-Vis signature observed is from an overlap in the previous
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peak at 13.8 minutes. Alternatively, the close proximity of two peaks at 13.8 and 14.0
minutes may be hiding a smaller peak that elutes during this time frame which would
indicate the transfer of two different donor substrates to two different aglycones, namely
gilvocarcin M and gilvocarcin E.
Interestingly, two additional sugar plasmid/chimeric GT constructs reconstituted
the natural gilvocarcin pathway, even though preliminary results indicated they were
unable to utilize TDP-D-fucofuranose.

S. lividans TK24/cosG9B3-GilGT-/pLNR-CG

(Figure 30) and S. lividans TK24/cosG9B3-GilGT-/pLN2-RG (Figure 31) both produced
a single compound with the same retention time (~14.7 minutes), UV-Vis spectrum and
mass of gilvocarcin E (m/z = 498, observed m/z = 497 in negative mode ESI-MS). These
results prove two additional chimeric glycosyltransferases are indeed functional;
however, it is unclear why the cGT-CG and cGT-RG constructs were unable to
complement cosG9B3-GilGT- mutant upon initial screening, when they obviously
retained the ability to do so.
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gilvocarcin E (51)

Figure 28. HPLC chromatogram trace of S. lividans TK24/cosG9B3-GilGT-/pLNRHOCR. This figure also includes the UV-Vis spectrum and mass data of a single peak at 14.6
min.
47

gilvocarcin analogues??

Figure 29. HPLC chromatogram trace of S. lividans TK24/cosG9B3-GilGT-/pDesI-CR.
This figure also shows the UV-Vis spectrum of three individual peaks designated with
stars.
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gilvocarcin E (51)

Figure 30. HPLC chromatogram trace of S. lividans TK24/cosG9B3-GilGT-/pLNR-CG.
This figure also includes the UV-Vis spectrum and mass data of a single peak at 14.75
min.
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gilvocarcin E (51)

Figure 31. HPLC chromatogram trace of S. lividans TK24/cosG9B3-GilGT-/pLN2-RG.
This figure includes the UV-Vis spectrum and mass data of a single peak at 14.75 min.
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One underlying issue throughout these experiments were the unpredictable expression
levels of gilvocarcin intermediates produced by the host S. lividans TK24/cosG9B3GilGT-. This can be monitored by the accumulation of defuco-gilvocarcin M (79) and E
(80) as these are shunt products of the biosynthetic pathway. In most cases, multiple
colonies of the chimeric GT containing recombinant strains had to be screened in order to
find a single colony producing 79 and 80 in observable quantities.

The typical

production of 79 and 80 produced from these strains were low, indicating poor expression
of the cosmid cosG9B3-GilGT-.
A double inactivation experiment was designed to increase the expression levels of
cosG9B3-GilGT- in which the repressor gene gilI was inactivated in addition to gilGT
through Redirect PCR Targeting.120 Inactivation of gilI was previously found to increase
the production yields of gilvocarcins (unpublished results by L. Zhu), therefore it was
hypothesized that inactivation of both gilI and gilGT would similarly increase the
production of defuco-gilvocarcins (78-80). Construction and subsequent expression of
the double inactivated cosmid, cosG9B3-GilI-GilGT- (Figure 32), in S. lividans TK24,
failed to produce defuco-gilvocarcins despite several colony screening attempts (data not
shown).

1.5 kb
1.0 kb
0.5 kb

Figure 32. PCR confirmation of double inactivation in cosG9B3-GilI-GilGT-. The
inactivation of gilI (~1 kb) was confirmed using primers that were flanking its coding
sequence by ~100 bp. These primers were used to amplify gilI from (A) cosG9B3 and
(B) cosG9B3-GilI-GilGT- templates. The small band in lane B is indicative of an FRT
scar left after gene inactivation. This process was repeated using primers that flank the
coding sequence of gilU by ~100 bp. The results are shown in lanes (C) cosG9B3 and
(D) cosG9B3-GilI-GilGT-.
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Discussion
In order to further broaden the glycodiversity of gilvocarcin-like aryl Cglycosides, a domain swapping approach was used to create six chimeric
glycosyltransferases utilizing the N- and C- terminal domains from GilGT, ChryGT and
RavGT. The resulting engineered glycosyltransferases, cGT-CR, cGT-CG, cGT-GC,
cGT-GR, cGT-RC and cGT-RG, were transformed into S. lividans TK24/cosG9B3GilGT- to evaluate their ability to transfer TDP-D-fucofuranose, the natural donor
substrate for GilGT.

In addition, each engineered glycosyltransferase was also placed

into nine sugar plasmids and again co-expressed with cosG9B3-GilGT- in S. lividans
TK24 to investigate their donor substrate promiscuity.

Together these experiments

clearly identified three functional chimeric C-glycosyltransferases, cGT-CR, cGT-CG
and cGT-RG, able to transfer TDP-D-fucofuranose. Preliminary results suggest that cGTCR may also be able to transfer NDP-4-amino-4,6-dideoxy-D-glucose (113).
Unfortunately, this study did not result in the isolation of novel gilvocarcin analogues;
however, cGT-CR, cGT-CG and cGT-RG are the only examples, to date, of functional
chimeric C-glycosyltransferases. Ultimately, the ability to test the natural donor
substrates for RavGT (TDP-D-ravidosamine (46)) and ChryGT (TDP-D-virenose (44))
would have been beneficial as it would have allowed for complete parental functionality
testing of the chimeric GTs, and would have provided further evidence that rational
glycosyltransferase engineering is possible through domain swapping.
As previously discussed the expression levels of S. lividans/cosG9B3-GilGTwere unpredictable and poor. This provided a restricted host for the screening of possible
substrate flexible glycosyltransferases. The prospect of an overproducing GilGT deficient
strain was exciting as it would have provided much more acceptor substrate for the
chimeric GTs to utilize, therefore producing larger quantities of glycosylated product.
This led to the generation of cosG9B3-GilI-GilGT-, a double mutant lacking the
gilvocarcin biosynthetic repressor gene, gilI, and gilGT in hopes of increasing defucogilvocarcin yields.

The expression of cosG9B3-GilI-GilGT- in S. lividans TK24,

however, did not produce defuco-gilvocarcin or any gilvocarcin intermediates. This limits
the practicality of further chimeric glycosyltransferase testing utilizing this screening
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method. The model in vivo vehicle for continued GT screening would only produce the
acceptor substrate of gilvocarcin V and lack genes for the biosynthesis of TDP-Dfucofuranose, thereby removing donor substrate competition when endogenous
deoxysugars are presented to the system. The competing deoxysugar pathways of TDPD-fucofuranose

and those encoded by deoxysugar biosynthetic genes on the sugar

plasmids could be an important factor in the inability of the chimeric glycosyltransferases
to produce novel gilvocarcin analogues. The biosynthesis of TDP-D-fucofuranose only
requires two steps, 4-ketoreduction and ring contraction, beyond the production of TDP4-keto-6-deoxy-D-glucose (42, Figure 18). 42 is the branching point for all deoxysugar
biosynthetic pathways utilized in this study. If the 4-ketoreductase, GilU, present in
cosG9B3-GilGT- is able to sequester a majority of 42 before the exogenous deoxysugar
biosynthetic genes can catalyze their pathway specific reactions, little to no exogenous
deoxysugars will be present for the chimeric glycosyltransferase to transfer.

This

underscores the need for an improved screening host and is a contributing factor for
designing specific aim 4.

Materials and Methods
Bacterial strains, culture conditions and plasmids
All complementation experiments were carried out in the heterologous host S.
lividans TK24.121 The mutant cosmid cosG9B3-GilGT- was introduced into S. lividans
TK24 through conjugal transfer according to standard protocols producing S. lividans
TK24/cosG9B3-GilGT-.122 Conjugation was carried out on MS agar (20 g/L mannitol, 20
g/L soya flour and 20 g/L agar) supplemented with 10 mM MgCl2 and overlaid with
nalidixic acid with appropriate antibiotics after 18 hours. Ex-conjugates were grown on
solid M2 media (4 g/L glucose, 10 g/L malt extract, 4 g/L yeast extract, 1g/L CaCO 3 and
15 g/L agar) supplemented with appropriate antibiotics. S. lividans TK24/cosG9B3GilGT- was transformed via protoplast transformation with cGT-CR, cGT-CG, cGT-GC,
cGT-GR, cGT-RC, cGT-RG and all 54 sugar plasmid/chimeric glycosyltransferase
constructs according to standard protocols.122 Protoplasts were regenerated on R2YE agar
media and overlaid after 18 hours with R3 soft agar supplemented with appropriate
antibiotics.122 Regenerated protoplasts were transferred to solid M2 agar supplemented
53

with appropriate antibiotics. For a comprehensive list of strains and plasmids used in this
study refer to Table 1. Lysogeny broth (LB) was utilized for growing Escerichia coli (E.
coli) strains throughout this study.
When antibiotics/antifungals were required for strain selection, 100 µg/mL of
ampicillin, 50

µg/mL of apramycin, 25 µg/mL of thiostrepton,

50

µg/mL of

chloramphenicol, 50 µg/mL of kanamycin and 25 µg/mL nalidixic acid was used.

Table 1. Strains and plasmids used in the chimeric glycosyltransferase study.
Strain/Plasmid
E. coli XL1-Blue-MRF
E. coli ET12567/pUZ8002
PCR-Blunt II-TOPO
pEM4
cosG9B3
cosRav32
cosChry1-1
cosG9B3-GilGTS. lividans TK24 (SLTK24)
S. lividans TK24/cosG9B3-GilGTcGT-CG
cGT-CR
cGT-GC
cGT-GR
cGT-RC
cGT-RG
pLNR-CG, CR, GC, GR, RC, RG
pLN2-CG, CR, GC, GR, RC, RG
pRHAM-CG, CR, GC, GR, RC, RG
pLNBIV-CG, CR, GC, GR, RC, RG
pDMN-1-CG, CR, GC, GR, RC, RG
pLNRHO-CG, CR, GC, GR, RC, RG
pDesI-CG, CR, GC, GR, RC, RG
pDesII-CG, CR, GC, GR, RC, RG
pDesIII-CG, CR, GC, GR, RC, RG
SLTK24/cosG9B3-GilGT-/all GTs

Characteristics and relevance
Host for routine cloning
Host for conjugal transfer
PCR fragment cloning vector
Streptomyces expression vector
Template for gilGT
Template for ravGT
Template for chryGT
gilGT deficient mutant
Streptomyces heterologous host
Host for screening chimeric GTs
Chimeric GT in pEM4
Chimeric GT in pEM4
Chimeric GT in pEM4
Chimeric GT in pEM4
Chimeric GT in pEM4
Chimeric GT in pEM4
(6x) Chimeric GT in pLNR
(6x) Chimeric GT in pLN2
(6x) Chimeric GT in pRHAM
(6x) Chimeric GT in pLNBIV
(6x) Chimeric GT in pDMN-1
(6x) Chimeric GT in pLNRHO
(6x) Chimeric GT in pDesI
(6x) Chimeric GT in pDesII
(6x) Chimeric GT in pDesIII
(60x) recombinant strains
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Fermentation and metabolite screening
Each recombinant strain was grown in a single 250 mL baffled Erlenmeyer flask
containing 100 mL of liquid SG media (20 g/L glucose, 10 g/L soy peptone, 2 g/L
CaCO3, 0.001 g/L cobalt-II-chloride, pH 7.2) with appropriate antibiotics. After five
days of fermentation at 28 oC with reciprocal shaking (250 rpm) 25 mL of the
fermentation broth was extracted 1:1 with ethyl acetate. The organic phase was separated
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and removed under vacuum. The dried extract was reconstituted with 500 µL of methanol
and screened on an HPLC-MS consisting of a Micromass ZQ 2000 (Waters) equipped
with HPLC (Waters Alliance 2695) and a photodiode array detector (Waters 2996). The
HPLC utilized a Symmetry C18 (4.6 x 250 mm, 5 µm) column running a linear gradient
of acetonitrile and acidified water at a flow rate of 0.5 mL/min (solvent A= 0.1% formic
acid in H2O; solvent V = acetonitrile; 0-15 min. 25% B to 100% B; 16-24 min. 100% B;
25-26 min. 100% to 25% B; 27-29 min. 25% B).

DNA isolation, DNA manipulation and PCR
Plasmid DNA isolations were conducted using GeneJet Plasmid mini-prep kits
(Fermentas).

All restriction endonuclease digestions, alkaline phosphate treatments,

ligations, and other DNA manipulations were performed according to standard
protocols.125 Native Pfu polymerase (Stratagene) was used to amplify each domain from
gilGT, ravGT and chryGT from cosG9B3, cosRav32 and cosChry1-1, respectively.91,117
Oligonucleotide primers used in this study are summarized in Table 3. A typical reaction
consisted of the following:
1 µL DNA template (~50-100 ng)
1 µL Forward primer (~200-250 ng)
1 µL Reverse primer (~200-250 ng)
1 µL dNTPs (10 mM)
5 µL Native Pfu buffer (10x)
2.5 µL DMSO
37.5 µL Distilled water (dH2O)
1 µL Native Pfu polymerase (2.5 U/µl)
PCR reactions were carried out on a TechGene thermal cycler (Techne) with
typical cycling conditions summarized in Table 2.

Table 2. PCR cycling conditions for Native pfu polymerase amplification.
Step
Initial denaturation
Denaturation
Annealing
Extension
Final extension

Temperature
98 oC
94 oC
Primer TM – (5-10)
72 oC
72 oC
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Duration
5 min.
45 sec.
45 sec.
1.5 min./kb of target
10 min.

Cycles
1
25
1

Each glycosyltransferase was amplified as two fragments corresponding to the Nand C-terminal domains using forward (F) and middle reverse (MR) primer pairs as well
as middle forward (MF) and reverse (R) primer pairs, respectively. The resulting PCR
amplified fragments were gel purified using a QIAquick Gel Extraction Kit (Qiagen) and
cloned into PCR-Blunt II-TOPO (Invitrogen).

Table 3. Oligonucleotide sequence of primers used to amplify gilGT, ravGT and chryGT
domains.
Primer
GilGT-F
GilGT-MR
GilGT-MF
GilGT-R
RavGT-F
RavGT-MR
RavGT-MF
RavGT-R
ChryGT-F
ChryGT-MR
ChryGT-MF
ChryGT-R

Oligonucleotide sequence (5′-3′)
CTTCTCTAGACGCGACAAGGACCGGTCACGGGAGGG
GGTGGCTAGCGCCCCGACCAGGCCGGGCGGGCAGAT
GCGCTAGCCACCTTCATGCGCTGGACCCCGCAC
TGGGGATGCATCGAATTCGAAAGCTTCGCTTCATCCTTTCCGCGCGAGGAG
CTGTCTAGACGACGGCCCCGACCCTACGGAGAA
CGTCGCTAGCGACGGGAGGAGGCTCGGGGGCAGAT
TCGCTAGCGACGCCCGGCCGCCCCATGCGCTGG
CGTCGGATGCATTGGAATTCGAAGCTTGCTGGCTCACCGAGAGGGTGCTCATCC
CGCGCTCTAGAGGGTGGCCAGCCCCGAAGGAGCAGC
CTCGGCTAGCGGCGGGATCAGGCTCGGCGGGCAGAT
CCGCCGCTAGCCGAGCGCGGCCGGCCGATGAGATGG
CCGGATGCATCGAATTCCAAGCTTTGGTGGGCCGGTGGCACGGGGTCAGCG

Cloning and preparation of chimeric glycosyltransferases
A general cloning strategy used for domain swapping of gilGT, ravGT and
chryGT is summarized in Figures 24 and 25. Through primer design, the amplification of
each N-terminal domain created a XbaI site 30-40 nucleotides upstream of their start
codons which ensured the amplification of their putative ribosomal binding sites (RBS).
On the opposite side, a unique in-frame NheI restriction site was engineered into the
sequences of each glycosyltransferase as described previously. The N- and C-terminals
of a given GT were amplified as two overlapping fragments that shared this NheI site
designed as the shuffling point for domain swapping. In this context, all C-terminal
domains also contained the in-frame NheI site. Immediately downstream of the stop
codon of each C-terminal a HindIII and EcoRI site were inserted for use in later cloning
strategies.
The resulting PCR amplified fragments were cloned into PCR-Blunt II-TOPO
vector which is used to quickly and easily clone and amplify blunt DNA fragments,
typically from PCR reactions.

Several TOPO clones were screened for fragment
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insertion as well as fragment orientation by SpeI/NheI (for C-terminal clones) and
NheI/EcoRV (for N-terminal clones) double digestion analysis.

Orientation was

confirmed because shuffling would occur by transferring the C-terminal domain from
their respective TOPO clones to various N-terminal containing TOPO clones. If the
orientations are in opposite directions the resulting shuffling would not create a
continuous open reading frame (ORF). These restriction analysis revealed six clones with
appropriate orientation; C1.1, G1.1, R1.19, C2.7, G2.2 and R2.4. The naming reflected
the parent GT, the domain and the exact colony screened. For example, R1.19 is R =
RavGT, 1 = N-terminal domain and 19 = colony number.
Shuffling was achieved by removing the C-terminal domains from C2.7, G2.2 and
R2.4 through NheI/EcoRV double digestion and ligating them into similarly prepared
C1.1, G1.1 and R1.19.

Screening the resulting constructs by EcoRI/XbaI double

digestion revealed 6 chimeric glycosyltransferases; CG.4, CR.6, GR.12, GC.6, RC.20 and
RG.2.

These were transferred to the Streptomyces expression vector pEM4 by

EcoRI/XbaI restriction digest and subsequent ligation into pEM4. Screening through
HindIII digestion analysis revealed six completed constructs; CG4.4, CR6.16, GR12.7,
GC6.16, RC20.7 and RG2.15. These pEM4 constructs were renamed to cGT-CG, cGTCR, cGT-GR, cGT-GC, cGT-RC and cGT-RG, respectively.
The six chimeric glycosyltransferases were individually integrated into nine sugar
plasmids directing the biosynthesis towards nine structurally distinct deoxysugars (see
Table 4 and Figure 27). Each sugar plasmid was found to contain a single HindIII
restriction site which was used to transfer the intact chimeric glycosyltransferase
including the constitutively active promoter, ermE*p, from cGT-CG, cGT-CR, cGT-GR,
cGT-GC, cGT-RC and cGT-RG. The resulting 54 constructs contained a single chimeric
glycosyltransferase and deoxysugar biosynthetic genes for the generation of an activated
deoxysugar (see Table 4).
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Table 4. Sugar plasmids used in this study, and their expected deoxysugar product.
Sugar
NDP-D-olivose (109)
NDP-L-olivose (110)
NDP-L-rhamnose (112)
NDP-L-digitoxose (43)
NDP-L-daunosamine (114)

Plasmid
pLNR126
pLN2126
pRHAM46
pLNBIV126
pDMN-1a

Sugar
NDP-L-rhodinose (111)
NDP-4-amino-4,6-dideoxy-D-glucose (113)
NDP-3-keto-4,6-dideoxy-D-glucose (116)
N,N-didemethyl-NDP-D-desosamine (115)

Plasmid
pLNRHO126
pDesIa
pDesIIa
pDesIIIa

a

Unpublished plasmids constructed by M. Kharel

Nucleotide sequences of generated chimeric glycosyltransferases
The following sequences (5′-3′) represent the entire chimeric glycosyltransferases as
found in pEM4 between the restriction sites XbaI and EcoRI. The shuffling point (NheI)
is indicated as NNN while the remaining restriction sites, start codons and stop codons
are designated by NNN, NNN and NNN, respectively.

cGT-CG
TCTAGAGGGTGGCCAGCCCCGAAGGAGCAGCATGAAAGTCCTCTTCATCGCC
GCGGGAACGAGCCCGGCGGGGGTCTTCGCCCTCGCCCCTCTCGCGACGGCGG
TGCGCAACGCAGGGCACGAGATCCTGGTGGCGGCCTTCGACGAGCTGACCCC
GGCCGTCGCGTCCGTCGGACTGCCCGTCGTGGCCGTCGCCGACGGCCACACG
ACCGAGAGCATCAAGGGACTCGACCGGCCGGGCGGACCGATCGGGTTCCCCT
GGGCACCCGAGCAGGAACTGCCGTACGTGGGACGTTGGTTCGGCCGCCAGGC
GGCCGTCGCCATGGACGGACTCCTGCGGCTCGCCGACGTGTGGCGCCCCGAC
CTCGTGGTCGGTGGCACGGACGCCCACGCCGCCGCCCTGCTCGGCTCCCGGC
TGGGCATCCCGTACGTCCGCCAGGCGTGGGACTGGCTCCACTTCGACGGAGC
GGAGCGCTACGCGAACGACGAACTGGCCCCCGAACTGGCGCAGGCCGGACT
CGAACGGCTCCCGGCACCCGACCTGTTCATCGACATCTGCCCGCCGAGCCTG
ATCCCGCCGCTAGCCACCTTCATGCGCTGGACCCCGCACAACATGCAGCGGG
CGATCGAGCCGTGGATGCTGACGGCTCCGGACGCCGGGCGCGTGTGCCTGAC
GATGGGAAGCTTCCGGTACGCCTTCCCCGGCGCGATGGACCGCATCTCGGCC
ATCGTCGAAGGGCTGCTGGAGCTCGAGGTCGAGGTCGTCGTGGCCATCGGCG
AGGCGGAGGGGCAGCGGCTGCAGGAGAAGTACCCCCGGGTGCGCGCCGGCT
GGATCCCGCTGGAGGCCATCCTCCCGACCTGTGAGGTGATCATCCATCCGGC
GGGCGGACTGACGGCCATCAACGCCATCAACACGGCGACTCCGCAGCTGATC
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CTCAACCCCTTCGAGGCCTTCGTCCCGAGGCTGAAGCACCTCACGGACTACG
GGTGCGCGCGGACGCTCTACCGCGAGGAGGGCACCCCGGAGGCGATCACGC
AGGTGGTCAAGGAGATGCTCGGGGATCCGTCCTACTCCTCCAGGGCCCGGAG
ACTGGCGGAGCAGGGCGCGACCGCGCCGACGGCCGTGGGCATGGTGCCGCT
GATCGAAGACCTCCTCGCGCGGAAAGGATGAAGCGAAGCTTTCGAATTC

cGT-CR
TCTAGAGGGTGGCCAGCCCCGAAGGAGCAGCATGAAAGTCCTCTTCATCGCC
GCGGGAACGAGCCCGGCGGGGGTCTTCGCCCTCGCCCCTCTCGCGACGGCGG
TGCGCAACGCAGGGCACGAGATCCTGGTGGCGGCCTTCGACGAGCTGACCCC
GGCCGTCGCGTCCGTCGGACTGCCCGTCGTGGCCGTCGCCGACGGCCACACG
ACCGAGAGCATCAAGGGACTCGACCGGCCGGGCGGACCGATCGGGTTCCCCT
GGGCACCCGAGCAGGAACTGCCGTACGTGGGACGTTGGTTCGGCCGCCAGGC
GGCCGTCGCCATGGACGGACTCCTGCGGCTCGCCGACGTGTGGCGCCCCGAC
CTCGTGGTCGGTGGCACGGACGCCCACGCCGCCGCCCTGCTCGGCTCCCGGC
TGGGCATCCCGTACGTCCGCCAGGCGTGGGACTGGCTCCACTTCGACGGAGC
GGAGCGCTACGCGAACGACGAACTGGCCCCCGAACTGGCGCAGGCCGGACT
CGAACGGCTCCCGGCACCCGACCTGTTCATCGACATCTGCCCGCCGAGCCTG
ATCCCGCCGCTAGCGACGCCCGGCCGCCCCATGCGCTGGGTGCCCGGCAACC
GCCAGCGGTCGCTGGAGCCGTGGATGTACACCAAGGGCGAGCGCCCCCGGAT
CTGCGTCACCTACGGCAGCTTCCGTACCGCCATGCCGCAGATCTTCGAGCACC
TGTGCGCCCTGCTGTCCCGGCTCGTGGACCTGGACGCCGAGATCGTGGTCGC
GGCGAACGAGGCCGCGACGGAGAAGCTGCGCGAGCGCTTCCCGCAGGTCCG
CGCCGGCTGGGTGCCGCTGGAGTTCCTGCTGCGCACCTGCGACGGCATCGTG
CACAGCGGCGGGCTGACCGCGCTGAACGCCATGTCCGCCGGCATCCCGCAGG
TGGTGCTCAACCAGTTCGTCGCCTTCGAGCCGTCGCTGGCCCTGTTGCAGCAG
CAGGGCTCCGCCGTCGTGCTGCACCGCGAGGAGGGCTCCCCCGACGGCACCT
TCGAAGCCTGCCGCAAGGTCCTGTCCGACGGGAGCTACGGCCAGCAGGCCCG
GGTCCTCGCCGACGAGCTCAACTCCCTGCCCACCCCGAACGACGTGGTGAAG
GACCTGGAAGGACTGGTGCGCGGATGAGCACCCTCTCGGTGAGCCAGCAAGC
TTCGAATTC
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cGT-GC
TCTAGACGCGACAAGGACCGGTCACGGGAGGGCGCCGCGTGAAGGCCCTCTT
CTACGCCGCGGGCACGAGCCCGGCCAGCGCGTTCGCCATCGGACCCCTCGCC
TCGGCACTCCGGTTGTCCGGGCACGACGTCCTGGTGGCGTCCTTCGAGGAGA
TGTCCGGCGCCGTCACCGGCATCGGTCTGCCGTCCCTCCCGGTGGCCCGGGG
GCACACGACCGAGAGCATCAAGGCGGCCGCCGGCGGCAAGCCGGCGATCGA
GTACCCCCACCGGCCCGAACAGGAGATGCCCTACCTGGGCCACTGGTTCGGG
CGTCAGGGAAGCCACGTCTTCGACGACCTGGTGGACGTCGCCCGGACGTGGG
GCGCCGACGTCCTGATCGCGGGGAGCCAGGGACACGGTGCCGAGATCGCCG
CCCGGTTCCTCGGCATCCCCTTCGTCCGGCAGTCCTGGGACCTGTTCGACGTC
GGCGGCTACGAGGAGTACCTCCTCGAGGAGATGGCGGACGAGCTGGCCAGG
ATCGGCTCGGACGCACTGCCCGACCCCTCACTGAAGATCGACATCTGCCCGC
CCGGCCTGGTCGGGGCGCTAGCCGAGCGCGGCCGGCCGATGAGATGGGTGCC
GGGCAACCGCCAGCGCAAGCTGGAGCCGTGGATGTACGGCAAGGGCGAGCG
CGCCCGGGTGTGCGTCACGCTCGGCAGCTTCCGCACCGCCATGCCGGAGATG
TTCGCCTACCTGTGCGCACTGGTGGAGCGGCTGACGGCACTCGACGCCGAGA
TCGTCGTCGCCGCCGACGAGACGGCCTCCCGGAAGATCCGGGAGCGCTTCCC
CGGCGTACGCGCCGACTGGGTGCCGATGGAGTTCCTCGTGCGCACCTGCGAC
ACGATCGTGCACGCGGGCGGCCTCACCACTCTCAACGCCATGGCGGCCGGCA
CCCCGCAGGTGGTGGTGAACCAGTTCCAGGCGTTCGAACCCTCGCTGCGGCT
GCTCGAGCGGCAGGGATGCAGCGTGGTCCTGCACCGGGACGACAAGTCCCCG
GACAACACCTTCGACGCCTGCGAGCGCATCCTCTCCGACGACGGGTACGCGC
ACCGGGCAGGTGAGCTGGCCCGCGAACTGGGCGCCCTGCCCCCGCCGGCCAC
GGTCGTCGGCGACCTGGAGGCGCTGGCCCGCCGCTGACCCCGTGCCACCGGC
CCACCAAAGCTTGGAATTC

cGT-GR
TCTAGACGCGACAAGGACCGGTCACGGGAGGGCGCCGCGTGAAGGCCCTCTT
CTACGCCGCGGGCACGAGCCCGGCCAGCGCGTTCGCCATCGGACCCCTCGCC
TCGGCACTCCGGTTGTCCGGGCACGACGTCCTGGTGGCGTCCTTCGAGGAGA
60

TGTCCGGCGCCGTCACCGGCATCGGTCTGCCGTCCCTCCCGGTGGCCCGGGG
GCACACGACCGAGAGCATCAAGGCGGCCGCCGGCGGCAAGCCGGCGATCGA
GTACCCCCACCGGCCCGAACAGGAGATGCCCTACCTGGGCCACTGGTTCGGG
CGTCAGGGAAGCCACGTCTTCGACGACCTGGTGGACGTCGCCCGGACGTGGG
GCGCCGACGTCCTGATCGCGGGGAGCCAGGGACACGGTGCCGAGATCGCCG
CCCGGTTCCTCGGCATCCCCTTCGTCCGGCAGTCCTGGGACCTGTTCGACGTC
GGCGGCTACGAGGAGTACCTCCTCGAGGAGATGGCGGACGAGCTGGCCAGG
ATCGGCTCGGACGCACTGCCCGACCCCTCACTGAAGATCGACATCTGCCCGC
CCGGCCTGGTCGGGGCGCTAGCGACGCCCGGCCGCCCCATGCGCTGGGTGCC
CGGCAACCGCCAGCGGTCGCTGGAGCCGTGGATGTACACCAAGGGCGAGCG
CCCCCGGATCTGCGTCACCTACGGCAGCTTCCGTACCGCCATGCCGCAGATCT
TCGAGCACCTGTGCGCCCTGCTGTCCCGGCTCGTGGACCTGGACGCCGAGAT
CGTGGTCGCGGCGAACGAGGCCGCGACGGAGAAGCTGCGCGAGCGCTTCCC
GCAGGTCCGCGCCGGCTGGGTGCCGCTGGAGTTCCTGCTGCGCACCTGCGAC
GGCATCGTGCACAGCGGCGGGCTGACCGCGCTGAACGCCATGTCCGCCGGCA
TCCCGCAGGTGGTGCTCAACCAGTTCGTCGCCTTCGAGCCGTCGCTGGCCCTG
TTGCAGCAGCAGGGCTCCGCCGTCGTGCTGCACCGCGAGGAGGGCTCCCCCG
ACGGCACCTTCGAAGCCTGCCGCAAGGTCCTGTCCGACGGGAGCTACGGCCA
GCAGGCCCGGGTCCTCGCCGACGAGCTCAACTCCCTGCCCACCCCGAACGAC
GTGGTGAAGGACCTGGAAGGACTGGTGCGCGGATGAGCACCCTCTCGGTGAG
CCAGCAAGCTTCGAATTC

cGT-RC
TCTAGACGACGGCCCCGACCCTACGGAGAAGCCATGAAAGTCCTGTTCATCG
CAGCGGGAACCAGCCCCGCGGGCGTCTTCGCCCTCGCCCCGCTCGCCACGGC
GGTGCGCAACGCCGGGCACGAGATCCTGGTCGCCTCCTTCGACGAGTTGACC
TCCAGCATCGAGGCGATCGGGCTGCCTCCGGTGGCCGTGGTCACCGAGCACA
CCACCGAGAGCATCAAGCAGCTGGACCGCCCCGGCGGCCCGATCGAGTTCCC
CTGGTCGCCCGACCAGGAACTGCCTTACGTGGGCCGTTGGTTCGGCCGGCAG
GCCGCCGTCAGCCTCGACGGACTCCTCGAACTGACCCGGCACTGGCGCCCCG
ACCTCGTCATCGGCGGCACCGACGCGCACGCCGCCGGGCTCGTCGCGGCCCA
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CCTCGGCGTCCCGCACGTCCGCCAGGCGTGGGACTGGCTGCACTTCGGCGGC
GCCGAGCAGTACGCCGCCGAAGAGCTCGCCCCCGAGCTGGAGCGGCTGGGC
CTGGCCGAACTGCCCGCCCCGGACATGTTCTTGGACATCTGCCCGCCGAGCCT
CCTCCCGTCGCTAGCCGAGCGCGGCCGGCCGATGAGATGGGTGCCGGGCAAC
CGCCAGCGCAAGCTGGAGCCGTGGATGTACGGCAAGGGCGAGCGCGCCCGG
GTGTGCGTCACGCTCGGCAGCTTCCGCACCGCCATGCCGGAGATGTTCGCCT
ACCTGTGCGCACTGGTGGAGCGGCTGACGGCACTCGACGCCGAGATCGTCGT
CGCCGCCGACGAGACGGCCTCCCGGAAGATCCGGGAGCGCTTCCCCGGCGTA
CGCGCCGACTGGGTGCCGATGGAGTTCCTCGTGCGCACCTGCGACACGATCG
TGCACGCGGGCGGCCTCACCACTCTCAACGCCATGGCGGCCGGCACCCCGCA
GGTGGTGGTGAACCAGTTCCAGGCGTTCGAACCCTCGCTGCGGCTGCTCGAG
CGGCAGGGATGCAGCGTGGTCCTGCACCGGGACGACAAGTCCCCGGACAAC
ACCTTCGACGCCTGCGAGCGCATCCTCTCCGACGACGGGTACGCGCACCGGG
CAGGTGAGCTGGCCCGCGAACTGGGCGCCCTGCCCCCGCCGGCCACGGTCGT
CGGCGACCTGGAGGCGCTGGCCCGCCGCTGACCCCGTGCCACCGGCCCACCA
AAGCTTGGAATTC

cGT-RG
TCTAGACGACGGCCCCGACCCTACGGAGAAGCCATGAAAGTCCTGTTCATCG
CAGCGGGAACCAGCCCCGCGGGCGTCTTCGCCCTCGCCCCGCTCGCCACGGC
GGTGCGCAACGCCGGGCACGAGATCCTGGTCGCCTCCTTCGACGAGTTGACC
TCCAGCATCGAGGCGATCGGGCTGCCTCCGGTGGCCGTGGTCACCGAGCACA
CCACCGAGAGCATCAAGCAGCTGGACCGCCCCGGCGGCCCGATCGAGTTCCC
CTGGTCGCCCGACCAGGAACTGCCTTACGTGGGCCGTTGGTTCGGCCGGCAG
GCCGCCGTCAGCCTCGACGGACTCCTCGAACTGACCCGGCACTGGCGCCCCG
ACCTCGTCATCGGCGGCACCGACGCGCACGCCGCCGGGCTCGTCGCGGCCCA
CCTCGGCGTCCCGCACGTCCGCCAGGCGTGGGACTGGCTGCACTTCGGCGGC
GCCGAGCAGTACGCCGCCGAAGAGCTCGCCCCCGAGCTGGAGCGGCTGGGC
CTGGCCGAACTGCCCGCCCCGGACATGTTCTTGGACATCTGCCCGCCGAGCCT
CCTCCCGTCGCTAGCCACCTTCATGCGCTGGACCCCGCACAACATGCAGCGG
GCGATCGAGCCGTGGATGCTGACGGCTCCGGACGCCGGGCGCGTGTGCCTGA
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CGATGGGAAGCTTCCGGTACGCCTTCCCCGGCGCGATGGACCGCATCTCGGC
CATCGTCGAAGGGCTGCTGGAGCTCGAGGTCGAGGTCGTCGTGGCCATCGGC
GAGGCGGAGGGGCAGCGGCTGCAGGAGAAGTACCCCCGGGTGCGCGCCGGC
TGGATCCCGCTGGAGGCCATCCTCCCGACCTGTGAGGTGATCATCCATCCGG
CGGGCGGACTGACGGCCATCAACGCCATCAACACGGCGACTCCGCAGCTGAT
CCTCAACCCCTTCGAGGCCTTCGTCCCGAGGCTGAAGCACCTCACGGACTAC
GGGTGCGCGCGGACGCTCTACCGCGAGGAGGGCACCCCGGAGGCGATCACG
CAGGTGGTCAAGGAGATGCTCGGGGATCCGTCCTACTCCTCCAGGGCCCGGA
GACTGGCGGAGCAGGGCGCGACCGCGCCGACGGCCGTGGGCATGGTGCCGC
TGATCGAAGACCTCCTCGCGCGGAAAGGATGAAGCGAAGCTTTCGAATTC

Double inactivation of gilI and gilGT
The double inactivation experiment was carried out using a modified PCRtargeting REDIRECT protocol.127 An overview of this process is described in section 4.1:
Inactivation of gilP and gilQ.

2.2 Genetic isolation of glycosyltransferase involved in polycarcin biosynthesis
Polycarcin V (61) is a gilvocarcin like aryl C-glycoside produced by Streptomyces
polyformus.61 61 differs from 49 only by its sugar moiety, namely L-rhamnose (92).
Interestingly, S. polyformus produces 61 and 49 as a concomitant 1:1 mixture, meaning
the cluster either contains two individual glycosyltransferases responsible for the transfer
of each deoxysugar or a single glycosyltransferase with donor substrate flexibility
transfers both L-rhamnose and D-fucofuranose.
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Figure 33. Structures of polycarcin V (61), elloramycin (117), steffimycin (118) and
aranciamycin (119).

Rhamnose

transferring

glycosyltransferases

are

commonly

referred

to

as

rhamnosyltransferases, and in general seem to contain inherent substrate promiscuity. In
this context, rhamnosyltransferases are an exciting combinatorial biosynthetic tool for
creating glycosylated natural product analogues.

The type II PKS derived natural

products elloramycin (117), steffimycin (118) and aranciamycin (119) all contain an Oglycosidically

linked

L-rhamnose

moiety,

and

have

had

their

respective

rhamnosyltransferase donor substrate specificities investigated (Figure 33).46,49-50,128132,171

Together, AraGT (aranciamycin), StfGT (steffimycin) and ElmGT (elloramycin)

have been found to transfer 15 individual donor substrates to their respective aglycones
(Figure 34). The donor substrates transferred included both

D-

and

L-

sugars and

incorporated several classes of sugars such as non-deoxy (120), deoxy (92 and 121),
dideoxy (93 and 122- 128, 156) and trideoxysugars (129-131).
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Figure 34. Sugar moieties transferred by the rhamnosyltransferases AraGT (red), StfGT
(green) and ElmGT (blue).
The relaxed donor substrate flexibility of several rhamnosyltransferases makes the
polycarcin pathway specific glycosyltransferase extremely desirable. The identification
of a rhamnosyltransferase that catalyzes a C-glycosylation and exhibits donor substrate
promiscuity would allow for an additional route to the production of gilvocarcin-like aryl
C-glycoside analogues.

Experimental design
In specific aim 1b, a genomic cosmid library of Streptomyces polyformus will be
constructed and screened for the presence of gilvocarcin-like glycosyltransferases.
Candidate glycosyltransferases will be sequenced and their gene products compared to
known

gilvocarcin-like

GTs

(gilGT,

chryGT

and

ravGT).

The

identified

glycosyltransferase/s will then be confirmed as the gilvocarcin V and/or polycarcin V
pathway

specific

glycosyltransferase.

Heterologous

expression

and

successful

complementation of the newly identified GT in S. lividans TK24/cosG9B3-GilGT- will
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indicate a TDP-D-fucofuranose transferring GT. Similarly, the same GT cloned into an Lrhamnose generating sugar plasmid and subsequent complementation in S. lividans
TK24/cosG9B3-GilGT- will allow for rhamnosyltransferase activity screening. The
identified rhamnosyltransferase will then be cloned into various sugar plasmids and
transformed into S. lividans TK24/cosG9B3-GilGT- to evaluate its donor substrate
promiscuity.
Results
S. polyformus cosmid library and screening
The genomic cosmid library of S. polyformus was constructed in the E. coliStreptomyces shuttle vector, pOJ446.133 Typically, two probes are used to screen the
genomic library to increase the probability of capturing an entire gene cluster within a
single cosmid. Probing the S. polyformus genomic library for polycarcin biosynthetic
genes would normally involve a keto-acyl synthase (KSα) and a NDP-glucose-4,6dehydratase (4,6-DH) probe as polycarcin biosynthesis requires the catalytic activity of
both of these enzymes for its backbone and sugar moiety, respectively.91,117 For this
study, however, we were interested in only the glycosyltransferase/s present in the
cluster, therefore probing with a KSα and 4,6-DH probe was unnecessary. Instead,
degenerate primers (PlcGT-Deg-F1/PlcGT-Deg-R1, see Table 7) were constructed from
conserved N-terminal regions (responsible for acceptor binding) of gilGT, ravGT and
chryGT and used to amplify partial candidate glycosyltransferase sequences directly from
S. polyformus genomic DNA (Figure 35). The resulting glycosyltransferase probe was
used to screen the S. polyformus genomic library as a digoxigenin (DIG)-labeled
glycosyltransferase gene probe. Initial colony hybridization led to over one hundred
positively hybridized colonies (Figure 36, A). These were taken for a second round of
hybridization in which each colony was scratched out in order to positively confirm
hybridization of individual colonies (Figure 36, B). The second round of hybridization
narrowed the colony count to twenty nine. Further restriction digest and PCR analysis
identified two distinct cosmids, cosPlc47 and cosPlc75, to be investigated further (see
section 2: S. polyformus cosmid library construction and screening).
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ChryGT
GilGT
RavGT

Figure 35. Nucleotide sequence alignment of the N-terminal region of gilGT, ravGT and
chryGT. This figure shows the conserved residues (boxed) used for generating degenerate
gilvocarcin-like glycosyltransferase primers.

Figure 36. Selection of (A) initial and (B) conformational colony hybridization discs
used in screening the S. polyformus genomic library.

Partial sequence analysis of cosPlc75
The degenerate glycosyltransferase primers used to probe the cosmid library were
designed to amplify a small N-terminal portion of gilvocarcin-like glycosyltransferases.
Amplification of this sequence from cosPlc47 and cosPlc75 revealed both cosmids
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contained an identical glycosyltransferase with high sequence homology to GilGT. To
get a complete gene sequence, cosPlc75 was used for primer walking experiments
(SeqWright) which extended the sequenced region roughly 500 nucleotides flanking the
internal glycosyltransferase sequence. This resulted in the full gene sequence of the
initially identified glycosyltransferase, now designated plcGT.
Sequence analysis of plcGT revealed a very high sequence homology to gilGT (84%
aa identity). When compared to ravGT and chryGT, however, the amino acid identity
dropped to roughly 52% suggesting PlcGT may act on the furanose sugar D-fucofuranose.
Primer walking also allowed for the identification of genes flanking plcGT, which
included the complete sequence of plcV (gilV homologue, 84% aa identity) and the partial
sequence of plcM (gilM homologue) and plcOIII (gilOIII homologue) (Figure 37). The
expression of both cosPlc75 and cosPlc47 in S. lividans TK24 failed to produce
gilvocarcin, polycarcin or any known gilvocarcin pathway intermediates suggesting
incomplete clusters (data not shown).

Figure 37. Gene sequences identified from partial sequencing of cosPlc75.

Complementation studies in S. lividans TK24/cosG9B3-GilGTWith the complete sequence of plcGT determined, complementation of S.
lividans TK24/cosG9B3-GilGT- was carried out to determine the ability of PlcGT to
transfer TDP-D-fucofuranose (47).

Transformation of pPlcGT into S. lividans

-

TK24/cosG9B3-GilGT resulted in successful reconstitution of the gilvocarcin pathway
as observed by the production of gilvocarcin M and E (Figure 38). These results support
the role of PlcGT as the glycosyltransferase responsible for the production of gilvocarcins
in S. polyformus. As only a single gilvocarcin-like glycosyltransferase was identified
through cosmid library screening, it is possible that PlcGT also transfers TDP-Lrhamnose (92) toward the production of polycarcins. To investigate this hypothesis,
PlcGT was cloned into the sugar plasmid pRHAM (pRHAM-PlcGT) and transformed
into S. lividans TK24/cosG9B3-GilGT-. Interestingly, the resultant recombinant strain
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failed to produce either polycarcins or gilvocarcins (Figure 39).

This result was

surprising as PlcGT was previously shown to produce gilvocarcins. In addition, the
inability to transfer

L-rhamnose

suggests that PlcGT is not involved in polycarcin

biosynthesis. Alternatively, it is possible that TDP-L-rhamnose is not being produced in
the fermentations from pRHAM, or that PlcGT utilizes an NDP-L-rhamnose substrate
other than TDP-L-rhamnose.
gilvocarcin E (51)

gilvocarcin M (50)
defuco-gilvocarcin E (80)

Figure 38. HPLC chromatogram trace of S. lividans TK24/cosG9B3-GilGT-/pPlcGT.
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defuco-gilvocarcin E (80)

Figure 39. HPLC chromatogram trace of S. lividans TK24/cosG9B3-GilGT-/pRHAMPlcGT.

Donor substrate specificity of PlcGT
To evaluate the donor substrate promiscuity of PlcGT, two constructs were
created in which plcGT was placed into the sugar plasmids pLNBIV and pLNRHO,
respectively. These sugar plasmids were chosen for two reasons; 1) their representative
sugars have been transferred by other rhamnosyltransferases and 2) they produce L-sugars
which in general are underrepresented in gilvocarcin type aryl C-glycosides.

The

resulting constructs, pLNBIV-PlcGT and pLNRHO-PlcGT, were transformed into S.
lividans TK24/cosG9B3-GilGT- and their metabolites were screened as previously
described. No new metabolites were observed from the resulting recombinant strains,
however, gilvocarcin E production was found to be restored in S. lividans
TK24/cosG9B3-GilGT-/pLNRHO-PlcGT (Figure 40 and 41). These results suggest
PlcGT exhibits a rigid donor substrate preference, and may not be a suitable
glycosyltransferase for glycodiversification studies.
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defuco-gilvocarcin E (80)

gilvocarcin E (51)

Figure 40. HPLC chromatogram trace of S. lividans TK24/cosG9B3-GilGT-/pLNRHOPlcGT.

defuco-gilvocarcin E (80)

Figure 41. HPLC chromatogram trace of S. lividans TK24/cosG9B3-GilGT-/pLNBIVPlcGT.
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Discussion
The natural concomitant production of gilvocarcins as well as polycarcins in S.
polyformus could arise from the activity of a single donor substrate flexible
glycosyltransferase or from two distinct glycosyltransferases responsible for transferring
D-fucofuranose

and

isolation

a

of

L-rhamnose,

respectively.

rhamnosyltransferase

as

Particular interest was given to the
previous

studies

have

established

rhamnosyltransferases as powerful tools for the glycodiversification of natural
products.46,49-50,128-132,171
In an attempt to identify a substrate flexible C-rhamnosyltransferase, a genomic
library of S. polyformus was generated and screened using degenerate primers based on
conserved N-terminal regions of gilvocarcin-like glycosyltransferases. Screening of the
library resulted in the isolation of two distinct cosmids, cosPlc47 and cosPlc75, which
were shown through preliminary sequencing to contain an identical glycosyltransferase.
A single cosmid, cosPlc75, was chosen for primer walking in order to obtain the entire
gene sequence of the identified glycosyltransferase. The resulting ORF was designated
plcGT, and was used in various complementation studies to determine its parental
functionality as well as donor substrate flexibility.
Complementation studies showed PlcGT could only accommodate
and was unable to transfer

L-rhamnose, L-digitoxose

or

D-fucofuranose

L-rhodinose

to defuco-

gilvocarcin. Together, these results suggest PlcGT to be a substrate specific
glycosyltransferase involved in only the gilvocarcin biosynthetic pathway of S.
polyformus. If this hypothesis is true, then an additional glycosyltransferase is present
within the genomic library of S. polyformus responsible for the production of polycarcins.
It is possible that the second glycosyltransferase may not share conserved N-terminal
sequences compared to gilvocarcin-like glycosyltransferases. This would explain the
inability

to

amplify

such

a

glycosyltransferase

from

the

gilvocarcin-like

glycosyltransferase based degenerate primers. In this context, two additional sets of
degenerate primers based on conserved regions of several rhamnosyltransferases (PlcGTDeg-F2/PlcGT-Deg-R2 and PlcGT-Deg-F2/ PlcGT-Deg-R3) were used in an attempt to
amplify the missing glycosyltransferase from S. polyformus (Table 7). Despite several
attempts, no PCR products were obtained from these experiments (data not shown). The
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inability to isolate a second glycosyltransferase from all degenerate primers used in this
study suggests, contrary to complementation studies, the lack of a second
glycosyltransferase. Again, the complementation studies using PlcGT to transfer TDP-Lrhamnose are not conclusive as it is unknown if TDP-L-rhamnose was actually present in
the fermentations. Furthermore, it is possible that the natural substrate of PlcGT may be
an alternative nucleotide activated NDP-L-rhamnose.
As described in section 2.1, S. lividans TK24/cosG9B3-GilGT- is not an ideal host for
screening glycosyltransferases for the transfer of sugars other than TDP-D-fucofuranose.
In this context, negative complementation results can not be used as conclusive evidence
to support the lack of glycosyltransferase activity towards a given donor substrate. There
are several possible contributing factors to negative complementation results, especially
when additional deoxysugar genes are expressed in S. lividans TK24/cosG9B3-GilGT-.
Without the use of real time quantitative reverse transcription PCR (real-time qRT-PCR),
there is no way to ensure the glycosyltransferase or exogenous deoxysugar genes are
being expressed in vivo unless you observe a glycosylated product. Additionally, the
competing deoxysugar biosynthetic pathways could lead to the formation of an unwanted
and incompatible donor substrate for the glycosyltransferase causing a possible falsenegative result or inhibition.
It should be noted that several gilvocarcin glycodiversification experiments were
being conducted in parallel to this study. It was found only after the isolation of the
plcGT sequence that GilGT could naturally transfer L-rhamnose. Unlike the studies
described herein, the aforementioned study was conducted in the biosynthetically
compromised TDP-D-fucofuranose mutant, cosG9B3-GilU-. Unfortunately, neither
PlcGT nor any other GT can be tested in this host as it contains the natural gilvocarcin
glycosyltransferase, GilGT. Additionally, attempts to express soluble PlcGT in E. coli
failed despite several attempts (data not shown).
In regards to the gilvocarcin and polycarcin biosynthetic pathways in S. polyformus,
taking into consideration all available evidence it is likely that PlcGT is responsible for
transferring both

D-fucofuranose

and

L-rhamnose

despite negative complementation

results suggesting otherwise. Taking into consideration that, (a) PlcGT was the only
gilvocarcin-like glycosyltransferase amplified from S. polyformus genomic DNA; (b)
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PlcGT and GilGT share 83% amino acid identity; and (c) GilGT can naturally transfer Lrhamnose it is unlikely that a second glycosyltransferase exists for the explicit transfer of
L-rhamnose

during polycarcin biosynthesis. In addition, the conserved orientation and

high amino acid sequence identity of the genes found in the partial polycarcin cluster
suggests the plc cluster to be highly similar to the gil cluster and only produces
polycarcin because unlike S. griseoflavus Gö 3952 (gil cluster), S. polyformus carries the
deoxysugar biosynthetic genes to produce activated L-rhamnose.

Materials and Methods
Bacterial strains, culture conditions and plasmids
All complementations, conjugations, protoplast transformations and culturing
conditions were carried out as described in section 2.1: Bacterial strains, culture
conditions and plasmids. A comprehensive list of strains and plasmids used in this study
can be found in Table 5.
Table 5. Strains and plasmids used in the polycarcin glycosyltransferase study.
Strain/Plasmid
E. coli XL1-Blue-MRF
E. coli ET12567/pUZ8002
PCR-Blunt II-TOPO
pGEM-T Easy Vector
pEM4
pOJ446
cosG9B3-GilGTS. lividans TK24 (SLTK24)
S. lividans TK24/cosG9B3-GilGTS. polyformus
pPlcGT (1)a
pRHAM-PlcGT (2)a
pLNBIV-PlcGT (3)a
pLNRHO-PlcGT (4)a
SLTK24/cosG9B3-GilGT-/(1)a
SLTK24/cosG9B3-GilGT-/(2)a
SLTK24/cosG9B3-GilGT-/(3)a
SLTK24/cosG9B3-GilGT-/(4)a

Characteristics and relevance
Host for routine cloning
Host for conjugal transfer
PCR fragment cloning vector
PCR fragment cloning vector
Streptomyces expression vector
Used for constructing library
gilGT deficient mutant
Streptomyces heterologous host
Host for screening chimeric GTs
Used for genomic library
pEM4 containing plcGT
pRHAM containing plcGT
pLNBIV containing plcGT
pLNRHO containing plcGT
Produces gilvocarcins
Produces defuco-gilvocarcins
Produces defuco-gilvocarcins
Produces gilvocarcins

a

Numbering used only for table simplification.
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Fermentation and metabolite screening
The recombinant strains created in this study were fermented and screened as
described in section 2.1: Fermentation and metabolite screening.
DNA isolation, DNA manipulation and PCR
Plasmid/cosmid DNA isolations and manipulations were carried out as described
in section 2.1: DNA isolation, DNA manipulation and PCR.

Advantage-GC 2

polymerase mix (Clonetech; Advantage GC-2) was used to amplify glycosyltransferase
probes from S. polyformus using primers summarized in Table 7. A typical reaction
consisted of the following:
1 µL DNA template (~50-100 ng)
1 µL Forward primer (~200-250 ng)
1 µL Reverse primer (~200-250 ng)
1 µL dNTPs (10 mM)
10 µL GC 2 PCR buffer (5x)
10 µL GC Melt (5M)
25 µL Distilled water (dH2O)
1 µL Advantage-GC 2 polymerase mix (50x)
PCR reactions were carried out on a TechGene thermal cycler (Techne) with
typical cycling conditions summarized in Table 6.

Table 6. PCR cycling conditions for Advantage-GC 2 polymerase mix amplification.
Step
Initial denaturation
Denaturation
Annealing
Extension
Final extension

Temperature
94 oC
94 oC
Primer TM – (5-10)
68 oC
68 oC

75

Duration
3 min.
30 sec.
45 sec.
1.0 min./kb of target
3 min.

Cycles
1
25
1

Table 7. Oligonucleotide sequence of primers used to amplify glycosyltransferase probes
and plcGT from S. polyformus. Restriction sites are represented by italicized sequences.
Primer
PlcGT-Deg-F1
PlcGT-Deg-R1
PlcGT-Deg-F2
PlcGT-Deg-R2
PlcGT-Deg-R3
plcGT-F
plcGT-R

Oligonucleotide sequence (5′-3′)
SCACACSACCGAGAGCATCAAG
AGGCRSGGCGGGCAGATGTC
CGSTWCGTSCCSTWCAACGG
GTSCCSSCSCCSSCGTGGTG
SSYSARBGYMGTKCCSSWGCCSCC
CTATCTAGAGGAGGAGCCCATGTGAAAGCCCTGTTCTAC
TAGGAATTCAAGCTTTCACTGCTTCACCTTTTC

S. polyformus cosmid library construction and screening
The genomic DNA of S. polyformus was isolated and a genomic library was
constructed according to standard protocols.122 Specifically, the isolated genomic DNA
was partially digested with BfuCI (roughly 30-40 kb fragments), purified using phenolchloroform and dephosphorylated with CIP (Figure 42, step 1). In parallel, the E. coli –
Streptomyces shuttle vector pOJ446 was digested with HpaI/BamHI and purified using
phenol-chloroform (Figure 42, step 2). BfuCI and HpaI create compatible overhangs
which are utilized in the ligation step between the partially digested S. polyformus
genomic DNA and fragmented pOJ446 creating a linear vector which is packaged and
transduced into E. coli XL1-Blue MRF cells using a Gigapack III packaging extract
(Stratagene) (Figure 42, steps 3-4). The resulting library contained over 8,000 colonies
and was calculated to have >99.9% chance to collectively cover the entire genome of S.
polyformus.
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Figure 42. Schematic representation of the method used to produce the S. polyformus
genomic library. 1 = BfuCI digestion of genomic DNA; 2 = HpaI/BamHI digestion of
pOJ446; 3 = ligation of resulting fragments from steps 1 and 2; 4 = Gigapack III
packaging and transduction into E. coli XL1-Blue MRF.
The degenerate primers PlcGT-Deg-F1and PlcGT-Deg-R1 were designed to
amplify a small 400 nucleotide region from the N-terminal domain of gilvocarcin-like
glycosyltransferases from the genomic DNA of S. polyformus (Figure 41 and Table 7).
The amplified DNA fragment was DIG-labeled and subsequently used as a probe to
screen the S. polyformus genomic library using a DIG DNA labeling kit (Roche). Initial
colony hybridization revealed roughly fifty candidate positive colonies (Figure 36, A).
These colonies and surrounding colonies were individually scratched out and re77

hybridized. This conformational hybridization step identified 29 positively hybridized
colonies (Figure 36, B). Cosmid DNA was isolated from each of the 29 colonies and
digested with BamHI to remove duplicate cosmids (Figure 43). The resulting 21 unique
cosmids were used as templates for PCR using the gilvocarcin-like glycosyltransferase
based degenerate primers. Only 12 of the 21 tested cosmids produced a strong PCR
product at the expected ~400 base pair (bp) range (Figure 44). These 12 PCR products
were gel purified using a QIAquick Gel Extraction Kit (Qiagen) and cloned into pGEM-T
Easy Vector (Promega). The resulting clones were sequenced revealing only two clones
with glycosyltransferase sequence homology. The sequence of these two PCR products,
from cosPlc47 and cosPlc75, were found to be identical. The cosmid cosPlc75 was
chosen for primer walking (SeqWright) and resulted in the complete nucleotide sequence
of plcGT as well as flanking regions.

Figure 43. BamHI digestion of 29 candidate polycarcin cosmids revealed 7 duplicates
and 1 sample without DNA.
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Figure 44. PCR products of the 21 unique polycarcin cosmids using the
glycosyltransferase degenerate primers PlcGT-Deg-F1 and PlcGT-Deg-R1.
Plasmid construction
The newly identified glycosyltransferase, plcGT, was amplified from S. polyformus
using Native Pfu polymerase and cloned into PCR-Blunt II-TOPO as described in section
2.1: DNA isolation, DNA manipulation and PCR. PCR was used to introduce a unique
XbaI site upstream of the plcGT start codon and EcoRI/HindIII sites directly downstream
of the stop codon. XbaI/EcoRI double digestion was used to transfer plcGT from TOPO
to pEM4 producing pPlcGT. plcGT along with ermE*p was removed from pPlcGT using
HindIII and ligated into the sugar plasmids, pLNBIV and pLNRHO.
plcGT sequence
The complete sequence (5′-3′) obtained from primer walking including plcV, plcGT
and flanking regions is shown below. Start codons and stop codons are designated by
NNN and NNN, respectively.

AGCCGGAAACGTCGTCTCCCTCATCTGGCACATGCACGCCGTACTGCGTCCG
plcV

CAGGAGACCCGATCGGAGATACCGGCATGAAGTTCGCCGCCGTCATCGTCGT
CAACTACCAGACTCCCTGGTACCAGCTCTCGCTAGACGAGCGCGTCGCCATC
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GAGCACCAGCACGTCTTCCCCAGCATCGGCGCCTTCGTGCAGCGGGGCGGCG
AGATCACCCCGGTCCGCGCCATCAAGTACGGCCGTGAGGCGGAGAGCTTCTT
CCTCCTCGGCTTCGACGACATGGAGGACTACCTGGACCTGGTCCGGGAGCTT
CGCTCAAGCCACCTGCTGACCTCGGGTCTCGCCGCCATCGAGTTCGAGACCG
TGGGGCTGAAGGAAGCCTACTTCGCGGAACGCGACAAAGACCGGTCACCGG
plcGT

CGGTGGCCTCGTGAAAGCCCTGTTCTACGCCGCGGGCACCAGCCCGGCCAGC
GCCTTCGCGATCGGCCCGCTCGCCTCCGCCCTCCGGGCGTCCGGGCACGACA
TCCTGGTCGCCTCCTTCGAGGAGATGTCCGGCGCCGTCACCGGCATCGGACT
GCCGTCCATCCCCGTGGCCCGTGGCCACTCGACCGAGAGCATCAAGGCCGCC
GTCGACGGCAGGCCGGCCATCGAGTACCCCCACCGGCCCGAACAAGAGATG
CCCTACCTGGGCCACTGGTTCGGCCGCCAGGGAAGCTATGTCTTCGACGACC
TGGTGGACATCGCCCGGACCTGGGGCGCGGACGTCCTGATCGCGGGCAGCCA
GGGACACGGCGCGGAGATCGCCGCCCGCCTCGTCGGCATCCCCTTCGTCCGC
CAGTCCTGGGACCTGTTCGACATCCACGGCTACGAGGAACACCTCCACGGCG
AACTGGCCGCGCAGTTGGCCCGCATCGGCGCGGACTCCCTGCCCGAACCGTC
GCTGCGCATCGACATCTGCCCTCCCGGACTGACGGACCTCACCGGCGGCACC
TTCATGCGCTGGACCCCGCACAACAAGCAGCGCCAGATCGAGCCGTGGATGC
TGACGGCCCCGGACCGGGGGCGGGTGTGTCTGACGATGGGCAGCTTCCGGTA
CGCCTTCCCGGGCGCGATGGACCGGATCTCGGCGATCGTGGAGCGGCTCCAG
GAACTTGAGACCGAGGTCGTCGTCGCCATCGGCGAGGCCGAAGGACAGCAG
ATCGAGGAGCGGTTCCCCGGGGTCCGGGCGGGCTGGATCCCGCTGGAGGCGA
TCCTCCCCACCTGTGAGGTGATCATCCATCCGGCGGGCGGCCTGACGGCGGT
CAACGCCATCAACACCGCCACACCCCAGCTCATCCTCAACCCCTTCGAGGCC
TTCGAACCCGCCCTGAAACGCCTCACCGACTACGGCTGCGCGCGGACGCTCT
ACCGGGAGGAGGGCACCCCCGCGGCGATAGCGCGGGTCGTCAAGGAGATGC
TCGGGGACTCCTCGTACTGCTCAAGGGCCCGGGATCTGGCGGCGCGGGCCGC
GACCGCGCCCACCGCCGTGGGCATGGTTCCGCTGATCGAAGANCTCGTCGCA
CGGGAGAAGCGGGAAAAGGTGAAGCAGTGACTTCGACGTTGACGATTCCTC
AGACCGACCTCGATCCGTACACCGACGCGTCGATCACCGACCCGTATCCGCT
CTACGGCGCCCTG
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Chapter 3: Polycarcin Sugar Residue Modification
In vitro methylation of L-rhamnosyl moiety of polycarcin V
The L-rhamnosyl moiety of polycarcin V (61) provides a unique opportunity to
employ a combinatorial biosynthetic approach to selectively modify the sugar moiety of a
gilvocarcin-like aryl C-glycoside. This study is particularly exciting for several reasons;
(a) no extensive sugar based SAR studies exist for a single gilvocarcin-like aryl Cglycoside; (b) this study may produce several polycarcin V analogues with improved
bioactivity or pharmaceutical properties; and (c) this study may provide a unique
combinatorial biosynthetic methodology for modifying sugar moieties of several natural
products.
Spinosyn A (26) and elloramycin A (117) are the only examples, to our
knowledge, of polyketide derived natural products containing permethylated L-rhamnose
moieties (Figure 45). L-rhamnosyl-O-methylation has been extensively studied in the
spinosyn biosynthetic pathway, and has been shown to be extremely important in
conferring spinosyn bioactivity.53 Through in vitro experimentation it was found that
every possible methylation pattern was achievable through the activity of three pathway
specific O-methyltransferases, SpnH, SpnI and SpnK, and is the biosynthetic rational
behind spinosyn H (132), J (133), K (134), P (135), T (136) and U (137) production in
Saccharopolyspora spinosa (Figure 45).134 Similarly, the L-rhamnosyl methylation steps
of elloramycin biosynthesis have been investigated and have been shown to effect the
bioactivity of elloramycin.54 Unlike spinosyn, the elloramycin

L-rhamnosyl-O-

methyltransferases, ElmMI, ElmMII and ElmMIII, were not as flexible as spinosyn
methyltransferases allowing for the production of only two permutations (138 and 139)
regarding the O-methylation pattern of L-rhamnose (Figure 45). It is important to note
that in both biosynthetic pathways, the modification of L-rhamnose occurred only after
glycosylation to their respective aglycones.
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Figure 45. Spinosyn A and elloramycin A are two examples of natural products
containing permethylated L-rhamnose. This figure also shows their naturally produced
methylated or partially methylated analogues, with respect to the L-rhamnose moiety.
The substrate flexibility of

L-rhamnosyl-O-methyltransferases

have not been

extensively studied, and it is unknown if these methyltransferases are specific to the
entire L-rhamnosyl-natural produce or only the L-rhamnose moiety itself. The recent
observation that OleY, an O-methyltransferase involved in methylating L-olivose (127)
after attachment to a macrolide core during oleandomycin biosynthesis, could recognize
and methylate various deoxysugars attached to a tetracyclic core suggests these
deoxysugar O-methyltransferases to be quite substrate promiscuous.49 In this context, we
plan to use ElmMI, ElmMII and ElmMIII to create a library of polycarcin V derivatives
carrying various L-rhamnose-O-methylation patterns, which in turn will be used for sugar
based SAR studies.

Experimental design
In specific aim 2, the elloramycin O-methyltransferases ElmMI, ElmMII and
ElmMIII will be cloned and expressed as soluble proteins in E. coli. The resulting
purified enzymes will be used in an in vitro assay with polycarcin V to ascertain their
ability to accept the unnatural dibenzochromenone backbone of 61. Reactions leading to
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the production of new polycarcin V analogues will be scaled up and their respective
products will be purified and structurally characterized using spectroscopic techniques.
The bioactivity of fully characterized polycarcin V analogues will then be evaluated to
determine the importance of individual sugar functional groups with respect to the
activity of polycarcin V.
Results
In vitro activity of ElmMI, ElmMII, ElmMIII and StfMII
To test the polycarcin methylation ability of these enzymes, N-terminal (His)6tagged proteins were expressed in E. coli and purified using immobilized metal ion
affinity chromatography (IMAC).

Soluble purified proteins were analyzed through

sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to confirm the
correct size of each protein (Figure 46, lanes 1-3). The expected size of His-tagged
ElmMI, ElmMII and ElmMIII were calculated to be 43.3 kDa, 45.0 kDa and 31.2 kDa,
respectively.

Additionally, the 2′-O-methyltransferase from steffimycin (118)

biosynthesis, StfMII, was prepared as an N-terminal His-tagged protein and purified
using IMAC. The expected size of His-tagged StfMII was calculated to be 45.6 kDa
which was observed in the SDS-PAGE gel containing purified StfMII (Figure 46, lane
4). StfMII was prepared after initial experiments showed ElmMI to be unable to
efficiently accommodate polycarcins (discussed below).
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75 kDa
50 kDa

37 kDa

Figure 46. SDS-PAGE analysis of N-terminal (His)6-tagged (1) ElmMI, (2) ElmMII, (3)
ElmMIII and (4) StfMII.

The initial in vitro assay was conducted using a mixture of polycarcin V, M and E
purified from S. polyformus. The purified mixture is roughly 75% polycarcin V (61),
20% polycarcin M (90) and 5% polycarcin E (91) (Figure 47, A). To test the ability of
ElmMI to methylate the 2′-OH-position of polycarcin V we incubated ElmMI with
polycarcins and S-adenosylmethionine (SAM). This reaction resulted in the formation of
a new, yet very small, peak in HPLC (Figure 47, B). The new peak had a UV-Vis
spectrum typical to that of polycarcins, and eluted (16.8 min) slightly after the control
polycarcins (Figure 47, A) suggesting an increase in lipophilicity. With these data and
the parental functionality of ElmMI, we propose 140 to be the 2′-O-methylated analogue
of polycarcin V, designated polycarcin A.
Similarly, we tested the ability of ElmMII to methylate the 3′-OH-position of
polycarcin V by incubating ElmMII with polycarcins and SAM (Figure 47, C).
Interestingly, the major new peak, 143, had an identical retention time (16.8 min) and
UV-Vis spectrum to that of polycarcin A (140). The minor new peaks, 144 and 145,
were analogous to the elution pattern of polycarcin M and E with respect to polycarcin V.
That is to say, the methyl congener elutes before the vinyl congener, while the ethyl
congener elutes immediately after the vinyl congener. In this context, we propose 143,
144 and 145 to be the 3′-O-methylated analogues of polycarcin V, M and E, respectively.
As we are only interested in the vinyl analogues, we have designated 143 as polycarcin
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B. The identical retention time of 140 and 143 can be explained by their structural
similarities. 140 and 143 only differ in the placement of a single methyl group at either
the 2′ or 3′ position, respectively; and this difference may not be reflected in the HPLC
profile of these two compounds.
The last enzyme, ElmMIII, has been proposed as the 4′-OH-methyltransferase in
elloramycin biosynthesis; however, it was shown to be unable to methylate the 4′-OH
position without the presence of at least a 2′-methoxy or 3′-methoxy group.135 This
substrate specificity was also observed when ElmMIII was incubated with polycarcins
and SAM (Figure 47, D).

The reaction of polycarcin with ElmMIII produced no

discernable new compounds, indicating an inability to methylate the naked L-rhamnose
moiety of polycarcins.
Lastly, sequential methylations were tested by incubating ElmMI, ElmMII and
ElmMIII with polycarcins and SAM (Figure 47, E). A strong peak at 16.8 min was
proposed to be polycarcin B (143) and not polycarcin A (140) simply due to the relative
inactivity exhibited previously by ElmMI. In addition, a new peak, 146, was observed at
20.6 min indicating even further methylation by ElmMIII (this was corroborated in
further experimentation). 146 is proposed to contain both 3′ and 4′-methoxy groups and
is designated as polycarcin C.
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Figure 47. HPLC chromatogram trace of methyltransferase assays using ElmMI, ElmMII
and ElmMIII. Reactions contained (A) polycarcins (61, 90 and 91), (B) ElmMI +
polycarcins, (C) ElmMII + polycarcins, (D) ElmMIII + polycarcins and (E) ElmMI +
ElmMII + ElmMIII + polycarcins. 140, 143 and 146 are polycarcin V analogues, while
144 and 145 are polycarcin M and E analogues, respectively.
From preliminary in vitro assays using ElmMI, ElmMII and ElmMIII it is
apparent that only two polycarcin V analogues (143 and 146) can be created utilizing
ElmMII and ElmMIII. The poor activity of ElmMI makes isolation of 140 virtually
impossible. To remedy this problem and to restore the possibility of permethylating the
L-rhamnosyl

moiety of polycarcin V, StfMII from steffimycin biosynthesis was cloned,

expressed and purified. Incubation of StfMII with polycarcins and SAM resulted in the
formation of a major peak in HPLC with a retention time of 16.8 min (Figure 48, B).
With the specific 2′-O-methyltransferase parental activity of StfMII we proposed this
new peak to be identical to polycarcin A (140). In addition to polycarcin A, two
additional peaks 141 and 142 were observed and believed to be the methyl and ethyl
congener of polycarcin A, respectively.
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61

90
91

A
140
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142

B

Figure 48. HPLC chromatogram trace of methyltransferase assay using StfMII. The
reactions contained (A) polycarcins 61, 90 and 91) and (B) StfMII + polycarcins. 140 is a
polycarcin V analogue, while 141 and 142 are polycarcin M and polycarcin E analogues.
With successful 2′-O-methylation by StfMII, it was possible to combine StfMII,
ElmMII and ElmMIII in different combinations to produce various methylated
derivatives of polycarcin V. Incubation of StfMII, ElmMII, polycarcins and SAM
resulted in the formation of 140-142, as expected from the activity of StfMII, and a new
peak with a retention time of 18.7 min in HPLC. The new peak, 147, had a typical UVVis spectrum to that of polycarcins and its increased retention time indicated increased
lipophilicity. With these results, we propose 147 to be the 2′,3′-dimethoxy analogue of
polycarcin V, designated polycarcin D. Interestingly, 146 and 147 have different
retention times despite their only difference being the position of a second methoxy
group at either the 4′-OH or 2′-OH, respectively.
Co-incubation of StfMII and ElmMIII only produced the products of StfMII
activity, namely 140-142 (Figure 49, C). Unlike in elloramycin biosynthesis where
ElmMIII can act on an elloramycin substrate containing only a 2′-methoxy group,
ElmMIII cannot methylate the analogous polycarcin V substrate, polycarcin A. We know
ElmMIII is active by its ability to methylate polycarcin B, as observed in Figure 49 trace
D, producing 146.
Finally, we attempted to permethylate polycarcin V by incubating StfMII,
ElmMII, ElmMIII, polycarcins and SAM (Figure 49, E). The HPLC analysis of this
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reaction revealed a major peak at 16.8 min indicating either 140 or 143.

The

accumulation of both 147 and to 146 indicates that both StfMII and ElmMII are
competing for 61 and producing 140 and 143 (Figure 50). Most importantly, however, is
the formation of a new peak, 148, with a retention time of 22.8 min. This new peak had a
typical UV-Vis spectrum to that of polycarcins and its increased retention time suggests a
further methylated product. With previous in vitro results and the fact that 147 is present
in the reaction mixture for the first time with ElmMIII, we propose 148 to be the
permethylated L-rhamnose analogue of polycarcin V, designated polycarcin F.
61
90
91

A
140

91 + 141
142

147

B
140

61 + 141
142

C
143

* 61 + 144
146

*

141 + 144

145

D
140 + 143
142 + 145

E

Figure 49. HPLC chromatogram trace of methyltransferase assays using StfMII, ElmMII
and ElmMIII. Reactions contained (A) polycarcins (61, 90 and 91), (B) StfMII +
ElmMII + polycarcins, (C) StfMII + ElmMIII + polycarcins, (D) ElmMII + ElmMIII +
polycarcins and (E) StfMII + ElmMII + ElmMIII + polycarcins. 140, 143, 146 and 147
are polycarcin V analogues, while 141 and 144 are polycarcin M analogues. The
remaining compounds, 142 and 145, are analogues of polycarcin E.
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147
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148
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Figure 50. Expanded region of trace E from Figure 49 showing the polycarcin V
analogues 146, 147 and 148.
Preliminary structural characterization of polycarcin analogues
The reactions discussed above were conducted on a very small scale and mass
data were not collected. To confirm the proposed structure of polycarcin A (140), the in
vitro reaction was scaled up and the peak corresponding to polycarcin A was purified
using analytical HPLC. To date, only around 2 mg of polycarcin A has been purified.
This has allowed for partial structural characterization of polycarcin A using 1H-NMR.
For comparison, the

1

H-NMR of polycarcin V was taken to show the signals

corresponding to the unmodified 2′-H, 3′-H, 4′-H, 2′-OH, 3′-OH and 4′-OH positions
(Figure 51). When comparing the 1H-NMR spectrums of polycarcin A and polycarcin V
it was observed that in polycarcin A the 2′-OH signal had been lost and a new signal had
appeared directly downfield of the 3′-H signal (Figure 52). This downfield shift is
characteristic of a proton connected to a carbon with a methoxy group versus a hydroxyl
group, and is what we would expect if polycarcin A contained a 2′-OCH3. Further
confirmation would require 2D NMR experiments, such as Heteronuclear Multiple Bond
Coherence (HMBC), to connect the methoxy protons to the 2′ position of polycarcin A.
Unfortunately, the amount of purified polycarcin A does not allow for such 2D
experiments to be conducted. These results, however, give convincing evidence that
polycarcin A is in fact the 2′-O-methoxy analogue of polycarcin V. It should be noted
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the additional methoxy group of polycarcin A was not observed in the 1H-NMR spectrum
and is believed to be hidden under the water signal.

2′-OH + 2′

4′ + 5′

1′
4′-OH 3′-OH
3′

Figure 51. Upfield 1H NMR spectrum for polycarcin V (61) highlighting the L-rhamnose
signals (500 MHz, DMSO-d6).
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5′
4′
1′

2′

4′-OH 3′-OH
3′

Figure 52. Upfield 1H NMR spectrum for polycarcin A (140) highlighting the
rhamnose signals (500 MHz, DMSO-d6).

L-

Discussion
The ability to produce methylated analogues of polycarcin V is extremely useful
in understanding the unique role sugar moieties play in the bioactivity of gilvocarcin-like
aryl C-glycosides. Specific modification of individual sugar functional groups would
allow for an opportunity to analyze the importance of these individual functional groups
toward the bioactivity of the given compound. This information could then be used in the
rational design of gilvocarcin-like aryl C-glycosides with improved activity.
The results presented here exemplify a method in which

L-rhamnosyl

methyltransferases from various biosynthetic pathways could be used to specifically
modify individual functional groups of polycarcin V. Specifically, StfMII, ElmMII and
ElmMIII were used to methylate the 2′-OH, 3′-OH and 4′-OH of polycarcin V,
respectively. Used individually or in combination, these enzymes successfully catalyzed
the formation of five new polycarcin V analogues proposed to be polycarcin A (140), B
(143), C (146), D (147) and F (148) (Figure 53).
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Figure 53. Engineered biosynthetic pathway leading to the production of five polycarcin
V analogues.

To isolate, purify and characterize the polycarcin V analogues, the in vitro
reactions were scaled up by increasing the overall volume of each reaction.
Unfortunately, increasing the reaction volume resulted in extensive protein precipitation
and therefore low yields were observed. Instead of increasing the reaction volume,
scaling up consisted of increasing the number of small scale reactions, and combining
them after the reaction was completed. This process is time consuming and still yields
low quantities of compound. Furthermore, methylation reactions conducted in vitro are
notorious for not going to completion. This is attributed to S-adenosylhomocysteine
(SAH), the demethylated product of SAM, produced as a byproduct during methylation
reactions and a known inhibitor of methyltransferases.136-138 Despite these factors,
roughly 2 mg of polycarcin A (140) was isolated and purified. Initial structural
characterization of 140 through 1H-NMR implies the presence of a 2′-methoxy group,
however, this can not be unequivocally assigned without further 2D NMR experiments.
13

C-NMR was attempted but there was not enough 140 to obtain clear carbon signals.
Together, these results illustrate the power of L-rhamnosyl-O-methyltransferases

in producing specific derivatives of natural products. This method could be used to create
methylated derivatives of several natural products containing
steffimycin (118) and aranciamycin (119).

L-rhamnose

including

Additionally, similar studies could be

conducted on natural products that contain sugars that slightly differ from L-rhamnose but
retain the stereochemistry of one or more of the 2′-OH, 3′-OH or 4′-OH positions such as
L-mycarose

(123), L-digitoxose (124) and L-olivose (127). Furthermore, these studies

could be conducted in vivo making the production of new analogues much easier than
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using an in vitro approach. The polycarcin V producer, S. polyformus, is recalcitrant to
DNA uptake making an in vitro approach impossible; however, several natural product
producing strains can be manipulated or the natural product can be heterologously
expressed. This would allow for in vivo expression of the exogenous methyltransferases
directly in the producing strain or heterologous host, thereby removing the need for an in
vitro assay.

Future Research
The goal of this study was to be able to conduct SAR experiments on the
produced polycarcin V analogues. To date, the analogues have not been isolated in
quantities to afford such studies. This will require continued in vitro reactions using the
methyltransferases discussed herein. Several important factors have been identified from
the small scale experiments that need to be considered to successfully produce these
polycarcin V analogues in vitro. First, the small scale reactions consisted of roughly 75%
polycarcin V, 20% polycarcin M and 5% polycarcin E.

It was shown that the

methyltransferases do not discriminate between the different polycarcin congeners
allowing multiple substrates to be methylated. This wastes valuable SAM co-factor and
complicates later purification processes. Since we are not interested in the M or E
congeners, it would be beneficial for large scale reactions to contain only polycarcin V.
Secondly, it was found that StfMII and ElmMII could utilize polycarcin V directly to
produce 140 and 143, respectively. For this reason, the production of 147 should not be
catalyzed by a one-pot enzymatic synthesis containing StfMII and ElmMII. This reaction
would allow for part of the starting material to be transformed into 143 and therefore will
reduce the overall yield of 147. Lastly, the ability to remove SAH from the reaction
mixture would greatly increase the overall yield of methylated products.

An S-

adenosylhomocysteine nucleosidase has recently been identified from E. coli that
converts SAH to S-ribosylhomocysteine and adenine, thereby eliminating its ability to
inhibit the methyltransferase reaction.139-140 An S-adenosylhomocysteine nucleosidase
could be used in conjunction with the methyltransferases used in this study to prevent
SAH inhibition and allow for higher yields of methylated products.
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Only two

L-rhamnosyl-O-methylated

analogues of polycarcin V were not

produced during this study. These two analogues would consist of a single methylation
at the 4′-OH position and two methylations at the 2′-OH and 4′-OH positions,
respectively. The inability to create these analogues can be attributed to the natural
programming of ElmMIII, as discussed above. An analogous enzyme from spinosyn
biosynthesis, SpnH, has been shown to be flexible enough to produce both of the
aforementioned methylation patterns in spinosyn J (133) and T (136) biosynthesis.141 It
would be fascinating to see if SpnH could also utilize polycarcin V, which contains a
drastically altered backbone compared to spinosyn. This experiment in combination with
the previously described study could allow for the complete derivatization of the
polycarcin V sugar moiety.

Materials and Methods
Bacterial strains, culture conditions and plasmids
All transformation and culturing conditions were carried out as described in
section 2.1: Bacterial strains, culture conditions and plasmids. A comprehensive list of
strains and plasmids used in this study can be found in Table 8.

Table 8. Strains and plasmids used in the expression of methyltransferases.
Strain/Plasmid
E. coli XL1-Blue-MRF
E. coli BL21 (DE3)
S. polyformus
cos16F4
stfB3
PCR-Blunt II-TOPO
pET28a(+)
pElmMI
pElmMII
pElmMIII
pStfMII

Characteristics and relevance
Host for routine cloning
Host for protein expression
Produces polycarcin V
PCR template for ElmMI, ElmMII and ElmMIII
PCR template for StfMII
PCR fragment cloning vector
Expression vector
elmMI cloned into pET28a(+)
elmMII cloned into pET28a(+)
elmMIII cloned into pET28a(+)
stfMII cloned into pET28a(+)
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DNA isolation, DNA manipulation and PCR
Plasmid DNA isolations, manipulations and PCR reactions were carried out as
described in section 2.1: DNA isolation, DNA manipulation and PCR. Please find Table
9 for a complete list of primers used in this study.

Table 9. Oligonucleotide sequence of primers used to amplify elmMI, elmMII, elmMIII
and stfMII. Restriction sites are represented by italicized sequences.
Primer
ElmMI-F
ElmMI-R
ElmMII-F
ElmMII-R
ElmMIII-F
ElmMIII-R
StfMII-F
StfMII-R

Oligonucleotide sequence (5′-3′)
ATCGCATATGGACTCCCCACAGGTG
CGATGAATTCAGGTCGCTTCCCGCAG
ATCGCATATGACCACCCCTTCACCC
CGATGAATTCATACGTAGTCGATCTC
ATCGCATATGACGGAATACGCCCGC
CGATGAATTCAGACGGTGGCCGGCTG
GGACATATGTCCGCTGAGAGTGAC
ATTGAATTCTCACTCCGCCGCCGG

Protein expression constructs
The primer pairs ElmMI-F and R, ElmMII-F and R, and ElmMIII-F and R were
used to amplify elmMI, elmMII and elmMIII from cos16F4, respectively. Likewise, the
primer pair StfMII-F and R was used to amplify stfMII from stfB3.143 The pfu amplified
PCR products were cloned into PCR-Blunt II-TOPO vector as described previously. All
genes were removed from TOPO and ligated into pET28a(+) as NdeI/EcoRI fragments
generating pElmMI, pElmMII, pElmMIII and pStfMII.

Cloning of the genes in

pET28a(+) results in a N-terminal (His)6-tagged protein, which can be purified using
IMAC.

Expression and purification of proteins
The expression constructs for ElmMI, ElmMII, ElmMIII and StfMII were
transformed into E. coli BL21 (DE3) according to standard protocols.125 Single colonies
from each transformation was inoculated into 10 mL of LB containing appropriate
antibiotics and grown for 5 hours at 37 oC to prepare seed cultures. One liter cultures (1
L Erlenmeyer baffled flasks) were then inoculated with each seed culture and grown with
the appropriate antibiotics at 37 oC with reciprocal shaking at 250 rpm. When the cultures
reached an OD600 of ~0.5, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a
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final concentration of 50 µM and allowed to continue shaking at 18 oC overnight, or 16
hours. After 16 hours, the pellet was collected by centrifugation (4000 x g, 15 min) and
washed twice with 25 mL lysis buffer (50 mM KH2PO4, 300 mM NaCl, 10 mM
imidazole, pH 7.6). The washed pellet was stored at -80 oC overnight and then used
when needed. To recover soluble proteins, the frozen pellet was lysed with a French
Press (Thermo Electron Corporation), and crude protein was recovered through
centrifugation (18000 x g, 30 min). The cell free lysate was then passed through a 15 mL
column containing 2 mL of Talon metal affinity resin (Clontech) pre-washed with 10 mL
of lysis buffer. The flow through was discarded and the column was washed again with
10 mL of lysis buffer. After washing the column, 3 mL of elution buffer (50 mM
KH2PO4, 300 mM NaCl, 200 mM imidazole, pH 7.6) was added to the column to elute
the soluble protein. The elution was collected in an Amicon Ultra centrifugal filter
(Millipore) and concentrated by centrifugation (12000 x g, 20-45 min). The concentrated
soluble protein was then quantified using the Bradford protein assay method and the
purity of each enzyme was visualized using SDS-PAGE analysis (Figure 46).144

Methylation reaction conditions
The methylation reaction assays were carried out in microcentrifuge tubes (USA
Scientific) using the following conditions: 50 mM NaH2PO4 (pH 7.4), 20 mM MgCl2, 2
mM SAM, 200 µM polycarcin V/M/E mixture, 20 µM methyltransferase/s in a final
volume of 400 µL. Once the reaction mixture was complete, the microcentrifuge tubes
were removed from light and allowed to incubate at 28 oC for 3 hours. After 3 hours, 400
µL of ethyl acetate was used to extract the polycarcin-like compounds from the reaction
mixture. The organic phase of the extraction was removed and then evaporated using a
SpeedVac (Savant). The dried extract was reconstituted using 50 µL of methanol and
this solution was analyzed using an HPLC (Waters Alliance 2695) and photodiode array
detector (Waters 2996) with the same column and linear gradient as described in section
2.1: Fermentation and metabolite screening.
The normally expensive co-factor SAM was purchased inexpensively as SAM-e
(Nature Made), an over-the-counter (OTC) dietary supplement in 200 mg tablets. These
tablets were divided into two equal portions and crushed using a mortar and pestle. The
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crushed half was then added to a 15 mL screw top vial (USA Scientific) containing 750
µL of dH2O, and the mixture was thoroughly mixed using a vortex (Fisher) for 1 min.
The resulting mixture was filtered using a 0.45 µm syringe-driven filter (Millipore) and
collected into a 1.5 mL microcentrifuge tube (USA Scientific).

The filtrate SAM

concentration was quantified using the SAM extinction coefficient (15400cm-1M-1 at 260
nm). The concentration of SAM prepared as described had a concentration typically ~
200 mM. These solutions were immediately used and/or stored for no more than 48
hours. This process was developed based on personal communications with Dr. S. Van
Lanen.

Copyright © Micah Douglas Shepherd 2011
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Chapter 4: Starter Unit Incorporation during Gilvocarcin V Biosynthesis
4.1 In vivo characterization of GilP and GilQ
Initial bioinformatic analysis of the gilvocarcin gene cluster revealed the presence of
a typical type II polyketide synthase consisting of two ketosynthase subunits (KSα/β) and
an acyl carrier protein (ACP).91 Interestingly, the gil cluster also contained two genes,
gilP and gilQ, with high sequence similarities to malonyl CoA:ACP transacylases
(MCATs) and acyltransferases, respectively. GilP shows 47/33% amino acid
similarity/identity to FabD, a characterized E. coli MCAT.

GilQ, however, shows

sequence identity to several acyltransferases found in type II PKS systems with nonacetate starter unit incorporation (discussed below). The inclusion of an MCAT
homologue in the gil cluster is unusual as it is often found that type II polyketide synthase
clusters do not posses a pathway specific MCAT, and instead recruit the endogenous fatty
acid synthase (FAS) MCAT.92-93 In the actinorhodin and tetracenomycin pathways, this
borrowed MCAT has been shown to be responsible for transferring both starter and
extender units to the type II minimal PKS as acetate and malonate, respectively.20-21
Unlike actinorhodin and tetracenomycin, gilvocarcins utilize two distinct starter
units. Early labeling studies revealed these starter units to be derived from acetate and
propionate which condense with 9 malonate extender units to produce 20- and 21-carbon
decaketides, respectively (Figure 54).87-89 The formation of 20- and 21-carbon
decaketides is followed by subsequent intramolecular aldol condensations and several
complex post-PKS modifications to produce 50 and 51 (see Biosynthetic Highlights of
Gilvocarcin V). At a yet unknown step during the biosynthesis of 51, oxidation of its
ethyl side chain by GilOIII produces the vinyl functional group of 49.42
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Figure 54. Labeling pattern of the 20- and 21- carbon decaketide formed by the minimal
gilvocarcin PKS.
The use of propionate or any starter unit other than acetate, in a type II PKS is
relatively uncommon and has been observed in only a handful of natural products
belonging to this class of secondary metabolites. Most notably, daunorubicin (149),
doxorubicin (150), hedamycin (37), R1128a-d (151-154) and fredericamycin A (155) are
type II PKS derived natural products with unique starter unit incorporation (Figure 55).
The daunorubicin and doxorubicin pathways, which share early PKS enzymes, were the
first to be investigated in regard to starter unit specificity.145-151 The daunorubicin cluster
contains a unique β-ketoacyl:ACP synthase III (KS III) homologue (DpsC) usually found
as a component of a type II FAS, and a single acyltransferase homologue (DpsD). A KS
III protein is typically involved in the initiation of fatty acid biosynthesis, and the
characterized KS III homologue, FabH, from E. coli K-12 has been shown to be involved
in transacylating acetyl-CoA and subsequently condensing with malonyl-ACP to produce
acetoacetyl-ACP.152 Further investigation of DpsC and DpsD determined the KS III
homologue, and not the acyltransferase homologue, to be responsible for conferring
starter unit specificity, and therefore propionyl-CoA incorporation.149,151 Similarly, both
KS III and acyltransferase homologues have been found in the gene clusters of several
type II PKS derived natural products utilizing unique starter units including hedamycin
(2,4-hexadienoate),

R1128A-D

(short-chain

fatty

acids),

fredericamycin

(2,4-

hexadienoate), frenolicin (butyrate), and aclacinomycin (propionate).153-157 In each case,
except hedamycin, the KS III homologue has been shown, or is believed, to be
responsible for the incorporation of the unique starter unit in their respective
pathways.153-154,158-160 In this context, it is interesting that the gil cluster lacks a KS III
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homologue and instead carries an acyltransferase that has been shown to be non-essential
in similar pathways in regard to starter unit specificity. This indicates that the minimal
gilvocarcin PKS likely incorporates propionate utilizing a protein with unique function
not seen in similar pathways. The only candidate genes present in the gil cluster that may
play a role in starter unit specificity are gilP and gilQ. The strong sequence similarity of
GilP to FabD suggests GilP functions as a typical MCAT during the biosynthesis of
gilvocarcin V, and does not determine starter unit selection. The acyltransferase, GilQ, is
therefore the most likely candidate for conferring starter unit specificity based on
bioinformatical analysis alone.

Figure 55. Examples of type II polyketide derived natural products with non-acetate
starter unit incorporation.
The initiation of the gilvocarcin biosynthetic pathway with propionate is
extremely important. The choice of starter unit directly influences the type of gilvocarcin
analogue produced by the pathway, because the starter unit becomes the C-8 side chain in
the final gilvocarcin compound. If acetate is incorporated as the starter unit the final
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gilvocarcin will contain a single carbon C-8 side chain producing gilvocarcin M (50).
However, if propionate is incorporated, the final gilvocarcin compound will contain a two
carbon C-8 side chain producing gilvocarcin E (51). At an undetermined step during the
biosynthesis of 51, GilOIII oxidizes the two carbon C-8 side chain to give the vinyl group
found in 49 (as discussed above).

As the vinyl group is essential for the

photo[2+2]cycloaddition reaction with DNA thymine base, gilvocarcin V is the most
bioactive compound compared to the methyl and ethyl congeners.

For this reason

gilvocarcin M and gilvocarcin E are unwanted side products of gilvocarcin V
biosynthesis. In order to engineer the gilvocarcin biosynthetic pathway towards only
gilvocarcin V production, a deeper understanding of starter unit specificity must be
obtained.
Experimental design
In specific aim 3a, the putative MCAT, gilP, and acyltransferase, gilQ, will be
inactivated from cosG9B3 using PCR-targeting REDIRECT technology. The resulting
mutants will be heterologously expressed in S. lividans TK24 and their metabolites will
be analyzed using HPLC-MS. In addition, gilQ and gilOIII will be overexpressed in S.
lividans TK24/cosG9B3 to evaluate the effect of increased intracellular GilQ and GilOIII
concentrations on gilvocarcin V production.

Results
Production profile of engineered strains
Traditional in vivo methods for investigating gilvocarcin biosynthesis are severely
hindered due to the inability to introduce genetic information into wild type S.
griseoflavus Gö3592. The successful isolation of cosG9B3, containing all the genes
required for gilvocarcin V production, has provided a useful tool for several successful
biosynthetic studies (see Gilvocarcin V Biosynthetic Highlights). To determine the exact
biosynthetic role of GilP and GilQ, two cosG9B3 mutants were constructed harboring an
in-frame deletion of gilP (cosG9B3-GilP-) and gilQ (cosG9B3-GilQ-). The resulting
cosmids were transformed, using conjugal transfer, into S. lividans TK24 producing S.
lividans TK24/cosG9B3-GilP- and S. lividans TK24/cosG9B3-GilQ-, respectively.
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Fermentation and HPLC-MS analysis of the mutant strains, as well as S. lividans
TK24/cosG9B3, were conducted to determine the percentage of gilvocarcin V, M and E
produced by each strain (Table 10).
Table 10. Percentage of individual gilvocarcin congeners produced by engineered strains
in this study.
Strain
SLTK24 /cosG9B3
SLTK24b/cosG9B3-GilPSLTK24b/cosG9B3-GilQSLTK24b/cosG9B3-pGilQGilOIII
SLTK24b/cosG9B3-pGilQ
b

% GM (50)a
34.6 ± 1.8
36.5 ± 1.6
77.2 ± 0.9
16.5 ± 0.7
11.6 ± 0.7

% GV (49)a
65.4 ± 1.8
52.3 ± 2.2
22.8 ± 1.2
83.5 ± 0.7
83.7 ± 0.6

% GE (51)a
0
11.2 ± 1.8
0
0
4.7 ± 0.01

a

Percentage of gilvocarcins calculated by the relative values of area under the curve taken from HPLCMS chromatogram traces (n =3), bS. lividans TK24 (SLTK24)

The control strain, S. lividans TK24/cosG9B3, produced roughly 35% and 65% of
gilvocarcin M and V, respectively. The gilP deficient mutant, S. lividans TK24/cosG9B3GilP-, produced gilvocarcins in percentages comparable to the control strain. Combining
both gilvocarcin V and E percentages from the gilP mutant reveals 63% propionate
incorporation. This observation clearly shows that the removal of GilP from the
gilvocarcin biosynthetic machinery does not influence the overall production of
gilvocarcins. This in not unexpected, as GilP shows high sequence similarity to MCATs,
and pathway specific MCATs are typically not required for type II PKS systems. This
result implies that in the absence of GilP, the endogenous FAS MCAT from S. lividans
TK24 is able to successfully transfer malonyl-CoA to the gil PKS. Furthermore, this
suggests GilP functions as a typical MCAT, and does not play an important role in the
selection of propionate during gilvocarcin V biosynthesis.
In contrast, analysis of the gilQ deficient strain showed a severely altered
gilvocarcin production profile (Table 10). S. lividans TK24/cosG9B3-GilQ- produced
significantly more gilvocarcin M than the control strain, 77% versus 35%, respectively.
Consequently the production of gilvocarcin V was reduced to roughly 23% compared to
65% in the control strain. The dramatic decrease in gilvocarcin V production suggests
GilQ primarily influences the use of propionate over acetate. Interestingly, the complete
abolishment of GV was not observed demonstrating GilP or an endogenous
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acyltransferase from S. lividans TK24 may have the ability, albeit at a much reduced rate,
to load and transfer propionate to the minimal gilvocarcin PKS.
Based on the above in vivo results, an additional strain was created in which GilQ
was over-expressed in S. lividans TK24/cosG9B3 to increase the propensity for catalysis
utilizing a two carbon starter unit.

The proposed increase of propionate primed

decaketides would lead to an increase in two carbon C-8 side chains that would need to
be converted to the vinyl said chain by GilOIII in order to produce gilvocarcin V (refer to
Figure 16). Normally, GilOIII can completely convert all two carbon C-8 side chains to
the vinyl functional group as evident by the absence of gilvocarcin E in S. lividans
TK24/cosG9B3 fermentations (Table 10). The possible increase in GilOIII substrate,
created by over-expressing GilQ, may saturate GilOIII leading to an incomplete oxidation
of the two carbon C-8 side chain preventing production of the ideal congener, gilvocarcin
V. For this reason, a second construct was created in which GilQ and GilOIII could be
over-expressed in S lividans TK24/cosG9B3 to completely flux all intermediates to 49.
The resulting strains, S. lividans TK24/cosG9B3/pGilQ and S. lividans
TK24/cosG9B3/pGilQGilOIII, were fermented and analyzed as discussed above (Table
10). Both strains increased 49 production to roughly 85% and reduced 50 production to
approximately 15% compared to 65% and 35% in control, respectively. The inclusion of
GilOIII in S. lividans TK24/cosG9B3/pGilQGilOIII was able to completely convert all
gilvocarcin E intermediates to 49, unlike S. lividans TK24/cosG9B3/pGilQ which
produced around 5% of 51.

The increase of 49 production in strains containing

additional GilQ further validates the unique role of this acyltransferase in starter unit
selectivity during gilvocarcin V biosynthesis.
Surprisingly, strains over-expressing GilQ not only increased the percentage of 49
produced compared to 51, but also significantly increased the overall production yield of
gilvocarcins (Table 11). Incredibly, S. lividans TK24/cosG9B3/pGilQ and S. lividans
TK24/cosG9B3/pGilQGilOIII increased gilvocarcin production to 450 mg/L and 200
mg/L, respectively. This correlates to a 10-20 fold increase when compared to the wild
type strain. Together, these findings suggest propionate incorporation is the earliest rate
limiting step of gilvocarcin biosynthesis and is primarily dependent upon the activity of
GilQ.
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Table 11. Total gilvocarcin yields produced by engineered strains over-expressing GilQ.
Strain
SLTK24b/cosG9B3
SLTK24b/cosG9B3/pGilQ
SLTK24b/cosG9B3/pGilQGilOIII

GM (50)
(mg/L)a
7±1
53 ± 11
33 ± 3

GV (49)
(mg/L)a
14 ± 3
376 ± 65
168 ± 10

GE (51)
(mg/L)a
0
21 ± 4
0

Total
(mg/L)a
21 ± 4
450 ± 79
201 ± 13

a

Production of gilvocarcins calculated by the relative values of area under the curve taken from HPLC-MS
chromatogram traces (n =3), compared to a gilvocarcin V standard curve. bS. lividans TK24 (SLTK24)

Discussion
The in vivo investigation into the roles of GilP and GilQ regarding starter unit
specificity revealed that only in the absence of GilQ did the production profile for
gilvocarcins change. The role of GilP as a gil pathway associated MCAT was indirectly
supported by the successful recruitment of an endogenous host FAS MCAT in the gilP
deficient mutant strain. Inactivation of gilQ led to a marked decrease in gilvocarcin V
production, and therefore a decrease in propionate priming during decaketide formation.
Interestingly, gilvocarcin V production was partially retained in S. lividans
TK24/cosG9B3-GilQ-, suggesting GilQ is primarily, although not completely,
responsible for propionate incorporation during 49 biosynthesis.
Utilizing this information, rationally designed recombinant strains, overexpressing GilQ, were created in which the preference for propionate incorporation was
increased 23% compared to the control strain.

In addition to increased propionate

incorporation, these strains were also able to produce gilvocarcins in yields 10-20 times
that of the wild type (S. griseoflavus Gö3592) or control strain (S. lividans
TK24/cosG9B3), correlating to up to 375 mg/L of gilvocarcin V production.
Materials and Methods
Bacterial strains, culture conditions and plasmids
All complementations, conjugations, protoplast transformations and culturing
conditions were carried out as described in section 2.1: Bacterial strains, culture
conditions and plasmids. A comprehensive list of strains and plasmids used in this study
can be found in Table 12.
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Table 12. Strains and plasmids used in investigating the role of GilP and GilQ in vivo.
Strain/Plasmid

Characteristics and relevance

E. coli XL1Blue-MRF
E.coli BW25113/pKD20
E. coli ET12567/pUZ8002

Cloning host
Host for homologous recombination
Host for conjugal transfer

pIJ790
PCR-Blunt II-TOPO
pEM4
cosG9B3 (1)a
pGilQ-1-TOPO
pGilQ-2-TOPO
pGilOIII-TOPO
pGilQ (4)a
p1Q
pGilQGilOIII (5)a
cosG9B3-GilPa
cosG9B3-GilQa
S. lividans TK24 (SLTK24)
S. lividans TK24/(1)a
S. lividans TK24/(2)a
S. lividans TK24/(3)a
S. lividans TK24/(1)a/(4)a
S. lividans TK24/(1)a/(5)a

pKD20 derived plasmid
PCR fragment cloning vector
Streptomyces expression vector
PCR template for gilP and gilQ
gilQ (PstI/NheI) cloned into TOPO
gilQ (NheI/XbaI) cloned into TOPO
gilOIII (XbaI/EcoRI) cloned into TOPO
gilQ cloned into pEM4
gilQ cloned into pEM4
gilQ and gilOIII cloned into pEM4
gilP deletion mutant of cosG9B3
gilQ deletion mutant of cosG9B3
Heterologous expression host
SLTK24 transformed with (1)a
SLTK24 transformed with (2)a
SLTK24 transformed with (3)a
SLTK24/cosG9B3 transformed with (4)a
SLTK24/cosG9B3 transformed with (5)a

References
Stratagene
Datsenko, K. et al.161

MacNeil, D. et al.123-124
Gust, B. et al.162
Invitrogen
Quiros, L. et al.112
Fischer, C. et al.91
This study
This study
This study
This study
This study
This study
This study
This study
Kieser, T. et al.121
Fischer, C. et al.91
This study
This study
This study
This study

a

Numbering used only for table simplification

Fermentation and metabolite screening
The recombinant strains created in this study were fermented and screened in
triplicate as described in section 2.1: Fermentation and metabolite screening.
DNA isolation, DNA manipulation and PCR
Plasmid/cosmid DNA isolations, manipulations and PCR reactions were carried
out as described in section 2.1: DNA isolation, DNA manipulation and PCR. Primers
used for inactivation experiments as well as over-expressing constructs are summarized
in Table 13.
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Table 13. Oligonucleotide sequence of primers used to inactivate and amplify gilQ and
gilP from cosG9B3. Restriction sites are represented by italicized sequences.
Primer

GilQ-Inact-F
GilQ-Inact-R
GilQ-Cntrl-F
GilQ-Cntrl-R
GilP-Inact-F
GilP-Inact-R
GilP-Cntrl-F
GilP-Cntrl-R
GilQ-F1
GilQ-R1
GilQ-F2
GilQ-R2
GilOIII-F
GilOIII-R

Oligonucleotide sequence (5′-3′)
CGTCCTTCCTGGCCGGCGTGACGGGCTGGTGAGCCGGTGATTCCGGGGAT
CCGTCGACC

CATGGCCGGCCTTGCGCGTTGCACGTAGTGCAATGGTCATGTAGGCTGGA
GCTGCTTC
TCTAGAGCAAGGTCCTCTCGGGATTC
ATGGGTGCCTCCCGGGAACTCG
GCGCCTCCACGACGACTTGGAACCCGAGGTGACGCGGTGATTCCGGGGAT
CCGTCGACC
ATGCGGCACTGCGTGCTTCACCGGCTCACCAGCCCGTCATGTAGGCTGGA
GCTGCTTC
TCTAGATCCGTCCCGATCACCACTG
GACTCCCATGGCAGCGAACTG
GGCCTGCAGGGCTGGTGAGCCGGTGAAGCACGCA
GCGTGCTAGCTTCTAGAATGGTCAACAGAATTCCTCGGCGACCT
TGGCTAGCCGGAGAAGCACGCAATGCCGCATCAGGCAACC
CGGTCTAGAGCGTTGCACGTAGTGCAATGGTCA
CCTCTAGAGGAAAGGATGAAGCGATGATCTCCACA
GTCGAATTCGACCACCGTCACGTCCTCGACG

Inactivation of gilP and gilQ
The inactivation of gilP and gilQ from cosG9B3 (previously unpublished results
by L. Zhu) was carried out using a modified PCR-targeting REDIRECT protocol
described elsewhere.90 Briefly, a chloramphenicol (catr) resistance gene with engineered
flanking flippase recognition target (FRT) and flippase (FLP) sites was used as a template
to amplify inactivation cassettes using the primer pairs GilQ-Inact-F + GilQ-Inact-R and
GilP-Inact-F + GilP-Inact-R (Table 13). The resulting chloramphenicol inactivation
cassettes were then introduced into E. coli BW25113/pKD20 (ampr) harboring cosG9B3
(aprr) by electroporation. Elevating the incubation temperature facilitates the loss of the
temperature sensitive pKD20, and resulting chl and apr resistant colonies were collected
and evaluated further. Sequences flanking the start and stop codons of both gilP and gilQ
were used to create control primer pairs (GilP-Cntrl-F+ GilP-Cntrl-R and GilQ-Cntrl-F +
GilQ-Cntrl-R) used to confirm the replacement of the targeted genes with the
chloramphenicol cassette (Table 13). FLP-mediated excision of the inactivation cassette
resulted in an 82 bp in-frame scar confirmed by the previously discussed control primer
pairs. The final mutated cosmids, cosG9B3-GilP- and cosG9B3-GilQ-, were transformed
into E. coli ET12567/pUZ8002 and conjugally transferred into S. lividans TK24
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producing S. lividans TK24/cosG9B3-GilP- and S. lividans TK24/cosG9B3/GilQ-,
respectively.
Over-expression constructs
The primer pair GilQ-F1 and GilQ-R1was used to amplify gilQ, including the
natural putative RBS, from cosG9B3. The amplified product was gel purified and cloned
into PCR-Blunt II-TOPO (Invitrogen), as described previously, creating pGilQ-1-TOPO.
Restriction digests were used to remove gilQ from pGilQ-1-TOPO as a PstI/NheI
fragment and subsequently ligated into pEM4 producing pGilQ. Similarly, gilQ and
gilOIII were amplified from cosG9B3 using the primer pairs GilQ-F2 + GilQ-R2 and
GilOIII-F + GilOIII-R, respectively. As before, both PCR products were cloned into
TOPO producing pGilQ-2-TOPO and pGilOIII-TOPO. In order to clone both genes into
pEM4, gilQ was first removed from pGilQ-2-TOPO as a NheI/XbaI fragment and ligated
in pEM4 digested with only XbaI producing p1Q. Additional restriction digest analysis
using HindIII/XbaI confirmed the correct orientation of gilQ in p1Q. Finally, gilOIII was
taken from pGilOIII-TOPO as an XbaI/EcoRI fragment and ligated in p1Q prepared
accordingly. The resulting construct, pGilQGilOIII, contained both gilQ and gilOIII
downstream of the constitutively active promoter, ermE*p. Both over-expression
constructs were then transformed via protoplast transformation into S. lividans
TK24/cosG9B3

creating

S.

lividans

TK24/cosG9B3/pGilQ

and

S.

lividans

TK24/cosG9B3/pGilQGilOIII.

4.2 In vitro characterization of GilP and GilQ
The above in vivo investigations into GilP and GilQ function suggests that GilQ is the
primary determinant for propionate incorporation, however, in the absence of GilQ, the
gilvocarcin biosynthetic machinery could continue to produce propionate primed
decaketides. This may be due to partially relaxed substrate specificity of GilP towards
acetyl-CoA (ACoA) and propionyl-CoA (PCoA). To investigate the possibility of GilP
assisted propionate incorporation as well as to further confirm the unique activity of
GilQ, we chose to examine the substrate flexibility of both GilP and GilQ towards
transferring individual acyl-CoA substrates to the activated ACP, RavC, from the related
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ravidomycin biosynthetic pathway.117,163 The natural gilvocarcin pathway specific ACP,
GilC, was not used in this study due to an inability to express it as a soluble protein.163

Experimental design
In specific aim 3b, the gilvocarcin genes, gilP and gilQ, will be expressed and
purified as soluble proteins from E. coli. The resulting purified enzymes will be subjected
to an acyl transfer assay where their specific activity towards transferring several acylCoA species will be evaluated. The acyl transfer assay will determine the ability of GilP
and GilQ to transfer acetyl-, propionyl, malonyl- and methylmalonyl-CoA to the holoRavC (activated RavC). In this context RavC and Svp (used to activate RavC) must also
be prepared as soluble proteins.

Results
GilP and GilQ acyl transfer specific activity
To test the substrate specificity of GilP and GilQ, N-terminal (His)6-tagged
proteins of GilP, GilQ, RavC, RavC1 and Svp were expressed in E. coli and purified
using IMAC (RavC1 will be discussed below). The correct size and purity of each protein
was confirmed by SDS-PAGE analysis (Figure 56). The calculated sizes of GilP, GilQ,
RavC, RavC1 and Svp were 33.7 kDa, 38.9 kDa, 11.3 kDa, 10.8 kDa and 25.6 kDa,
respectively. Svp appears to be larger than expected, but it has been reported to run high
on SDS-PAGE gels.164
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10 kDa

Figure 56. SDS-PAGE analysis of N-terminal (His)6-tagged proteins (1) RavC, (2)
RavC1, (3) Svp, (4) GilP and (5) GilQ.
Expression of the Streptomyces ACPs, RavC and RavC1, in E. coli resulted in
almost the exclusive production of inactive or apo-ACPs. ACPs contain a conserved
serine residue which

must

be phosphopantetheinylated, or activated, by a

phosphopantetheinyl transferase (PPTase). The terminal thiol of the Coenzyme A (CoA)
derived phosphopantetheinyl arm of the activated ACP (holo-ACP) is responsible for the
catalytic activity of ACPs. Commonly, heterologous expression of ACPs results in
predominantly the inactive form (apo-ACPs). To circumvent this problem, promiscuous
PPTases have been identified, such as Svp, that can readily convert purified apo-ACPs to
functional holo-ACPs (Figure 57).
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ACP

ACP

ACP

Figure 57. Activating the acyl carrier protein. The functional holo-ACP is produced by
the transfer of the phosphopantetheinyl prosthetic group from CoA to apo-ACP via a
phosphopantetheinyl transferase, such as Svp.
An acyl transfer assay was utilized in which purified GilP and GilQ were
incubated separately with holo-RavC and individual
CoA,

14

C-malonyl-CoA,

14

C-propionyl-CoA, and

14

C-acyl-CoA species (14C-acetyl-

14

C-methylmalonyl-CoA).

The

reactions were conducted in triplicate and their compositions are summarized in Table
14, reactions 1-30. The ability of GilP and GilQ to transfer specific

14

C-acyl-CoAs to

holo-RavC (14C-acyl-CoA-RavC) were monitored by scintillation counting, and
represented as specific activity in Table 15.
Table 14. List of reaction combinations for acyl transfer assays (1- 30) and self loading
studies (31-33).
Reaction
#
1,2,3
4,5,6
7,8,9
10,11,12
13,14,15
16,17,18
19,20,21
22,23,24
25,26,27
28,29,30
31
32
33

holo-RavC
(8 µM)
X
X
X
X
X
X
X
X
X
X
X
X

GilP
(0.8 µM)
X
X
X
X
X
X
X

GilQ
(0.8 µM)
X
X
X
X
X
-

14

MCoA
(8 µM)
X
X
X
X
X

14

ACoA
(8 µM)
X
X
-

14

MMCoA
(8 µM)
X
X
-

14

PCoA
(8 µM)
X
X
-

(X), added to reaction; (-), not added to reaction; 14MCoA, 14C-malonyl-CoA; 14ACoA, 14C-acetyl-CoA; 14MMCoA, 14Cmethylmalonyl-CoA; 14PCoA, 14C-propionyl-CoA, final concentration for 100 µL reactions shown in parenthesis.
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Table 15. Specific activity of GilP and GilQ
Acyltransferase
GilP
GilP
GilP
GilP
GilQ
GilQ
GilQ
GilQ

Specific Activity a
(unit/mg)
16 x 103
463 x 103
86 x 103
301 x 103
16 x 103
27 x 103
51 x 103
15 x 103

14

C-labeled Substrates
14

C-acetyl-CoA
C-malonyl-CoA
14
C-propionyl-CoA
14
C-methylmalonyl-CoA
14
C-acetyl-CoA
14
C-malonyl-CoA
14
C-propionyl-CoA
14
C-methylmalonyl-CoA
14

Relative Activity
1
29
5
19
1
2
3
1

a

One unit is defined as the amount of His6-GilP or His6-GilQ required to catalyze the synthesis of 1 pmol of
acetyl, malonyl, propionyl or methylmalonyl-RavC per sec at pH 7.5 and 30 oC with 8 µM RavC and 8 µM
14
C-labeled substrates.

The specific activity of GilP clearly shows a strong preference toward malonylCoA, and is comparable to other characterized Streptomyces MCAT proteins.165
Similarly, GilP shows a strong preference for methylmalonyl-CoA. This may be an
artifact created by the way MCAT binds the carboxylic acid moiety of acyl-CoA
molecules. As methylmalonyl-CoA and malonyl-CoA both contain a carboxylic group
and differ only at their beta position, it is reasonable to observe high specific activity for
methylmalonyl CoA. Interestingly, GilP shows significant activity for propionyl-CoA,
with a relative activity of 1 to 5 when compared with malonyl-CoA. This suggests that
GilP can in fact transfer propionyl-CoA, and explains the presence of gilvocarcin V in the
strains lacking the critical starter unit determining enzyme, GilQ.
Comparing the specific activity of GilQ reveals a preference for propionyl-CoA over
any other acyl-CoA species tested.

Surprisingly, GilQ only shows a 2-fold higher

preference for producing propionyl-RavC compared to malonyl-RavC, and is roughly
60% less active than GilP at utilizing propionyl-CoA.
In addition to RavC, RavC1 was included in initial acyl transfer reactions. RavC and
RavC1 are ACPs found in the ravidomycin biosynthetic gene cluster. There are only a
few examples of type II PKS systems containing two individual ACP proteins. One
example, R1128A-D (151-154), has two unique ACPs that were found to be specific for
initiation and elongation. It was hypothesized that RavC and RavC1 may also serve a
similar purpose in the biosynthesis of ravidomycin; however, initial results indicated that
neither ACP exhibited substrate preference (data not shown). Based on these preliminary
results, RavC1 was removed from further experimentation and concluded that RavC and
RavC1 are most likely functional repeats.
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holo-RavC self loading capability
It is well documented that holo-ACPs contain an intrinsic ability to load acyl-CoA
species in the absence of an acyltransferase.166 It is therefore important to quantify the
self loading ability of holo-RavC in order to validate the previous acyl transfer assay.
This will allow confirmation that during the acyl transfer assay acyl-RavC species were
created by acyltransferase activity and not by the self loading properties of holo-RavC.
Under identical conditions as the acyl transfer assay, holo-RavC and GilP were incubated
separately and together with
presence of

14

14

C-malonyl-CoA (Table 14, reactions 31-33).

C-malonyl-RavC and

14

The

C-malonyl-GilP were quantified using scintillation

counting as before, and the results are summarized in Figure 58. The initial rate of holoRavC (reaction 31) and GilP (reaction 32) self loading of

14

C-malonyl-CoA were

calculated to be 0.03 µM min-1 and 0.67 µM min-1, respectively. The production of 14Cmalonyl-RavC through 14C-malonyl transfer by GilP (reaction 33) was calculated to have
an initial rate of 3.81 µM min-1. These results show the initial rate of self loading by
holo-RavC or GilP could not significantly contribute to the acyl transfer assay

14

C-

radiolabeled proteins accumulated in the time frame tested.

Figure 58. Non-linear regression curve of the self loading properties of holo- RavC (●)
and GilP (■) compared to holo-RavC + GilP (▲).
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Activity of GilPS90A, GilQS111A and RavCS39A
Bioinformatical analysis of gilP, gilQ and ravC revealed the anticipated
conserved active site motifs for acyltransferases (xGHSxGE) and ACPs (LGxDSLxxVE).
To confirm the activity exhibited by GilP, GilQ and RavC were due to the expected
active site sequences, the active Ser residue was replaced with Ala using site directed
mutagenesis. The resulting proteins GilPS90A, GilQS111A, and RavCS39A were
substituted for their wild type counterparts in several acyl transfer reactions to determine
their ability to transfer or load acyl-CoA substrates (Table 16).

Table 16. List of reaction combinations used to test the loading and transfer functionality
of the mutated proteins GilPS90A, GilQS111A, and RavCS39A.
Reaction
#
34
35
36
37
38
39

holo-RavC
(8 µM)
X
X
-

GilP
(0.8 µM)
X
X
-

GilQ
(0.8 µM)
X
-

RavCS39A
(8 µM)
X
X
-

GilPS90A
(0.8 µM)
X
X
-

GilQS111A
(0.8 µM)
X

M-CoA
(8 µM)
X
X
X
X
-

P-CoA
(8 µM)
X
X

(X), added to reaction; (-), not added to reaction; M-CoA, 14C-malonyl-CoA; P-CoA, 14C-propionyl-CoA; final concentration
for 100 µL reactions shown in parenthesis.

Phosphor imaging was used to visualize the activity of the generated mutants
(Figure 59). GilPS90A and GilQS111A, unlike GilP and GilQ, were both shown to be
unable to load

14

C-malonyl-CoA or

14

C-propionyl-CoA to holo-RavC, respectively

(Figure 59, reactions 34 and 36-39). The slight loading of holo-RavC seen in reaction 36
is due to the self loading property of holo-RavC and is not due to the presence of
GilPS90A. Similarly, the removal of the active site serine in RavCS 39A also inhibited
loading of

14

C-malonyl-CoA by the functional GilP (Figure 59, reaction 35).

The

inactivity of all mutants generated suggests that their activity is due to the expected active
site motifs.
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Reaction #

34

35

36

Reaction #

37

34

35

36

37

38 39

38 39

37 kDa
25 kDa
20 kDa
15 kDa
10 kDa

Figure 59. 14C-acyl transfer assay using mutated GilPS90A, GilQS111A, and RavCS39A.
Discussion
Taken together, the in vivo and in vitro investigation into GilP and GilQ
functionality allows us to delineate the earliest steps of gilvocarcin biosynthesis. From
bioinformatical analysis as well as experimental data it is clear that GilP and GilQ
function as acyltransferases, and work with the gilvocarcin PKS to produce 20- and 21carbon decaketides primed with acetate or propionate starter units, respectively. The
severe reduction in gilvocarcin V production by the GilQ deficient strain suggested that
GilQ is the primary determinant for starter unit specificity; however, the presence of
gilvocarcin V in the absence of GilQ hinted at an additional route for propionate
incorporation. The specific activity of GilP revealed that it addition to strong malonylCoA preference, GilP could also accept propionyl-CoA explaining the presence of
propionate primed gilvocarcin congeners in strains lacking GilQ. It is interesting that
even though GilP has a higher specific activity towards loading propionyl-CoA than
GilQ, the loss of GilQ, and not GilP, in an in vivo system drastically reduces 49
production. This can be explained by the primary MCAT functionality of GilP which is
to load and transfer malonyl-CoA for the extension of the growing ketide. Even though
GilP can load propionyl-CoA it does so at a much reduced rate compared to malonylCoA as evident in both in vivo and in vitro experimentation. GilQ on the other hand
prefers propionyl-CoA over malonyl-CoA, and despite the fact that it has a lower specific
activity towards loading propionyl-CoA; in an in vivo environment, GilP would almost
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exclusively load malonyl-CoA while GilQ would be responsible for loading propionylCoA (Figure 60, route A and elongation).
The initiation of acetate in gilvocarcin M biosynthesis is likely facilitated by GilP;
however, unlike traditional acetate initiation where malonyl-CoA is decarboxylated by
the KSβ subunit to create acetyl-CoA, we propose direct loading and transfer of acetylCoA to holo-ACP facilitated by GilP.

This hypothesis is supported by the recent

observation that acetyl-CoA and malonyl-CoA are absolute requirements for the
production of 20-carbon decaketides by the gil PKS.163

Additionally, the highly

conserved glutamine (or glutamate) residue of type II KSβ found to be responsible for
decarboxylation is replaced by a shorter aspartate residue in the gil KSβ, GilB. This
aspartate residue may be too short to initiate decarboxylation of the ACP-bound malonate
necessitating the need for direct loading and transfer of acetyl-CoA (Figure 60, route B).
To the best of our knowledge, GilQ is the first and only characterized
acyltransferase responsible for non-acetate initiation in a type II PKS pathway.
Ravidomycin and chrysomycin are the only additional gilvocarcin-like aryl C-glycosides
with isolated biosynthetic gene clusters, and both were found to contain a GilQ
homologue.117 In this context, GilQ as well as RavQ and ChryQ may comprise a unique
category of type II PKS acyltransferases that control selection and utilization of the nonacetate starter unit propionyl-CoA.
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Figure 60. The role of GilP, GilQ and RavC in initiation and elongation during the
biosynthesis of gilvocarcins.
Materials and Methods
Bacterial strains, culture conditions and plasmids
All transformation and culturing conditions were carried out as described in
section 2.1: Bacterial strains, culture conditions and plasmids. A comprehensive list of
strains and plasmids used in this study can be found in Table 17.
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Table 17. Strains and plasmids used in the expression of GilP, GilQ, RavC, RavC1 and
Svp.
Strain/Plasmid

Characteristics and relevance

References

E. coli XL1Blue-MRF
E. coli BL21 (DE3)

Cloning host
Host for protein expression

Stratagene
Invitrogen

PCR-Blunt II-TOPO
pET28a(+)
cosG9B3
cosRav32
pGilQ-3-TOPO
pRavC1-TOPO
pET-GilP
pET-GilQ
pET-RavC
pET-RavC1
pET-GilPS90A
pET-GilQS111A
pET-RavCS39A
pBS18

PCR fragment cloning vector
Protein expression vector
PCR template for gilP and gilQ
PCR template for ravC and ravC1
gilQ (NdeI/BamHI) cloned into TOPO
ravC1 (NdeI/EcoRI) cloned into TOPO
gilP cloned into pET28a(+)
gilQ cloned into pET28a(+)
ravC cloned into pET28a(+)
ravC1 cloned into pET28a(+)
gilPS90A in pET28a(+)
gilQS111A in pET28a(+)
ravCS39A in pET28a(+)
svp cloned into pQE-70 expression vector

Invitrogen
Novagen
Fischer, C. et al.91
Kharel, M. et al.117
This study
This study
Kharel, M. et al.163
This study
Kharel, M. et al.163
This study
This study
This study
This study
Sanchez, C. et al.164

DNA isolation, DNA manipulation and PCR
Plasmid DNA isolations, manipulations and PCR reactions were carried out as
described in section 2.1: DNA isolation, DNA manipulation and PCR. Please find Table
18 for a complete list of primers used in this study.

Table 18. Oligonucleotide sequence of primers used to amplify gilQ, ravC, gilP and
ravC1. Restriction sites are represented by italicized sequences.
Primer
GilQ-F3
GilQ-R3
RavC1-F
RavC1-R
GilP-S90A-F
GilP-S90A-R
GilQ-S111A-F
GilQ-S111A-R
RavC-S39A-F
RavC-S39A-R

Oligonucleotide sequence (5′-3′)
AACATATGGTGCCGCATCAGGCAACC
AAGGATCCTCAACAGAATTCCTCGGC
ATTCATATGACCACCGGCACGTTCACC
ATTGAATTCTCACGCCGCGTTGACCAGCTC
CATCGCGGGCCACGCTCTGGGCGAGTAC
GTACTCGCCCAGAGCGTGGCCCGCGATG
GCTGGTCGGTCACGCCGTGGGCGAGCTG
CAGCTCGCCCACGGCGTGACCGACCAGC
CTGGGGTACGACGCCCTGGCGCTGC
GCAGCGCCAGGGCGTCGTACCCCAG
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Protein expression constructs
The primer pairs GilQ-F3 + GilQ-R3 and RavC1-F + RavC1-R were used to
amplify gilQ and ravC1 from cosG9B3 and cosRav32, respectively. The pfu amplified
PCR products were gel purified and cloned into PCR-Blunt II-TOPO vector, producing
pGilQ-3-TOPO and pRavC1-TOPO, respectively. Restriction digests were used to
remove gilQ and ravC1 as NdeI/BamHI and NdeI/EcoRI fragments and subsequently
ligated into pET28a(+) generating pET-GilQ and pET-RavC1, respectively.

The

remaining protein expression constructs used in this study (GilP, RavC and Svp) were
reported elsewhere.163-164
Primer sets GilP-S90A-F + GilP-S90A-R, GilQ-S111A-F + GilQ-S111A-R and
RavC-S39A-F + RavC-S39A-R were used with the QuickChange lightning site-directed
mutagenesis kit (Stratagene) to produce pET-GilPS90A, pET-GilQS111A, and pETRavCS39A from pET-GilQ, pET-GilP and pET-RavC, respectively.

Expression and purification of proteins
The expression of soluble GilP, GilQ, RavC, RavC1, Svp, GilPS90A, GilQS111A,
and RavCS39A proteins were carried out as described in section 3.1: Expression and
purification of proteins.

RavC and RavC1 activation reaction conditions
The production of holo-ravC and holo-RavC1 was obtained through a modified
protocol presented elsewhere.167 The reaction conditions were as follows:

50 mM

KH2PO4 (pH 7.5), 12.5 mM MgCl2, and a 1:20:200 molar ratio of Svp:apo-ACP:CoA.
The reaction was incubated at 30 oC and 10 µL samples were taken at 60 min time
intervals and analyzed by HPLC with a Platinum C4-EPS-300 column (250 x 4.6 mm, 5
µm; Grace, Deerfield, IL). Samples were eluted with linear gradients from solvent A
(0.1% trifluoroacetic acid (TFA) in 10% acetonitrile) to solvent B (0.1% trifluoroacetic
acid in 90% acetonitrile): 0 to 5 min, 5% B; 5 to 32 min, gradient from 5 to 95% B; 32-40
min, hold at 95% B; and 40 to 45 min, gradient from 95 to 5% B. Peaks were collected,
dried under vacuum and analyzed by matrix assisted laser desorption ionization time of
flight (MALDI-TOF) mass spectrometry.

Under these conditions apo-RavC and apo118

RavC1 were converted to their active holo-forms in 60 min (Figure 61). Peak 1 had a
mass of 11187 Da and was representative of apo-RavC (cal. 11197 Da), and peak 2 had a
mass of 11524 Da indicating the presence of holo-RavC (cal. 11537 Da).
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Figure 61. Conversion of apo-RavC (peak 1) to holo-RavC (peak 2) at time points (A) 0
min and (B) 60 min.

Acyl transfer assay conditions
An acyl transfer assay was set up to determine the specific activity of GilP and
GilQ to form radiolabeled acyl-RavC. The radiolabeled acyl-CoAs used in this study
were malonyl-CoA (malonyl-2-14C, Perkin Elmer), acetyl-CoA (acetyl-1-14C, Perkin
Elmer), methylmalonyl-CoA (methyl-14C, American Radiolabeled Chemicals), and
propionyl-CoA (propionyl-1-14C, American Radiolabeled Chemicals). 100 µL reactions
were set up consisting of 50 mM KH2PO4 (pH 7.5), 12.5 mM MgCl2, 1 mM tris(2carboxyethyl)phosphine (TCEP), 8 µM holo-RavC, and 0.8 µM purified GilP or GilQ
(see Table 14, reactions 1-30). This was allowed to equilibrate at 30 oC for 5 min and
then the reaction was initiated by the addition of 8 µM radiolabeled acyl-CoA. The
reaction was quenched with trichloroacetic acid (TCA) after 30 seconds at 30 oC to a
final concentration of 7% TCA. 200 µg of bovine serum albumin (BSA) was added to
the quenched reaction and was kept on ice for 15 min.

Protein was collected by

centrifugation (13000 x g, 10 min) and washed twice with cold 7% TCA. The pellet was
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then dissolved with 100 µL of a 1:1 solution of 2 M NaOH and 2 M Tris Base. The
reconstituted pellet was then combined with 500 µL of scintillation cocktail (Research
Products International) and analyzed on a liquid scintillation analyzer (2200CA TRICARB, Packard).

GilP and RavC self loading assay conditions
The self loading study of GilP and RavC followed the same reaction conditions as
the acyl transfer assay discussed above. However, instead of a single 30 second time
point as discussed above, the self loading reactions (Table 14, reactions 33-33) were
quenched at 0 sec, 10 sec, 30 sec, 1 min, 3 min, 5 min, 10 min, 30 min and 60 min. The
14

C-labeled proteins were collected and quantitated by liquid scintillation counting as

described above. This data was then used to calculate the initial rate of self loading by
GilP and RavC.

Mutant activity assay conditions
Activity of the mutant proteins, GilPS90A, GilQS111A, and RavCS39A, were tested
using the same reaction conditions as described above utilizing different combinations of
wild type and mutant proteins (see Table 16).

Copyright © Micah Douglas Shepherd 2011
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Chapter 5: Production of Proposed Gilvocarcin Intermediates
Assembly of partial gilvocarcin biosynthetic gene clusters
Biosynthetic investigations into the enzymatic cascade leading to gilvocarcin V
biosynthesis has primarily been elucidated through cosG9B3 based gene inactivations
and complementation experiments. These experiments, combined with bioinformatical
analyses, have provided evidence that allows us to predict the biosynthetic steps leading
to gilvocarcin V production (Figure 16). However, despite rigorous experimentation,
almost the entire post-PKS set of reactions remain unclear. The only exception is GilR,
an oxidoreductase proven through in vitro experimentation to oxidize the hemi-acetal of
pregilvocarcins (75-77) to the lactone in gilvocarcins (49-51).101
The lack of isolable substrates is the most prominent factor limiting the
characterization of a majority of the post-PKS reactions. It was recently shown that all
gilvocarcin enzymes believed to be involved in gilvocarcin post-PKS reactions, except
GilGT, could be expressed as soluble proteins in E. coli (unpublished results by M.
Kharel). In order to identify new intermediates from late stage biosynthetic reactions,
and to further confirm the function of specific enzymes, a plasmid based approach was
utilized in which partial gilvocarcin clusters could be assembled in various combinations
to investigate unknown reactions, isolate unknown intermediates and provide substrates
for further in vitro analyses.
Furthermore, this plasmid based approach may be used to create more stable
gilvocarcin mutants. For example, the GilU mutant, cosG9B3-GilU-, produces the most
active gilvocarcin analogue to date, 4′-hydroxy-gilvocarcin V (81). Unfortunately, S.
lividans TK24/cosG9B3-GilU- produces 81 in yields of 0.5 mg/L.85 A synthetic construct
could be assembled in which all genes responsible for 81 production are placed under the
control of a strong promoter, such as ErmE*p, to increase the overall yield of this
important analogue. Additionally, the production profile of S. lividans TK24/cosG9B3GilGT- is notoriously unpredictable.

This has created difficulties in further

glycodiversification studies of gilvocarcin V (as discussed in section 2). Using this
approach, it would be possible to place all genes needed for defuco-gilvocarcin V (78)
production and omit all deoxysugar biosynthetic genes. This would provide an ideal host
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for introducing exogenous glycosyltransferases and deoxysugars towards creating sugar
derivatives of 49.
Experimental design
In specific aim 4, genes from a large operon in cosG9B3, containing gilH, OI, G,
A, B, C, F, K, OIV, P and Q, will be subcloned into an integrating vector (pSET152) and
a self replicating expression vector (pUWL201PW) to determine their ability to produce
dehydro-rabelomycins (64 and 65). The ErmE*p promoter will be incorporated into
these plasmids to ensure strong expression of the biosynthetic genes. The placement and
number of ermE*p copies used will also be investigated to determine their optimal
configuration for metabolite production.

Once a successful construct is identified,

additional post-PKS enzymes, gilOII, M, MT, R and OIII will be added to the base
construct in various combinations and their metabolite production will be analyzed via
HPLC-MS as describe previously.
Results
Metabolite production of partial cluster constructs
Analysis of the gilvocarcin gene cluster revealed that gilG/gilA, gilA/gilB,
gilC/gilF and gilOIV/gilP share stop and start codons (Figure 62, red arrows). In order
to retain the natural nucleotide sequence integrity of the gilvocarcin cluster, PCR was
used to amplify gilH-OI, gilG-A-B, gilC-F-K and gilOIV-P-Q as four large fragments,
allowing the overlapping ORFs to remain unaltered. Assembly of these fragments into
pSET152 resulted in the addition of only 6 nucleotides between each fragment. This
created only 18 nucleotide changes, dispersed among 3 positions, when compared to the
natural sequence in cosG9B3.

Figure 62. Partial gilvocarcin cluster highlighted with important features utilized in this
study. EcoRV (EV) and EcoRI (E) sites are shown by the dotted line, and the red arrow
indicates ORF overlaps.
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Two pSET152 based constructs (pSET-GCOIV and pSET-HGCOIV) were created
using the PCR fragments discussed above (Figure 63). pSET152 carries the integration
function and attachment site of ΦC31, and allows for site specific integration of the
plasmid into the attB site of S. lividans TK24 chromosome.121

Integration is

advantageous because it produces a much more stable host than using a self replicating
plasmid system. Both pSET-GCOIV and pSET-HGCOIV were transformed into S.
lividans TK24 through conjugation, and integration was confirmed through PCR. The
resulting strains, S. lividans TK24/pSET-GCOIV and S. lividans TK24/pSET-HGCOIV
were both unable to produce any gilvocarcin intermediate. Theoretically, both strains
contain genes that should be able to produce 2,3-dehydro-UWM6 compounds (67 and 68)
that will then be converted to dehydro-rabelomycins (64 and 65) spontaneously or
through the activity of GilOI. The exact promoter regions of the gil cluster are unknown.
pSET-GCOIV was tested without the addition of ermE*p to see if a natural promoter
contained within the cloned sequence or a promoter downstream of the attB site of S.
lividans TK24 could induce transcription of the biosynthetic genes. It was therefore not
surprising that pSET-GCOIV did not produce gilvocarcin metabolites. Alternatively,
genes included in pSET-HGCOIV were cloned downstream of the strong constitutive
promoter, ermE*p. Successful integration and expression of this plasmid should have
resulted in the formation of 64 and 65.

Figure 63. Gene placement and restriction sites used in creating pSET-GCOIV and
pSET-HGCOIV. SpeI (S), XbaI (X), NdeI (Nd) and AvrII (A) sites are shown by the
dotted line. Broken restriction sites are illustrated with a back slash.
An alternative cloning strategy was taken in which natural occurring restriction
sites from cosG9B3 were utilized in conjunction with PCR to clone a completely
unaltered fragment of cosG9B3covering gilH through gilQ. The sequence of gilQ was not
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complete as the natural restriction site used in this study removed the last six nucleotides
of its gene sequence (Figure 62). As discussed earlier, GilQ is involved in propionate
incorporation during early gilvocarcin V biosynthesis. The absence of GilQ activity will
only result in a loss or reduction of propionate primed intermediates produced by the
engineered constructs.
The previous constructs were based on the integration vector pSET152. To test
the effectiveness of self replicating plasmids, pUWL201PW was chosen for two reasons.
First, pUWL201PW contains a copy of ermE*p and an engineered RBS removing the
need to clone the natural RBS; and secondly, the multiple cloning site (MCS) of
pUWL201PW offered the appropriate restriction sites needed to design the cloning of
several genes.

The base construct, pSGC-HQ, was designed with a single ermE*p

promoter upstream of the large gilH, OI, G, A, B, C, F, K, OIV, P and Q fragment, and a
second ermE*p directly upstream of the first promoter (Figure 64). The cloning strategy
was to introduce additional genes between the two promoters to ensure strong promotion
of all genes. In this context gilOII, gilM, gilMT and gilR were cloned between these two
promoters to create the constructs shown in Figure 64.

Figure 64. Gene placement and restriction sites used in creating pSGC constructs. EcoRI
(E), HindIII (H) and NdeI (Nd) sites are shown by the dotted line.
Fermentation of S. lividans TK24/pSGC-HQ resulted in the accumulation of
metabolites believed to be dehydro-rabelomycin (64) and dehydro-homo-rabelomycin
(65) (Figure 65). This determination was made based on identical retention times and
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UV-Vis spectra of the compounds accumulated in S. lividans TK24/pSGC-HQ compared
to dehydro-rabelomycins (64-66). This result was exciting as it confirmed the successful
expression of genes contained within the base pSGC-HQ construct. The production of
both 64 and 65 was surprising. The production of such high quantities of a propionate
primed intermediate compared to the acetate primed intermediate indicates the presence
of a functional GilQ protein.

It is possible that an in-frame stop codon is found

downstream of the restriction site in which GilQ was cloned. If this in-frame stop codon
is relatively close to this restriction site, the translated protein of the modified gilQ ORF
may remain functional explaining the presence of propionate primed dehydro-homorabelomycin (65). Most fascinating, however, is the possible production of dehydrorabelomycin V (66) in the absence of GilOIII. The oxidation of the ethyl side chain to
form the vinyl functional group is known to involve GilOIII.42 Furthermore, the inability
of the GilOIII mutant to produce vinyl side chain congeners in S. lividans TK24 indicates
endogenous host enzymes can not complement the reaction. To confirm that gilOIII was
not accidentally incorporated into the construct, PCR was used in an attempt to amplify
gilOIII from pSGC-HQ. This experiment resulted in no PCR fragments suggesting
gilOIII was not present in the construct (data not shown). The elution pattern and
intensity of peaks 1-3 in Figure 65 are identical to that of expected M, V and E
congeners, respectively. However, based on the lack of mass data to support the presence
of a vinyl congener, it must be concluded that most likely peak two in Figure 65 is
actually dehydro-homo-rabelomycin and not dehydro-rabelomycin V. Furthermore, the
UV-Vis of peak three can be explained by the overlap between peaks two and three,
which may allow for the spectra of peak three to be similar to that of dehydro-homorabelomycin.
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Figure 65. HPLC chromatogram trace of S. lividans TK24/pSGC-HQ including the UVVis spectrum of peaks 1, 2 and 3.

The successful production of gilvocarcin intermediates by S. lividans
TK24/pSGC-HQ provided a working system in which additional post-PKS enzymes
could be added to continue the biosynthesis toward gilvocarcin intermediates and/or
defuco-gilvocarcin M and E. Unfortunately, the expression of pSGC-M, pSGC-MT,
pSGC-MMT and pSGC-R in S. lividans TK24 did not produce observable amounts of
any gilvocarcin intermediates. This suggested that the addition of genes to pSGC-HQ
negatively affected the ability of the constructs to be expressed. For an unknown reason
it seems that transcription is not proceeding as expected in constructs with genes inserted
between the two promoters of pSGC-HQ. To try to eliminate any possible problems
caused by including two promoters, an additional set of constructs were created in which
only a single promoter from pUWL201PW was used to promote transcription of all
downstream genes (Figure 66, pSGC* constructs). In addition, pSET-HQ was created in
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which the same gene fragment found in pSGC-HQ was introduced into pSET152 (Figure
66). The successful integration and production of dehydro-rabelomycin from such a
strain would be beneficial as this strain could be used as a host in which individual postPKS genes could be introduced on smaller plasmid based gene constructs.

Figure 66. Gene placement and restriction sites used in creating pSET-HQ and the
pSGC* constructs. SpeI (S), XbaI (X), NdeI (Nd), HindIII (H) and EcoRI (E) sites are
shown by the dotted line. Broken restriction sites are illustrated with a back slash.
Unfortunately, all pSGC* constructs failed to express gilvocarcin intermediates in
S. lividans TK24. Similarly, the integrated pSET-HQ strain was also unable to produce
any gilvocarcin metabolites. From these results, it seems that the two ermE*p system
utilized previously was not contributing to the lack of transcription, however, the root
cause remains unknown. In general, when cloning large consecutive genes it is typical to
add additional genes downstream of the previous gene. This cloning strategy proved
difficult for cloning the gilvocarcin genes due to a very limited amount of acceptable
restriction sites that could be used.

This resulted in previous approaches in which

additional genes were added on the 5′ end of the fragment rather than the 3′ end.
In a final attempt to construct a partial gilvocarcin cluster that could be used to
investigate gilvocarcin post-PKS reactions, a cloning strategy was designed for the
addition of genes downstream of gilQ.

The resulting base construct, pSGC**-HQ,

included the entire unmodified nucleotide sequence of cosG9B3 from the start codon of
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gilH through the stop codon of gilQ. The addition of gilOII to pSGC**-HQ produced
pSGC**-OII and both of these constructs were transformed into S. lividans TK24 to
screen for metabolite production (Figure 67). Again, both strains failed to produce
gilvocarcin intermediates.

Figure 67. Gene placement and restriction sites used in creating pSGC** constructs.
SpeI (S), EcoRI (E), NdeI (Nd), NheI (Nh) and HindIII (H) sites are shown by the dotted
line. Broken restriction sites are illustrated with a back slash.
Discussion
A plasmid based approach was taken to assemble a minimal set of gilvocarcin
genes responsible for producing dehydro-rabelomycins (64 and 65). This metabolite was
chosen as all the genes needed for this biosynthetic product are conserved to large operon
in the gilvocarcin cluster. This operon was cloned using several approaches and cloning
strategies to produce six different constructs that could serve as the foundation for
additional studies (Figures 63, 64, 66 and 67). In addition, the post-PKS genes, gilM,
gilMT, gilOII and gilR were added to these base constructs in various combinations in
order to investigate GilM and GilMT function, isolate new gilvocarcin intermediates as
well as to produce a stable defuco-gilvocarcin producer.
One construct, pSGC-HQ, was able to successfully produce dehydrorabelomycin, however, addition of post-PKS enzymes resulted in a failure to produce
gilvocarcin associated metabolites in all cases despite altering the cloning strategy,
promoter position, number of promoter copies and gene placement.

The lack of

production from these constructs suggest a problem with transcription, however it
remains unknown why pSGC-HQ could be successfully transcribed and the similar
construct pSET-HQ could not. Furthermore, it is surprising that pSGC-HQ worked well
using the double ermE*p system while the remaining pSGC constructs failed to produce
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any gilvocarcin metabolites. Further experimentation using real-time qRT-PCR could
determine if the problem truly lies with the ermE*p promoter and transcription.
Alternatively, a resistance gene could be cloned downstream of gilQ in pSGC**-HQ and
the constructs ability to transmit resistance in S. lividans TK24 could be investigated. If
the strain showed resistance it would suggest the genes downstream of ermE*p are being
transcribed properly and the problems encountered in this study are probably due to the
inactivity of individual gilvocarcin proteins and not from transcription.

Materials and Methods
Bacterial strains and culture conditions
All transformation and culturing conditions were carried out as described in
section 2.1: Bacterial strains, culture conditions and plasmids. A comprehensive list of
strains and plasmids used in this study can be found in Table 19.
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Table 19. Strains and plasmids used in the construction of partial gilvocarcin clusters.
Strain/Plasmid
Characteristics and relevance
E. coli XL1Blue-MRF
Cloning host
PCR-Blunt II-TOPO
PCR fragment cloning vector
pSET152
Streptomyces integration vector
pEM4
Used for cloning ermE*p
pUWL201PW
Streptomyces expression vector
pET28a(+)
Used as a cloning vector
pBluescript II SK(+)
Used as a cloning vector
cosG9B3
Template for gil genes
TOPO-OIV
TOPO with gilOIV,P,Q
TOPO-CFK
TOPO with gilC,F,K
TOPO-GAB
TOPO with gilG,A,B
TOPO-HOI
TOPO with gilH,OI
pEM4-HOI
pEM4 with gilH,OI
TOPO-2-HOI
TOPO with ermE*p,gilH,OI
pSET-OIV
pSET152 with gilOIV,P,Q
pSET-COIV
pSET152 with gilC,F,K,OIV,P,Q
pSET-GCOIV (1)a
pSET152 with gilG,A,B,C,F,K,OIV,P,Q
pSET-HGCOIV (2)a
pSET152 with ermE*p,gilH,OI,G,A,B,C,F,K,OIV,P,Q
TOPO-OII
TOPO with gilOII
TOPO-M
TOPO with gilM
TOPO-MT
TOPO with gilMT
TOPO-R
TOPO with gilR
pET-OII
pET28a with gilOII
pET-OIIM
pET28a with gilOII,M
pET-OIIMT
pET28a with gilOII,MT
pET-OIIMMT
pET28a with gilOII,M,MT
pET-OIIMMTR
pET28a with gilOII,M,MT,R
pBlu-G9B3-EV
pBluescript with partial gil cluster (EcoRV)
pUWL-HOI
pUWL201 with ermE*p,gilH,OI
pSGC-HQ (3)a
pUWL201 with ermE*p,gilH,OI,G,A,B,C,F,K,OIV,P,Q
pSGC-OII (4)a
pUWL201 with gilOII,ermE*p,gilH,OI,G,A,B,C,F,K,OIV,P,Q
pSGC-M (5)a
pUWL201 with gilM,OII,ermE*p,gilH,OI,G,A,B,C,F,K,OIV,P,Q
pSGC-MT (6)a
pUWL201 with gilMT,OII,ermE*p,gilH,OI,G,A,B,C,F,K,OIV,P,Q
pSGC-MMT (7)a
pUWL201 with gilM,MT,OII,ermE*p,gilH,OI,G,A,B,C,F,K,OIV,P,Q
pSGC-R (8)a
pUWL201 with gilM,MT,R,OII,ermE*p,gilH,OI,G,A,B,C,F,K,OIV,P,Q
pSET-HOI
pSET152 with ermE*p,gilH,OI
pSET-HQ (9)a
pSET152 with ermE*p,gilH,OI,G,A,B,C,F,K,OIV,P,Q
TOPO-3-HOI
TOPO with gilH,OI
pUWL-2-HOI
pUWL201PW with gilH,OI
pSGC*-HQ (10)a
pUWL201 with gilH,OI,G,A,B,C,F,K,OIV,P,Q
pSGC*-OII (11)a
pUWL201 with gilOII,H,OI,G,A,B,C,F,K,OIV,P,Q
pSGC*-M (12)a
pUWL201 with gilM,OII,H,OI,G,A,B,C,F,K,OIV,P,Q
pSGC*-MT (13)a
pUWL201 with gilMT,OII,H,OI,G,A,B,C,F,K,OIV,P,Q
pSGC*-MMT (14)a
pUWL201 with gilM,MT,OII,H,OI,G,A,B,C,F,K,OIV,P,Q
pSGC*-R (15)a
pUWL201 with gilM,MT,R,OII,H,OI,G,A,B,C,F,K,OIV,P,Q
TOPO-Q
TOPO with partial gilQ
TOPO-4-HOI
TOPO with gilH,OI
pET-Q
pET28a with partial gilQ
pET-HQ
pET28a with partial gilH,OI,Q
pET**-HQ
pET28a with gilH,OI,G,A,B,C,F,K,OIV,P,Q
TOPO-2-OII
TOPO with gilOII
pSGC**-HQ (16)a
pUWL201PW with gilH,OI,G,A,B,C,F,K,OIV,P,Q
pSGC**-OII (17)a
pUWL201PW with gilH,OI,G,A,B,C,F,K,OIV,P,Q,OII
SLTK24b
Heterologous expression host
SLTK24b/(1-17)a
SLTK24b transformed with (1-21)a
a
Numbering used only for table simplification, bS. lividans TK24, cUnpublished work by M. Kharel
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DNA isolation, DNA manipulation and transformations
Plasmid DNA isolations, manipulations and PCR reactions were carried out as
described in section 2.1: DNA isolation, DNA manipulation and PCR. Please find Table
20 for a complete list of primers used in this study.
Table 20. Oligonucleotide sequence of primers used in creating partial gilvocarcin
clusters. Restriction sites are represented by italicized sequences.
Primer
GilOIVPQ-F
GilOIVPQ-R
GilCFK-F
GilCFK-R
GilGAB-F
GilGAB-R
GilHOI-F
GilHOI-R
GilHOI-pEM4-F
GilOII-F
GilOII-R
GilM-F
GilM-R
GilMT-F
GilMT-R
GilR-F
GilR-R
GilHOI-F2
GilQ-F
GilQ-R
GilHOI-F3
GilOII-F2
GilOII-R2

Oligonucleotide sequence (5′-3′)
TTACTAGTCATATGTCTAGAGTGGGGACATGACGGAGC
TTACTAGTTCAACAGAATTCCTCGGCGACCTCA
AACATATGACTAGTGAGAAGGAGCAAGGAATG
AATCTAGATCACCTCTGCGACACGGCGG
TTCATATGACTAGTCCAGAGGAGGAAGAACCCTTGT
TTCCTAGGTCATTTCCCGACGATCAG
TTACTAGTCTCTACCGCTCATAATCTGGCCGCT
AATCTAGACCTAGGTTACGCGGCGGGCTGACC
TTCATATGACTAGTCAGGAAACAGCTATGAC
TTCATATGTCGCTAGCTCGAATTCGACACCTCATGGAAGGCC
AGAAGCTTTCACGACGCGTACCCCTC
ATACTAGTGAGAGGAGTGGCGCTCGATGCCAA
ATGAATTCATTGCTAGCGAACTTCATGCCGGGCTCTCCGA
ATACTAGTGTCGAAGGGACATCATGACCATTACTGCATCGGG
ATGAATTCATTGCTAGCGTCACCGGCTGCGGGGAGAGC
ATACTAGTGAGGGGTACGCGTCGTGACCGCTT
ATGAATTCATTGCTAGCTCCTCTCAGAGTCCTATGGACAT
TTAAGCTTCTCTACCGCTCATAATCTGGCCGCT
TCGGATCCGGAGGAGCTCAAGGGTG
AAGCTTATCACTAGTTGGTCAACAGAATTCCTC
GGCATATGATCAGGATCGCCGTC
TATGCTAGCGGAAGGCCTCATGCCGATCAT
AGTAAGCTTGTAACTAGTCGGTCACGACGCGTACCCCTC

Preparing partial cluster constructs
pSET constructs
The primer pairs GilOIVPQ-F + GilOIVPQ-R, GilCFK-F + GilCFK-R, GilGABF + GilGAB-R, and GilHOI-F + GilHOI-R were used to amplify fragments of cosG9B3
consisting of the complete genes gilOIV-P-Q, gilC-F-K, gilG-A-B, and gilH-OI,
respectively. The gilOIV-P-Q, gilC-F-K, gilG-A-B and gilH-OI PCR fragments were
amplified with engineered restriction sites SpeI/NdeI/XbaI, NdeI/SpeI, NdeI/SpeI and
SpeI on their 5′ ends, respectively. The 3′ ends were also engineered with SpeI, XbaI,
AvrII and AvrII/XbaI, respectively. Each PCR amplified fragment was cloned into the
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PCR-Blunt TOPO-II cloning vector producing TOPO-OIV, TOPO-CFK, TOPO-GAB
and TOPO-HOI. Initially, the gilOI-P-Q fragment was removed from TOPO-OIV as a
SpeI fragment and ligated into pSET152 (XbaI). The resulting plasmid, pSET-OIV, was
used as the foundation for adding additional gilvocarcin genes. TOPO-CFK was digested
with NdeI/XbaI, removing gilC-F-K, and ligated into pSET-OIV (NdeI/XbaI) producing
pSET-COIV. Similarly, TOPO-GAB digested with AvrII/XbaI, removing gilG-A-B, and
ligated into pSET-COIV (NdeI/SpeI) producing pSET-GCOIV. In order to include the
constitutively active promoter ermE*p, TOPO-HOI was digested with SpeI/XbaI,
removing gilH-OI, and ligated into pEM4 (XbaI). The correct orientation was confirmed
by a HindIII/XbaI digest. This plasmid, pEM4-HOI, was then used as template for PCR.
The primers GilHOI-pEM4-F and GilHOI-R were used to amplify ermE*p, gilH and
gilOI from pEM4-HOI introducing NdeI/SpeI and AvrII/XbaI sites at the 5′ and 3′ end,
respectively. The resulting PCR fragment was cloned into TOPO to create TOPO-2-HOI.
Finally, TOPO-2-HOI was digested with NdeI/AvrII and ligated into pSET-GCOIV
(NdeI/SpeI) to produce the final construct, pSET-HGCOIV.
The construct pSET-HOI was created by removing ermE*p, gilH and gilOI from
TOPO-2-HOI (discussed below) as a SpeI/EcoRI fragment and ligating it into pSET152
(XbaI/EcoRI). The large EcoRI fragment from pBlu-G9B3-EV was then placed into
pSET-HOI (EcoRI) creating pSET-HQ. The orientation of the EcoRI fragment was
confirmed as described below.
pSGC constructs
The previously created construct pEM4-HOI was digested with HindIII/EcoRI
and ligated into pUWL201PW (HindIII/EcoRI). The gene sequence of gilOI contains an
EcoRI site near its stop codon, therefore the resulting plasmid, pUWL-HOI, contained the
complete sequence of ermE*p and gilH, but only the partial sequence of gilOI. A large
EcoRV fragment from cosG9B3 including gilOI, G, A, B, C, F, K, OIV, P, Q and T was
subcloned into pBluescript II SK(+) creating pBlu-G9B3-EV (see Figure 63). An EcoRI
fragment was taken from pBlu-G9B3-EV, cuts inside gilOI and gilQ, and ligated into
pUWL-HOI (EcoRI). The correct orientation was confirmed by amplifying a gilOI-G
fragment and confirming the correct size. The resulting plasmid pSGC-HQ, contained
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the complete gene sequences of ermE*p, gilH, OI, G, A, B, C, F, K, OIV and P as well as
partial sequence of gilQ. This plasmid was used to further build the gilvocarcin cluster.
The PCR primer pairs GilOII-F + GilOII-R, GilM-F + GilM-R, GilMT-F +
GilMT-R and GilR-F + GilR-R were used to amplify gilOII, gilM, gilMT and gilR from
cosG9B3, respectively. The amplified product of gilOII contained the restriction sites
NdeI/NheI/EcoRI and HindIII at its 5′ and 3′ ends; while gilM, gilMT and gilR were
amplified containing NheI and SpeI/EcoRI restriction sites at their 5′ and 3′ ends,
respectively. The resulting PCR products were cloned into PCR-Blunt II-TOPO vector
creating TOPO-OII, TOPO-M, TOPO-MT and TOPO-R constructs. Initially, TOPO-OII
was digested with NdeI/HindIII and ligated into pET28a(+) (NdeI/HindIII) to produce
pET-OII. This construct was used to build part of the gilvocarcin cluster before being
added to the main construct. A NheI/EcoRI fragment was removed from TOPO-M,
containing gilM, and ligated into pET-OII (NheI/EcoRI) forming pET-M. Similarly,
TOPO-MT was digested with NheI/EcoRI and ligated into pET-OII (NheI/EcoRI)
forming pET-MT. The same NheI/EcoRI fragment from TOPO-MT was also ligated into
pET-M (NheI/SpeI) creating pET-MMT. TOPO-R was also digested with NheI/EcoRI
and the resulting fragment was ligated into pET-MMT (NheI/SpeI) to produce pET-R.
The final constructs were created by digesting pET-M, pET-MT, pET-MMT and pET-R
with NdeI/HindIII and ligating them into pSGC-HQ (NdeI/HindIII) producing pSGC-OII,
pSGC-M, pSGC-MMT and pSGC-R, respectively.
pSGC* constructs
To create constructs containing only a single copy of ermE*p, the primer pair
GilHOI-F2 + GilHOI-R was used to amplify gilH and gilOI with unique HindIII
restriction placed at the 5′ end. As before, gilOI contains an EcoRI site within its
nucleotide sequence, and this EcoRI site is used for further cloning. The PCR product
was cloned into TOPO producing TOPO-3-HOI. The gilvocarcin genes were removed
through HindIII/EcoRI digestion and placed into pUWL201PW (HindIII/EcoRI)
producing pUWL-2-HOI. The large EcoRI fragment from pBlu-G9B3-EV was ligated
into pUWL-2-HOI forming pSGC*-HQ. The orientation of the EcoRI fragment was
confirmed as described above. NdeI/HindIII fragments taken from pET-OII, pET-M,
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pET-MT, pET-MMT and pET-R (described above) were ligated into pSGC*-HQ to
produce pSGC*-OII, pSGC*-M, pSGC*-MT, pSGC*-MMT and pSGC*-R.
pSGC** constructs
Flanking regions of the gilQ stop codon were amplified from cosG9B3 using
primers GilQ-F and GilQ-R.

The amplified product contained a BamHI site and

SpeI/HindIII sites at its 5′ and 3′ prime ends, respectively.

In pSGC and pSGC*

constructs, only the partial gilQ sequence was included. This approach allows for the
complete gene sequence of gilQ to be included in the engineered gilvocarcin cluster. The
amplified PCR product was cloned into TOPO to produce TOPO-GilQ. This small
fragment was removed from TOPO-GilQ and placed into pET28a(+) using
BamHI/HindIII creating pET-Q. The primer pair GilHOI-F3 + GilHOI-R was used to
amplify gilH and gilOI from cosG9B3 with an NdeI site upstream of its natural RBS.
Again, the natural EcoRI site within gilOI was used in further cloning steps. The
resulting PCR product was cloned into TOPO producing TOPO-4-HOI. This construct
was digested with NdeI/EcoRI, removing gilH and gilOI, and ligated into pET-Q
(NdeI/EcoRI) forming pET-HQ. The large EcoRI fragment from pBlu-G9B3-EV was
ligated into pET-HQ (EcoRI) creating a complete fragment, identical to cosG9B3,
covering the genes gilH, OI, G, A, B, C, F, K, OIV, P and Q. This construct, pSGC**HQ was used as the foundation for further expansion of the gilvocarcin cluster. The
primer pair GilOII-F2 + GilOII-R2 was used to amplify gilOII from cosG9B3. The
resulting PCR product included NheI and SpeI/HindIII sites at the 5′ and 3′ prime ends,
respectively; and was cloned into TOPO vector. The resulting construct was designated
TOPO-2-OII and was digested with NheI/HindIII and ligated into pSGC**-HQ
(SpeI/HindIII) producing pSGC**-OII.
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Chapter 6: Summary
In summary, the studies reported in this dissertation are aimed at producing
glycodiversified analogues of gilvocarcin-like aryl C-glycosides and understanding the
biosynthetic propensity towards propionate starter unit incorporation during gilvocarcin
V (49) biosynthesis. The insights gained from these studies provide the framework for
further combinatorial biosynthetic investigations to produce gilvocarcin analogues.
In specific aim 1a, we utilized the gene sequences from gilGT, chryGT and
ravGT to create six rationally designed chimeric GTs with improved donor substrate
flexibility compared to their wild type activity. This led to the identification of three
functional chimeric C-glycosyltransferases able to produce 49. Attempts to test the donor
substrate flexibility of the chimeric GTs were inhibited by the lack of a suitable host, but
preliminary results showed promising results for their use in producing gilvocarcin
analogues with altered sugar moieties.
In specific aim 1b, the polycarcin V (61) rhamnosyltransferase, plcGT, was
isolated from S. polyformus genomic DNA for its proposed ability to transfer both
furanose and pyranose sugars. This in addition to being a rhamnosyltransferase, which
are in general donor substrate promiscuous, made plcGT a valuable resource for further
glycodiversification studies. Preliminary investigation into the activity as well as donor
substrate promiscuity revealed that PlcGT was likely involved in transferring both
furanose and pyranose sugars but was rather substrate specific.
In specific aim 2, the L-rhamnose moiety of 61 was modified using a unique
combinatorial biosynthetic approach in which rhamnosyl-O-methyltransferases from the
steffimycin and elloramycin pathways were used to produce a library of five Omethylated-L-rhamnose analogues of polycarcin. This library provides a unique
opportunity for SAR studies regarding specific residues of the sugar moiety as well as
providing additional analogues with possible increased pharmacological properties.
In specific aim 3a and 3b, the acyltransferases GilP and GilQ were investigated
to determine their role in starter unit specificity. The biosynthesis of 49 requires the
incorporation of a propionate starter unit which is atypical of a type II PKS system.
Furthermore, the concomitant production of 49 and 50 during gilvocarcin fermentation
illustrates an ability to also initiate polyketide biosynthesis with acetate. In vivo and in
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vitro characterization of GilP and GilQ revealed the primary determining factor for
propionate incorporation during the biosynthesis of gilvocarcin V was GilQ. This led to
genetically engineered strains producing 10-20 times more gilvocarcin V compared to the
wild type strains.
In specific aim 4, a plasmid based approach to organize a minimal set of
gilvocarcin genes to produce pathway intermediates was undertaken. The goal of this
study was initially to design a plasmid that would facilitate further gene incorporation
and could produce the early shunt products dehydro-rabelomycin (64) and dehydrohomo-rabelomycin (65). This would allow individual genes to be added to the growing
plasmid to both evaluate genes role in gilvocarcin biosynthesis, but also allow for
pathway intermediates to be isolated. Furthermore, the successful preparation of these
plasmids would allow for their use in complementation experiments and would provide
an ideal system for glycodiversification studies. A single construct, pSGC*-HQ, was
identified that could produce 64 and 65; however, the incorporation of additional genes
resulted in the abolishment of metabolite production.
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